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InTrODuCTIOn
Obesity and osteoporosis are common and complex disorders with important conse-
quences for human health and for society. The two conditions are intimately linked, as 
evidenced by epidemiological studies showing that obesity protects from osteoporosis 
while low body weight poses a strong risk factor 1, 2. Obesity, defined as a body mass 
index (BMI) of 30 kg/m2 and over, has become a global epidemic and represents an 
important risk factor for type 2 diabetes mellitus, hypertension, cardiovascular disease, 
stroke, some types of cancer and disability. Osteoporosis, a skeletal disorder character-
ized by loss of bone strength and proneness to fractures, is a major health threat to 
hundreds of millions of elderly individuals worldwide and prevalence will continue to 
rise as populations age. Osteoporosis and obesity result from an interaction between 
genetic factors and environment. Although the growing prevalence of obesity is most 
likely driven by changing lifestyles encompassing increased caloric intake and decreased 
energy expenditure through physical activity, individual susceptibility varies widely and 
is strongly influenced by genetic factors. Heritability estimates for BMI, the most widely 
used parameter of obesity, range from 30 to 70% in family- and twin studies 3. There are 
also genetic influences on obesity-related traits like total body fat mass, lean mass and 
measures of fat distribution 4-8, but the heritability of these parameters is less clear than 
that of BMI. A large contribution of genes has also been documented for the susceptibly 
to develop osteoporosis. Heritability estimates for bone mineral density (BMD), the most 
widely used parameter for osteoporosis, range between 50 and 85% 9. The age-adjusted 
heritability of osteoporotic fractures is smaller (between 25 and 50%) and may be in-
dependent to that of BMD 10, possibly due to other important factors associated with 
fractures such as falls. 
Sex Differences
Although the importance of sex as a key determinant in health and illness has been 
recognized for a long time 11, systematic studies of sex-differences in medicine are still 
rare. There is a well known sexual dimorphism in human body composition with adult 
males having greater body height, total lean mass and bone mineral density, and a lower 
fat mass than females 12. Moreover, there are differences in fat distribution with males 
showing more upper body or so-called “android” or “central abdominal” distribution of 
adipose tissue and females a more peripheral or “gynoid” distribution with bigger hips 
and thighs.
Specific fat depots may confer differential metabolic risk. In particular, central abdomi-
nal fat may be more strongly associated with the development of metabolic risk factors 
and cardiovascular disease as compared with lower body subcutaneous fat 13-15. Evidence 
12 Chapter 1
for sex-specific genetic effects on body composition, however, is scarce since few stud-
ies have systematically investigated potential sex-differences in the genetic architecture 
of body composition. This knowledge is important for the design of genetic studies 
and also for studies on the relationship of body composition with common diseases 
like cardiovascular disease and type 2 diabetes. Although the vast majority of studies 
on osteoporosis have been performed in women, sex differences are well known for 
example in disease prevalence and patterns of risk factors 16, while sex-specific genetic 
effects have been reported for BMD 17. 
Relationship between obesity and osteoporosis
The incidence of both obesity and osteoporosis increases with age but, paradoxically 
we, obesity appears to protect from osteoporosis. There is a clear positive association 
between body weight and body mass index (BMI) with bone mineral density (BMD) 
as well as increased fracture risk with low BMI. 1, 2, 18. Possible explanations for higher 
BMD in heavier people include the well known mechanical loading influence on bone 
health, i.e., the weight-bearing effect of both fat and lean mass, while lean mass is also 
thought to influence bone through muscle mediated effects of physical exercise. Body 
composition may also influence bone health through other physiological processes. For 
example, adipose tissue may influence BMD through the production of hormones and 
adipokines by adipocytes. There is ongoing controversy about the relative importance 
of the fat and lean components of the body to BMD 18, 19. In postmenopausal women fat 
mass has been shown most consistently to be positively related to BMD, possibly medi-
ated by higher estrogen levels, which are normally very low after menopause. However, 
several discrepancies can be found in the literature, e.g., fat mass being important in 
young but not in old women and in old but not in young men 20. Some researchers even 
claim the existence of a detrimental effect of body fat on bone 21, 22. 
The effect of fat distribution on BMD is far from clear. Studies on the relationship be-
tween body fat distribution and BMD have yielded conflicting results, probably because 
most of them included a small number of subjects and/or were not population based 
and used different techniques for measurement of BMD and fat distribution. Also, the 
effect of adiposity on the relationship between fat distribution and BMD was not always 
considered as a confounder, potentially leading to an overestimation of the effect of 
abdominal fat distribution on BMD.
Environmental influences
Important environmental (lifestyle) factors contributing to the development of obesity 
are excessive caloric intake and low physical activity. Interestingly, diet and physical 
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activity are also related to osteoporosis. Other lifestyle factors, such as a decreased 
exposure to sunlight (to ensure adequate production of vitamin D) and excessive use of 
cigarettes, alcohol and caffeine, can negatively influence BMD. Dietary factors that have 
been favourably associated with osteoporosis are the intake of calcium and vitamin D, 
but other nutrients may also play a role. These include the amount and type of proteins 
and the acid/base balance of the diet 23 and potentially the intake of boron, silicium and 
vitamin K, although hard evidence for the role of these nutrients is lacking 24. Recently, 
mildly elevated homocysteine concentrations were identified as a novel and potentially 
modifiable risk factor for age-related osteoporotic fractures, independent of BMD 25, 26. 
Homocysteine levels are influenced by nutritional factors, in particular by dietary intake 
of the B vitamins folate, riboflavin, pyridoxine and cobalamin, which serve as co-factors 
or substrates for the enzymes involved in the homocysteine metabolism. It is not known 
whether these B vitamins can lower the risk of osteoporotic fractures by decreasing 
homocysteine levels. 
Genetic studies
Despite the high heritability of body mass index and bone mineral density, knowledge 
on the genetic background of obesity and osteoporosis is still very limited. Several 
approaches are used to find genes that are associated with common disease or traits 
including genome-wide linkage analysis, candidate genes analysis and genome-wide 
association studies (GWAS). The purpose of these genetic studies is providing new 
routes to understanding the aetiology of disease, as well as identifying tools for better 
disease prediction, prevention and treatment. 
Genome-wide linkage analysis examines the whole genome in a hypothesis-free 
approach with a limited number (usually a few hundred) of genetic markers in populations 
of related individuals to identify an approximate chromosomal location of genetic 
variation related to a disease or trait. This technique has been very successful at the 
identification of the genetic variation underlying single-gene (monogenic/Mendelian) 
disorders but much less successful for common human diseases or traits. Monogenic 
disorders leading to early, severe, obesity affect the central regulation of appetite. These 
conditions are rare, except for mutations in the melanocortin 4 receptor (MC4R) that 
account for about 5% of morbidly obese patients (BMI > 40 kg/m2)27. Monogenetic 
conditions with abnormal low BMD (e.g., osteogenesis imperfecta, osteoporosis 
pseudoglioma symdrome) or high BMD (e.g., pycnodysostosis, sclerosteosis and Van 
Buchem’s disease) have led to the identifications of genes related to collagen production 
(e.g. collagen type 1A1 (COL1A1)), low-density lipoprotein receptor-related protein 5 
(LRP5), cathepsin K and the sclerosteosis (SOST) gene28-30. Such genetic discoveries have 
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attracted commercial interest and resulted in the development of new medication for 
osteoporosis, currently being tested in clinical trials. 
In the candidate gene approach a particular known gene of interest (e.g., based on 
predicted function) is assessed in a case control or population-based setting for associa-
tion of one or more genetic variants in the gene with the trait or disease of interest. Many 
genes with plausible candidacy have been associated with measures of obesity and 
osteoporosis. The 2005 Human Obesity Gene Map update reports over 1.100 studies, 
including 550 genes, markers and chromosomal regions apparently linked to or associ-
ated with obesity phenotypes 27. However, only very few of these associations have been 
replicated in independent large-scale studies. The same holds for osteoporosis, where 
many candidate gene association studies have been underpowered 31. Since the launch 
of the Genetic Markers for Osteoporosis (GENOMOS) consortium in 2003, systematic 
replication has been performed in 18,000 - 45,000 subjects of several candidate genes 
including estrogen receptor alpha (ESR1) 32, collagen type 1A1 (COL1A1) 33, vitamin D 
receptor (VDR) 34, transforming growth factor beta 1 (TGFB1) 35 and low-density lipopro-
tein receptor-related protein 5 and 6 (LRP5 and LRP6) 36. These studies have convincingly 
established the association of ESR1 with fractures and of LRP5 with BMD and fractures.
Genome-wide association studies have only recently been introduced to the field of 
genetic epidemiology research, owing to developments like the completion of the refer-
ence sequence of the human genome 37 and the International HapMap 38. Combined 
with recent advances in micro-array genotyping technology these developments have 
facilitated the large-scale assessment of common genetic variation in thousands of 
individuals 39. During the past 2 years, more than 200 GWA studies have reproducibly 
described over 300 common genetic variants associated with common diseases and 
traits, albeit each explaining only a small fraction of the genetic variation40, 41.
SIRT1 as an example of the candidate gene approach
An intriguing new candidate gene for metabolic diseases and survival is SIRT1, a con-
served protein that belongs to the group of NAD+-dependent histone deacetylases 
named Sirtuins, which are related to longevity in lower organisms like yeast, flies, and 
worms 42, 43. SIRT1 has also been implicated in life span extension during caloric restric-
tion in model organisms 44-46. Dietary restriction is one of the most robust methods for 
extending lifespan and delaying age-related disease among various species, including 
yeast, flies and rodents and potentially non-human primates 47, 48. SIRT1 protects cells 
against oxidative stress and ageing and it also has an important function in endocrine 
signalling, specifically in glucose and fat metabolism 49-53. It interacts with peroxisome 
proliferator-activated receptor-gamma (PPARγ) to repress its transcriptional activity, 
leading to inhibition of adipogenesis during fasting and activation of lipolysis 49. Treat-
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ment of mice with resveratrol, a naturally occurring SIRT1 agonist present in red wine 
and grapes, was recently shown to prevent diet-induced obesity and insulin resistance 
and increase their survival 54, 55. SIRT1 is thus a strong candidate gene for obesity as 
well as for survival. Its activity may be modulated by dietary factors such as precursors 
for NAD+, i.e., dietary niacin (vitamin B3) intake and nicotinamide riboside which was 
recently discovered as a SIRT stimulator present in milk 56. But also antioxidant vitamins 
and caloric intake might in theory modify SIRT1 expression or activity and thus interact 
with genetic variations in SIRT1. These potential interactions have not been studied in 
humans so far.
OuTlIne Of The TheSIS
In this thesis, epidemiological, genetic and nutritional studies are presented on the 
metabolic diseases obesity and osteoporosis, and on survival. In a family-based study, 
the heritability of body composition is estimated as well as the existence of sex-specific 
genetic effects. Then, studies are presented estimating the relationship body fat distri-
bution and bone mineral density and between the intake of dietary B vitamins and bone 
mineral density and fractures. As an example of the candidate gene approach, studies 
are reported investigating the SIRT1 gene in relation to obesity and survival and in inter-
action with diet. Last, genetic studies on obesity and osteoporosis are presented using 
the newest technique in gene finding, i.e., genome-wide association. In the general 
discussion the findings are placed into perspective and suggestions for future research 
are given. The thesis ends with a summary and conclusions. 
Chapter 2 addresses the sex-specific heritability of various body composition pa-
rameters estimated by anthropometry and total body DXA in the Erasmus Rucphen 
Family (ERF) study. Based on the well-known sexual dimorphism in body composition it 
is hypothesized that there may be sex-specific genetic effects influencing these traits. A 
statistical tool is used, called variance decomposition procedures, to partition variation 
of body composition into genetic and environmental components common to both 
sexes and to men and women separately and the correlation is calculated between 
genetic components in men and women. 
Chapter 3 presents the results of our study on the association between bone mineral 
density (BMD) and various measures of body fat distribution obtained by anthropom-
etry and total body DXA in the ERF study. We also report whether body mass index (BMI) 
and serum insulin and adiponectin levels influence the relation between fat distribution 
and BMD. 
Chapter 4 shows the relation between the intake of dietary homocysteine-related B 
vitamins (riboflavin, pyridoxine, folate and cobalamin) and BMD and the risk of fracture 
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in 5,304 elderly individuals from the large population-based cohort of the Rotterdam 
study. It is of clinical relevance to know if the intake of B vitamins associated with ho-
mocysteine levels can explain the relationship of homocysteine levels with fractures, 
because supplementing B vitamins in the elderly could be a low cost and probably safe 
measure to prevent osteoporotic fractures. 
Chapter 5 describes the results of the analysis on the association between SIRT1 
genetic variation and BMI, the risk of obesity and longitudinal weight change in elderly 
subjects from the Rotterdam study and in subjects from the ERF study. 
Chapter 6 presents the results of the study on the association of SIRT1 genetic 
variation with mortality in elderly subjects from the Rotterdam study and additionally 
in subjects with increased oxidative stress (type 2 diabetes and smokers), where SIRT1 
might be very important to protect cells against oxidative stress. In addition, we studied 
the interaction between SIRT1 genetic variants and dietary intake of niacin (vitamin B3), 
a precursor for NAD+ that SIRT1 needs. 
Chapter 7 addresses a potential gene-diet interaction on BMI at the SIRT1 locus in 
subjects from the Rotterdam study. Specifically, an interaction is investigated with 
dietary intake of energy, fat, calcium, milk, antioxidant vitamins (betacarotene, vitamin 
C and E) and niacin. Data in the subjects from the ERF study is used for replication of 
findings with milk intake. 
Chapter 8 describes the results of a study using genome-wide association (GWA) to 
identify novel common variants influencing BMI and central abdominal fat as reflected 
in waist circumference (WC). GWA data on BMI and WC are meta-analysed in 31,373 in-
dividuals of Caucasian descent from eight population-based studies within the Cohorts 
for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium. 
Chapter 9 reports a meta-analysis of GWA data on the lumbar spine and femoral neck 
BMD in 19,195 Caucasian subjects from five studies, within the setting of the GEnetic 
Factors of OSteoporosis (GEFOS) consortium with the purpose to identify novel loci 
influencing BMD. 
Chapter 10 contains a general discussion and presents future perspectives
Chapter 11 concludes with a summary and conclusions of the thesis.
Chapter 12 presents the summary and conclusions in Dutch
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AbSTrACT 
background Despite well-known sex differences in body composition it is not known 
whether sex-specific genetic or environmental effects contribute to these differences. 
Methods We assessed body composition in 2,506 subjects from a young Dutch genetic 
isolate participating in the Erasmus Rucphen Family study by dual-energy X-ray absorp-
tiometry and anthropometry. We used variance decomposition procedures to partition 
variation of body composition into genetic and environmental components common to 
both sexes and to men and women separately and calculated the correlation between 
genetic components in men and women. 
results After accounting for age, sex and inbreeding, heritability ranged from 0.39 for 
fat mass index to 0.84 for height. We found sex-specific genetic effects for fat percent-
age (fat%), lean mass, lean mass index (LMI), and fat distribution, but not for BMI and 
height. Genetic correlations between sexes were significantly different from 1 for fat%, 
lean mass, LMI, android fat, android:gynoid fat ratio and waist: hip ratio (WHR), indicat-
ing that there are sex-specific genes contributing to variation of these traits. Genetic 
variance was significantly higher in women for the waist-, hip- and thigh circumference 
and WHR, implying that genes account for more variance of fat distribution in women 
than in men. Environmental variance was significantly higher in men for android:gynoid 
fat ratio.
Conclusions Sex-specific genetic effects underlie sexual dimorphism in several body 
composition traits. The findings are relevant for studies on the relationship of body 
composition with common diseases like cardiovascular disease and type 2 diabetes and 
for genetic association studies.
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AbbrevIATIOnS  
h2  heritability
ρG genetic correlation 
σ  standard deviation 
σE  environmental standard deviation
σEF   environmental standard deviation female
σEM   environmental standard deviation male
σG genetic standard deviation
σGF  genetic standard deviation female
σGM   genetic standard deviation male
σ 2E  environmental variance 
σ 2EF   environmental variance female
σ 2EM   environmental variance male
σ 2G  genetic variance
σ 2GF   genetic variance female
σ 2GM  genetic variance male
DXA  dual-energy x-ray absorptiometry
ERF  Erasmus Rucphen Family study
E × S  environment by sex interaction
fat%  fat percentage
FMI  fat mass index
G × S  genotype by sex interaction
LMI  lean mass index
WHR  waist:hip ratio
WTR  waist:thigh ratio 
InTrODuCTIOn
Obesity has become a global epidemic and represents an important risk factor for type 
2 diabetes mellitus, hypertension, cardiovascular disease, stroke, some types of cancer 
and disability. Although the growing prevalence of obesity is most probably caused by 
increasing energy intake and decreasing energy expenditure by physical activity, indi-
vidual susceptibility varies widely and is strongly influenced by genetic factors. Twin, 
adoption and family studies have shown that between 40% – 80% of inter-individual 
variation of BMI is heritable 1-3. There are also significant genetic influences on obesity-
related traits like total body fat mass, lean mass and measures of fat distribution 4-8, but 
the heritability of these variables is less clear than that of BMI. 
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Although the importance of sex as a key determinant in health and illness has been 
recognized for a long time 9, systematic studies of sex differences in medicine are still 
lacking. There is a well-known sexual dimorphism in human body composition with 
adult men having greater body height, total lean mass and bone mineral mass, and a 
lower fat mass than women 10. Moreover, there are differences in fat distribution with 
men showing more upper body or so-called “android” distribution of adipose tissue and 
women a more peripheral or “gynoid” distribution with bigger hips and thighs. 
Given the large genetic effects on body composition, it is possible that different 
(although partly overlapping) genes contribute to variation in body composition in 
men and women and/or that the genetic determinants of body composition may be 
modulated by sex-specific hormonal, environmental, and nutritional factors. Despite 
its genetic determination, sex can also be considered an environmental factor that can 
modify both the penetrance and expressivity of a wide variety of traits 11, 12. Evidence 
for sex-specific genetic effects (or a genotype by sex interaction) on body composition, 
however, is scarce since few studies have systematically investigated potential sex-
differences in the genetic architecture of body composition. Studies on sex differences 
in heritability of BMI have shown inconsistent results. Some studies found evidence for a 
higher heritability of BMI in women than in men 2, 3, 12-14 or the other way around 15-17 or no 
difference 18, 19. In the Diabetes Heart Study 7, heritability estimates were larger in women 
for BMI and lean mass but not for fat percentage (fat %) assessed by dual-energy x-ray 
absorptiometry (DXA). However, these differences were considered not significant con-
sidering the large standard errors. Sex-specific differences in heritability can be caused 
by differences in additive genetic variance, non-genetic (environmental) variance or 
total phenotypic variance. Using variance decomposition procedures, also known as 
variance components analysis, variation in traits can be partitioned into genetic and 
environmental components and genetic correlations can be calculated between men 
and women. Using this procedure, Comuzzie et al 20 found evidence for genotype by sex 
interaction for several anthropometric variables in Mexican Americans, but no data were 
available in this study on fat and lean mass. 
The aim of the present study was to determine heritability of a large set of body com-
position variables determined by DXA and anthropometry in a large extended pedigree 
from a genetically isolated population in the Netherlands and to explore potential 
sex-specific differences in the relative influence of genetic and environmental factors 
on body composition. Specifically, we considered the following questions: (1) are there 
different genes that contribute to the variation of body composition in men and women 
(i.e. are there qualitative sex differences) and (2) is the magnitude of the genetic and/or 
environmental variation larger in one sex than in the other (i.e. are there quantitative sex 
differences in genetic and/or environmental variances)? 
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MeThODS
Study population
This study was carried out within the Erasmus Rucphen Family (ERF) study, a family-
based cohort study that is embedded in the Genetic Research in Isolated Populations 
(GRIP) program in the South West of the Netherlands. The aim of this program is to 
identify genetic risk factors in the development of complex disorders 21-23. Genealogical 
records demonstrated that almost all of the inhabitants of this isolated population could 
be traced back to about 150 individuals who founded this community around 1750. The 
population is characterized by minimal immigration up until the last few decades. About 
20,000 inhabitants are now scattered over eight adjacent villages. Genealogical informa-
tion on this population was reconstructed using church and municipality records and 
is currently available in the form of a large database including over 63,000 individuals 
records. 
For the ERF study, 22 families that had at least five children baptised in the community 
church between 1850 and 1900 were identified with the help of genealogical records. 
All living descendants of these couples and their spouses were invited to take part in 
the study. Data collection started in June 2002 and was finished in February 2005. In 
this study, we focused on the 2,506 participants for whom complete phenotypic and 
genealogical information was available. PEDSTATS 24 was used to produce summary 
statistics of the pedigree and correlations of the variables by pair type. 
The Medical Ethics Committee of Erasmus Medical Center Rotterdam approved the 
study. Written informed consent was obtained from all participants. 
Data collection
At the research center, located within the community, extensive clinical examinations 
were performed, including the collection of fasting blood samples, anthropometric 
measurements, and personal interviews. A research physician obtained information on 
medical history, medication use, smoking and alcohol use in a personal interview.
Anthropometric measurements
Height and weight were measured with the participant dressed in light underclothing. 
BMI was calculated from these data as weight (kg)/ height2 (m2). Circumferences of the 
waist, hip and thigh were measured on uncovered skin using a tape measure with the 
participant in the upright position. Waist circumference was measured halfway between 
the rib cage and the pelvic bone. Hip circumference was measured at the maximal 
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circumference of the hips. Thigh circumference was measured mid-way between the 
upper border of the patella and the inguinal fold on the right leg. The waist:hip ratio 
(WHR) and waist:thigh ratio (WTR) were calculated from these measurements. Figure 1a 
shows the sites of circumference measurements.
Dual-energy x-ray absorptiometry (DXA) measurements
DXA scans were performed using a Prodigy total-body fan-beam densitometer and 
analyzed with the encore 2005 software v.9.3 (DPX; Luna, Madison, WI, USA). Total body 
scans were auto-analyzed with this software, in which an algorithm that divides body 
measurements into areas corresponding to head, trunk, arms and legs is implemented. 
Total body fat mass (g), lean mass (g), and regional fat mass were obtained from total 
body scans. The trunk region was limited by an upper horizontal border below the chin 
(neck cut), vertical borders lateral to the ribs, and a lower border by the iliac crest. The 
arm region was limited by cuts that cross the arm sockets, as close to the body as pos-
sible and separate the arms and hands from the body. The leg region is limited above 
by the oblique lines passing through the hip joint, and cuts that separate the hands 
and forearms from the legs and a center leg cut which separates the right and left leg. 
Two additional regions were defined using the software provided by the manufacturer; 
the so-called “android” and “gynoid” region. The “android” region has a lower boundary 
at the pelvis cut and the upper boundary above the pelvis cut by 20% of the distance 
between the pelvis and neck cuts. The lateral boundaries are the arm cuts. The “gynoid 
region” has an upper boundary between the upper part of the greater trochanters 
and a lower boundary defined at a distance equal to twice the height of the “android 
region”. The lateral boundaries are the outer leg cuts. The android and gynoid fat mass 
and android:gynoid fat ratio were calculated from these measurements. A schematic 
representation of the android and gynoid region is shown in Figure 1b. All analyzes were 
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(a) The sites of the circumference measurements. 
(b) The regions of  “android” and “gynoid”  fat assessed by DXA.
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Sex-specific genetic effects and body composition 27
verified by a trained technician who performed adjustments when necessary. Daily 
quality-assurance tests were performed with a calibration block supplied by the manu-
facturer. Repeated measurements on the calibration block had coefficients of variation 
less than 1%. 
Definitions
Body weight = total fat mass + total lean mass + bone mineral content. Body mass index 
(BMI) = body weight (kg)/ height2 (m2). Fat mass index (FMI) = total fat mass (kg)/ height2 
(m2). Lean mass index= total lean mass (kg)/ height2 (m2). Total body fat percentage 
(fat%): (total fat mass / body weight) x 100.
Statistical analysis
Baseline characteristics for men and women were compared using Mann-Whitney U test 
in SPSS for Windows, version 11.0. Inbreeding coefficients were computed with PEDIG 
software 25, using all the available genealogical information. Spearman correlations 
between inbreeding values and the body composition phenotypes were calculated 
using SPSS. General linear models were used to test phenotypic association between 
various body composition variables. In order to satisfy distributional assumptions, the 
phenotype distributions were normalized by natural log or square root transformation 
to ensure normally distributed residuals. A full pedigree-variance components approach 
based on maximum likelihood methods as implemented in the SOLAR 2.1.2 (Sequential 
Oligogenic Linkage Analysis Routines) software package was used to estimate the 
heritability of body composition variables 26. Univariate quantitative genetic analysis 
was performed to partition the phenotypic variance of body composition variables into 
additive genetic and environmental variance components using maximum likelihood 
variance decomposition methods 27, 28.
The phenotypic variance of the body composition variables, which reflects the inter-
individual variation, was partitioned into its additive genetic (σ2G) and residual envi-
ronmental (σ2E) variance components 29. Heritability was estimated as the ratio of the 
additive genetic variance to the sum of the additive genetic and environmental variance, 
that is including sources of residual variance as measurement error: h2 = Additive σ2G / 
(σ2G + σ2E). Dominance variance, which, in conjunction with additive and environmental 
variance, comprises broad sense heritability, was not estimated. Dominance effects are 
more easily modeled in twin than in family studies but they are difficult to model in 
extended pedigrees. Similar to the assumptions made in current genome-wide associa-
tion studies, we assumed additive effects. 
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To evaluate sex-specific effects on the variation of body composition variables we 
used a standard sex-limitation modeling approach that allows testing for specific pat-
terns of interaction, such as genotype by sex interaction (G x S) 20, 30-32. The test for G x 
S interactions is based on hypotheses concerning the nature of the variance–covari-
ance relationship of a trait between male–female relative pairs The expected genetic 
covariance (or shared heritability) between a male and female relative pair is defined as 
covariance (GM, GF) = 2f ρG(M,F) σGM σGF where f is the coefficient of kinship between the 
two individuals, ρG(M,F) the genetic correlation between the expressions of the trait in the 
two sexes, and σGM and σGF the genetic SDs for men and women. 
In the absence of a G x S interaction (i.e., the null hypothesis), the genetic correlation 
between male and female relative pairs should be 1 (ρG(M,F) = 1.0) and male and female 
genetic SDs will be equivalent (σGM = σGF ). Conversely, if there is G x S interaction, the 
genetic correlation between the sexes, ρG(M,F) will be significantly <1.0 (implying quali-
tative sex differences) and/or the genetic SDs will be significantly different between 
the sexes (σGM ≠ σGF), implying quantitative sex differences in the genetic variance. 
Additionally, environment by sex interactions (E x S), or quantitative differences in the 
environmental variance, would be indicated by the environmental SDs not being equal 
between the sexes (σEM ≠ σEF ). 
To evaluate G x S interactions influencing body composition traits, a full model was fit-
ted in which ρG, σGM, σGF, σEM and σEF variables were freely estimated using maximum-
likelihood methods. In addition, we fitted three nested models, in which one of these 
variables was constrained, as follows: model 1, in which the genetic correlation between 
men and women was constrained to one (ρG= 1); model 2 in which genetic SDs were 
constrained to be equal (σGM = σGF); and model 3, in which environmental SDs were con-
strained to be equal (σEM = σEF). Likelihood ratio tests (LRT) were used to test whether 
the nested models fit the data significantly worse than the full model. The LRT statistic 
follows an asymptotic X2 distribution with 1 df when comparing the full model with the 
nested models, in which the SDs were constrained to be equal (full model against model 
2; and full model against model 3). However, in the case of the model that restricted the 
genetic correlation to 1, this assumption does not hold since the genetic correlation was 
constrained to the upper boundary of the parameter space (ρG=1). As a result of this 
constraint, the test statistic is not distributed as an asymptotic χ1
2 distribution, but rather 
as a 1/2:1/2 mixture of a χ1
2 distribution and a point mass at zero 31-33.
Three basic inferences concerning the nature of sex-based interactions can be made. 
(1) rejection of the model constraining the genetic correlation between the groups to 1 
(ρG(M,F)= 1.0) implies that different genes or a different subset of genes contribute to the 
variance in body composition variables in men and women; (2) rejection of the model 
constraining the genetic SDs of the groups to be equal (σGM = σGF ) implies that the 
magnitude of the genetic effect is different between the two sexes; and (3) rejection of 
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the model constraining the environmental SDs of the groups to be equal (σEM = σEF ) 
implies an interaction between the residual environment and the sex.
All analyses were adjusted for age and inbreeding quartiles (given that the distribution 
of inbreeding coefficients was not normally distributed) and for sex when heritability 
was estimated for both men and women.
reSulTS
Table 1 shows the number of pairs of relatives present in the large pedigree. The aver-
age number of generations in the pedigree used for analysis was 5.6 (range 4 - 7) and the 
average family size was 113.9 (range 34 - 268). The average number of women per family 
was 63.9 (range 18 - 145) and of men 50.1 (range 13 - 123). 
Table 2 shows the general characteristics of the study population. As expected men had 
significantly increased body height, weight, lean mass and LMI, while body fat (total fat, 
FMI and fat%) was lower than in women. Android fat was significantly higher in men 
while gynoid fat was higher in women. Thus, the android:gynoid fat ratio was higher in 
men as well as the WHR.
The median inbreeding coefficient (interquartile range) was 0.002 (0.008). Inbreeding 
was significantly correlated with some traits, namely: height (Spearman r = - 0.163, p< 0.01), 
weight (r = - 0.082, p< 0.01), fat mass (r = - 0.043, p< 0.05), lean mass (r = - 0.076, p< 0.01), 
Table 1. Number of relative pairs within the pedigree of the ERF study population 
        Pairs
 
Total Phenotyped 
subset
Female-Female Male-Male Opposite sex
Pedigree members 4,283 2,506
Number of families 22 22
Founders 1,389 479
Non-founders 2.894 2,027
Relative pairs
Sib-pairs 3,436 1,454 459 285 710
Half-Sibs 101 53 19 8 26
Cousins 13,614 5,906 1,782 1,201 2,923
Parent-Child 5,788 1,560 508 303 749
Grandparent-Grandchild 5,556 156 61 23 72
Avuncular 10,741 2,851 883 611 1,357
Number of relative pairs in column 3, 4 and 5 denotes the number for which phenotypic information is available 
for both members of the pairs
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gynoid fat mass (r = - 0.042, p< 0.01) and thigh circumference (r = - 0.037, p< 0.05), 
but not with BMI, FMI, fat %, LMI , android fat mass, android:gynoid ratio, waist and hip 
circumference, WHR and WTR. 
Table 3 shows the genetic, residual environmental variance and heritability estimates 
for men and women combined after accounting for age, sex and inbreeding. Heritability 
estimates ranged from 0.39 for FMI to 0.84 for body height. The heritability estimate 
for body weight (0.52) was higher than that for BMI (0.44) possibly because weight 
is related strongly to the highly heritable trait body height while BMI is corrected for 
height. A similar trend was seen was for the heritability estimate of fat mass (0.46) versus 
FMI (0.39) and lean mass (0.57) versus LMI (0.45). Heritability estimates of circumfer-
ence measurements were between 0.40 (for waist) and 0.48 (for thigh). The heritability 
estimates of the circumference ratio’s WHR and WTR were 0.40 and similar to the fat 
distribution variable estimated by DXA in the form of the android:gynoid fat ratio (0.43).
Correlations for each trait by pair type can be found in the Electronic supplementary 
material (ESM) Table 1 (www.springerlink.com/content/xn6293535815362t).
Table 2. General characteristics of the ERF study population 
  Women Men        p 
Number 1,405 1,101
Age (years) 47.5 ± 14.5 48.2 ± 14.2     < 0.01
Height (m) 1.62 ± 0.06 1.75 ± 0.07     < 0.01
Weight (kg) 69.3 ± 13.2 83.2 ± 13.9     < 0.01
Body mass index (kg/m2) 26.4 ± 4.9 27.3 ± 4.2     < 0.01
Total fat mass (kg) 26.5 ± 9.8 22.3 ± 8.9     < 0.01
Fat mass index (kg/m2) 10.1 ± 3.7 7.3 ± 2.9     < 0.01
Fat percentage (%) 37.4 ± 7.5 26.0 ± 7.0     < 0.01
Total lean mass (kg) 39.9 ± 4.9 57.9 ± 7.0     < 0.01
Lean mass index (kg/m2) 15.2 ± 1.7 19.0 ± 1.9     < 0.01
Android fat mass (kg) 2.34 ± 1.2 2.57 ± 1.2     < 0.01
Gynoid fat mass (kg) 5.09 ± 1.54 3.61 ± 1.3     < 0.01
Android:Gynoid fat ratio 0.45 ± 0.15 0.71 ± 0.20     < 0.01
Waist circumference (cm) 81.5 ± 12.2 93.7 ± 11.7     < 0.01
Hip circumference (cm) 101.3 ± 9.3 99.3 ± 7.3     < 0.01
Thigh circumference (cm) 39.1 ± 1.04 39.3 ± 0.96     < 0.01
Waist:hip ratio 0.80 ± 0.08 0.94 ± 0.08     < 0.01
Waist:thigh ratio 1.63 ± 0.20 1.85 ± 0.20     < 0.01
Values are presented as percentage or mean ± SD
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Tables 4 and 5 show the results of the sex-specific genetic analyses on the variation of 
the body composition traits, including the heritability estimates for women and men 
separately with the sex-specific estimates of genetic and environmental variances (σ2) 
and the correlation between genetic components of body composition variables in men 
and women (ρG). We found evidence for sex-specific genetic effects for all traits except for 
height, BMI, gynoid fat mass and the WTR, while for body weight and fat mass and FMI this 
evidence was borderline significant (p=0.06) (Table 5). The genetic correlations between 
men and women were significantly different from 1 for fat%, lean mass, LMI, android fat, 
android:gynoid fat ratio and WHR (Table 5). This indicates that different genes or a differ-
ent subset of genes contribute to the variance of these body composition variables in 
men and women. The genetic variance was significantly higher in women than in men for 
the waist, hip and thigh circumference and for WHR (Tables 4 and 5). For the WHR, the ge-
netic correlation was, in addition, significantly different from 1. This indicates that for the 
circumference measurements we found no evidence that different genes contribute to 
variation in these body composition variables but these same genes account for a larger 
magnitude of the genetic effect in women than in men. Evidence for an E x S interaction 
was found only for the android:gynoid fat ratio, with men showing significantly greater 
environmental variance for this trait than women (p< 0.01). For lean mass, total fat mass 
and gynoid fat mass differences were of borderline significance (p=0.05–0.07).
Table 3. Heritability estimates and variance components of the body composition parameters in 2,506 
male and female ERF participants  
σ2G σ2E h2
Height (m) 28.44 (1.78) 5.56 (0.98) 0.84
Weight (kg) 1.56 (0.15) 1.44 (0.12) 0.52
Body mass index (kg/m2) 8.59 (1.01) 11.11 (0.95) 0.44
Total fat mass (kg) 0.40 (0.04) 0.47 (0.04) 0.46
Fat mass index (kg/m2) 5.96 (0.73) 9.43 (0.70) 0.39
Total fat mass (%) 21.33 (2.41) 29.13 (2.12) 0.42
Lean mass (kg) 9.35 (0.86) 7.01 (0.63) 0.57
Lean mass index (kg/m2) 1.82 (0.21) 2.25 (0.19) 0.45
Android fat mass (kg) 5.65 (0.63) 7.44 (0.55) 0.43
Gynoid fat mass (kg) 5.29 (0.54) 5.58 (0.44) 0.49
Android:gynoid fat ratio 0.95 (0.11) 1.24 (0.09) 0.43
Waist circumference (cm) 0.64 (0.08) 0.95 (0.07) 0.40
Hip circumference (cm) 0.30 (0.03) 0.36 (0.03) 0.46
Thigh circumference (cm) 0.46 (0.05) 0.51 (0.04) 0.48
Waist:hip ratio 1.20 (0.14) 1.77 (0.12) 0.40
Waist:thigh ratio 0.32 (0.04) 0.46 (0.03) 0.40
Estimates were adjusted for sex, age and inbreeding. Values are presented as variance (SE)
σ2G: genetic variance; σ2E: environmental variance; h2: additive heritability
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DISCuSSIOn
In this study we found evidence for a difference in genetic background between men and 
women for most of the body composition variables studied, namely for fat%, lean mass, 
LMI, and for measures of fat distribution by circumferences and by DXA. Specifically, 
the magnitude of the genetic correlations was significantly different from 1 for fat%, 
lean mass, LMI, android fat, android:gynoid fat ratio and WHR, indicating that different 
genes or different, although partly overlapping, subsets of genes contribute to variation 
of these traits in men and women. Furthermore, genetic variance was almost twice as 
large in women as in men for all circumferences and for WHR, suggesting that genetic 
determinants of fat distribution account for more variance in women. For height, BMI, 
gynoid fat mass and the WTR differences between the sexes were not significant while 
for weight, fat mass and FMI they were borderline significant. Evidence for sex-specific 
environment effects was only found for the android:gynoid fat ratio, with men showing 
significantly greater environmental variance than women, with borderline significant 
differences for lean mass, total fat mass and gynoid fat mass. 
Table 4. Sex-specific variance components for the body composition parameters in 2506 ERF participants 
  Women   Men  
  σ2G σ2E h2   σ2G σ2E h2 ρ G
Height (m) 1.08 (0.09) 0.18 (0.06) 0.86   1.29 (0.12) 0.21 (0.08) 0.86 0.96 (0.05)
Weight (kg) 1.92 (0.24) 1.35 (0.19) 0.59 1.31 (0.23) 1.31 (0.20) 0.50 0.89 (0.10)
BMI (kg/m2) 10.44 (1.58) 11.38 (1.42) 0.48   7.43 (1.46) 9.38 (1.35) 0.44 0.86 (0.12)
Total fat mass (kg) 0.48 (0.06) 0.36 (0.05) 0.57   0.38 (0.08) 0.51 (0.07) 0.43 0.82 (0.11)
FMI (kg/m2) 15.81 (2.26) 14.86 (1.93) 0.52   11.40 (2.32) 16.5 (2.15) 0.41 0.81 (0.12)
Total fat mass (%) 28.33 (4.02) 24.42 (3.36) 0.54   19.79 (3.90) 27.7 (3.61) 0.42 0.74 (0.12)
Lean mass (kg) 0.09 (0.01) 0.05 (0.01) 0.64   0.12 (0.02) 0.08 (0.01) 0.59 0.84 (0.09)
LMI (kg/m2) 1.79 (0.27) 1.82 (0.23) 0.50   2.47 (0.43) 2.17 (0.37) 0.53 0.74 (0.12)
Android fat mass (kg) 0.07 (0.01) 0.06 (0.01) 0.54   0.06 (0.01) 0.07 (0.01) 0.43 0.75 (0.12)
Gynoid fat mass (kg) 0.06 (0.01) 0.04 (0.01) 0.59   0.05 (0.01) 0.06 (0.01) 0.44 0.87 (0.11)
Android:gynoid fat 
ratio 1.07 (0.14) 0.72 (0.11) 0.60   1.34 (0.23) 1.36 (0.20) 0.50 0.57 (0.11)
Waist circ. (cm) 0.90 (0.13) 0.89 (0.11) 0.50   0.50 (0.11) 0.83 (0.11) 0.38 0.77 (0.14)
Hip circ. (cm) 0.42 (0.06) 0.35 (0.05) 0.55   0.22 (0.04) 0.29 (0.04) 0.43 0.83 (0.12)
Thigh circ. (cm) 0.62 (0.08) 0.45 (0.06) 0.58   0.32 (0.07) 0.53 (0.06) 0.38 0.95 (0.12)
Waist:hip ratio 1.73 (0.26) 1.81 (0.22) 0.49   0.93 (0.21) 1.30 (0.19) 0.42 0.73 (0.13)
Waist:thigh ratio 2.63 (0.50) 5.19 (0.48) 0.34   2.02 (0.60) 4.98 (0.59) 0.29 0.77 (0.17)
Estimates were adjusted for age and inbreeding. Values are presented as variance (SE) 
σ2G : genetic variance; σ2E: environmental variance; h2:  additive heritability; ρ G : genetic correlation between 
women and men
BMI: body mass index; FMI: fat mass index; LMI: lean mass index
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The finding of small but significantly negative correlations between inbreeding and 
some of the traits, especially height, could point towards recessive alleles.
Our results of no sex-specific genetic effects for BMI are in agreement with some fam-
ily studies 18, 19, but they are in contrast with twin studies that found higher 2, 3, 13, 14, or 
lower 15-17 heritability estimates in women than in men. Schousboe et al. 6 found slight 
differences between women and men in the extent of additive genetic and common 
environmental influences on BMI, anthropometric measures of fat distribution and 
fat% and LMI estimated by bioelectrical impedance in twins, but CIs were broad and 
overlapped for most estimates. In the Diabetes Heart Study 7 women appeared to have 
higher heritability of BMI and lean mass by DXA but differences were also not significant 
considering large SEs 
Table 5. Model estimates from sex-specific variance partitioning of body composition parameters in 
2,506 ERF participants   
  ρG = 1 σ2GF = σ
2GM σ
2EF = σ
2EM
Log-
likelihood
Log-
likelihood
χ2
p 
value
Log-
likelihood
χ2
p 
value
Log-
likelihood
χ2
p 
value(Full 
model)
(Nested 
model)
(Nested 
model)
(Nested 
model)
Height (m) -6315.24 -6315.46 0.44 0.25 -6316.44 2.41 0.13 -6315.29 0.11 0.74
Weight (kg) -3399.15 -3399.72 1.15 0.14 -3400.94 3.59 0.06 -3399.15 0.01 0.90
BMI (kg/m2) -5844.98 -5845.61 1.26 0.13 -5846.09 2.20 0.14 -5845.59 1.21 0.27
Total fat mass (kg) -1870.45 -1871.69 2.48 0.06 -1870.93 0.96 0.33 -1872.05 3.21 0.07
FMI (kg/m2) -6300.35 -6301.56 2.42 0.06 -6301.32 1.94 0.16 -6300.51 0.32 0.57
Total fat mass (%) -6981.80 -6983.97 4.35 0.02 -6983.01 2.43 0.12 -6982.02 0.45 0.50
Lean mass (kg) 272.44 270.96 2.96 0.04 271.08 2.73 0.10 270.49 3.90 0.05
LMI (kg/m2) -3834.56 -3837.19 5.27 0.01 -3835.60 2.09 0.15 -3834.92 0.73 0.39
Android fat mass 
(kg)
-5282.68 -5284.87 4.39 0.02 -5283.27 1.19 0.28 -5283.33 1.31 0.25
Gynoid fat mass 
(kg)
-5045.57 -5046.23 1.32 0.13 -5046.25 1.36 0.24 -5047.20 3.27 0.07
Android:gynoid 
fat ratio
-3004.31 -3011.57 14.52 0.00 -3004.83 1.04 0.31 -3008.23 7.83 0.01
Waist circ. (cm) -2639.99 -2641.26 2.55 0.06 -2642.76 5.54 0.02 -2640.05 0.12 0.73
Hip circ. (cm) -1516.06 -1517.09 2.06 0.08 -1520.75 9.38 0.00 -1516.63 1.13 0.29
Thigh circ. (cm) -2004.34 -2004.42 0.14 0.35 -2008.81 8.04 0.00 -2004.79 0.89 0.34
Waist:hip ratio -3405.85 -3407.68 3.65 0.03 -3408.96 6.207 0.01 -3407.40 3.09 0.08
Waist:thigh ratio -4561.15 -4561.96 1.631 0.10 -4561.44 0.59 0.44 -4561.18 0.07 0.79
ρG: genetic correlation between women and men;  BMI: body mass index; FMI: fat mass index; LMI: lean mass 
index
σ2GF: genetic variance females; σ
2GM: genetic variance males; σ
2EF: environmental variance females; σ
2EM: 
environmental variance males
p values based on a 1/2:1/2 mixture of a χ2 (1df ) and a point mass of zero
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Few of these studies used the same method of variance decomposition procedures to 
partition variation in body composition into genetic and environmental effects common 
to both sexes and to men and women separately and/or calculated genetic correlations 
between sexes. Several twin studies used self-reported data on height and body weight, 
potentially influencing outcomes. One study using the same approach as we did found 
evidence for sex-specific genetic effects for several anthropometric variables, including 
skinfold thicknesses, in a pedigree of 409 Mexican-Americans but no data were available 
on fat and lean mass 20. Consistent with our findings, no significant sex-specific effect was 
found for weight and height. Aside from these studies, the issue of sex-specific genetic 
effects on body composition variables has not been formally addressed and especially 
data from lean and fat mass assessed by DXA are lacking. 
The heritability estimates of the body composition variables in our study are well 
within the range of estimates reported in other family studies but are in general lower 
than those reported in twin studies. Possible explanations for higher estimates of herita-
bility in twin than in family studies are increased variation in the apparent environmental 
influences in family studies due to generational differences between parents and their 
offspring as well as age differences between family members. Heritability in twin studies 
can, on the other hand, be inflated if the monozygotic twin pairs have been exposed to 
more similar environment than the dizygotic twin pairs 6. 
Our findings of sex-specific genetic effects on body composition are important for 
several reasons. Both increased adiposity and android fat deposition are associated with 
increased risk of chronic disorders like cardiovascular disease and diabetes. An under-
standing of the genetic architecture of these risk factors and of their sexual dimorphism 
should lead to better insight into the relationship between these factors and complex 
diseases that may differ between sexes. This improved understanding may ultimately 
lead to better risk prediction and risk reduction. Also, in the search for genes that are 
associated with obesity, android fat deposition and muscularity, it is important to take 
into account sex differences by performing sex-stratified analyses. 
There are some limitations to our study. As in many studies on heritability, we have 
not adjusted our analyses for covariates like smoking, diabetes status, dietary intake 
and physical activity. The latter two variables are not available in our study. In the 
Diabetes Heart Study, adjustments for these covariates resulted in only minor changes 
in the heritability estimates of body composition 7. We studied individuals with a wide 
age range, including both pre- and postmenopausal women and we tried to overcome 
this limitation by adjusting all our analyses for age. Insufficient power precluded us to 
study sex-specific differences in different age groups. It is possible that the sex-specific 
effects we found may vary by age since gender differences in body composition are also 
not constant across the age range and most pronounced in adolescence and young 
adulthood 10. Previous studies have examined possible age effects on genetic and en-
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vironmental influences on BMI with unclear and inconsistent results 3, 6, 16. The genetic 
make-up of genetically isolated populations may differ from a general population as 
a result of genetic drift and founder effects. Even though our population is a genetic 
isolate we found no evidence that it deviates much from the general population in its 
genetic composition 23, 34. However, as was pointed out again recently 35, heritability 
estimates are by definition population specific and replication of our findings in other 
populations is necessary. We acknowledge that multiple testing may influence some of 
the significant findings in our study. Corrections (e.g., Bonferroni) would be too strin-
gent since most body composition traits we studied are highly correlated. Considering 
the consistency of the results across sexes, we do not expect multiple testing to play a 
substantial role in the interpretation of our findings. 
Strength of the study is the availability of a large population with extensive informa-
tion on body composition and genealogy and the use of validated formal testing of 
sex-specific effects with variance decomposition procedures. 
In conclusion, we found evidence for sex-specific genetic effects that may underlie sex 
differences in several body composition traits. The findings are relevant for the design 
of genetic association studies like Genome-wide Association and for studies on the 
relationship of body composition and fat distribution with common diseases such as 
cardiovascular disease and type 2 diabetes.
36 Chapter 2
referenCeS
1. Comuzzie AG, Allison DB. The search for human obesity genes. Science. 1998;280(5368):1374-1377.
2. Harris JR, Tambs K, Magnus P. Sex-specific effects for body mass index in the new Norwegian twin 
panel. Genet Epidemiol. 1995;12(3):251-265.
3. Herskind AM, McGue M, Sorensen TI, Harvald B. Sex and age specific assessment of genetic and en-
vironmental influences on body mass index in twins. Int J Obes Relat Metab Disord. 1996;20(2):106-
113.
4. Carey DG, Nguyen TV, Campbell LV, Chisholm DJ, Kelly P. Genetic influences on central abdominal 
fat: a twin study. Int J Obes Relat Metab Disord. 1996;20(8):722-726.
5. Samaras K, Spector TD, Nguyen TV, Baan K, Campbell LV, Kelly PJ. Independent genetic factors 
determine the amount and distribution of fat in women after the menopause. J Clin Endocrinol 
Metab. 1997;82(3):781-785.
6. Schousboe K, Visscher PM, Erbas B, et al. Twin study of genetic and environmental influences on 
adult body size, shape, and composition. Int J Obes Relat Metab Disord. 2004;28(1):39-48.
7. Hsu FC, Lenchik L, Nicklas BJ, et al. Heritability of body composition measured by DXA in the 
diabetes heart study. Obes Res. 2005;13(2):312-319.
8. Malis C, Rasmussen EL, Poulsen P, et al. Total and regional fat distribution is strongly influenced by 
genetic factors in young and elderly twins. Obes Res. 2005;13(12):2139-2145.
9. Blair ML. Sex-based differences in physiology: what should we teach in the medical curriculum? 
Adv Physiol Educ. 2007;31(1):23-25.
10. Wells JC. Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab. 
2007;21(3):415-430.
11. Eaves LJ, Last KA, Young PA, Martin NG. Model-fitting approaches to the analysis of human behav-
iour. Heredity. 1978;41(3):249-320.
12. Neale MC, Cardon LR. Methodology for genetic studies of twins and families. Dordrecht, the Neth-
erlands: Kluwer Academic Publishers 1992.
13. Allison DB, Heshka S, Neale MC, Lykken DT, Heymsfield SB. A genetic analysis of relative weight 
among 4,020 twin pairs, with an emphasis on sex effects. Health Psychol. 1994;13(4):362-365.
14. Hur YM. Sex Difference in Heritability of BMI in South Korean Adolescent Twins. Obesity (Silver 
Spring). 2007;15(12):2908-2911.
15. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been 
reared apart. N Engl J Med. 1990;322(21):1483-1487.
16. Korkeila M, Kaprio J, Rissanen A, Koskenvuo M. Effects of gender and age on the heritability of 
body mass index. Int J Obes. 1991;15(10):647-654.
17. Souren NY, Paulussen AD, Loos RJ, et al. Anthropometry, carbohydrate and lipid metabolism in the 
East Flanders Prospective Twin Survey: heritabilities. Diabetologia. 2007;50(10):2107-2116.
18. Tambs K, Moum T, Eaves LJ, et al. Genetic and environmental contributions to the variance of body 
mass index in a sample of first- and second-degree relatives. Am J Hum Biol. 1991;3:257-261.
19. Weiss LA, Pan L, Abney M, Ober C. The sex-specific genetic architecture of quantitative traits in 
humans. Nat Genet. 2006;38(2):218-222.
20. Comuzzie A, Blangero J, Mahaney M, Mitchell B, Stern M, Maccluer J. Quantitative Genetics of Sexual 
Dimorphism in Body Fat Measurements. American Journal of Human Biology. 1993;5:725-734.
21. Vaessen N, Heutink P, Houwing-Duistermaat JJ, et al. A genome-wide search for linkage-disequi-
librium with type 1 diabetes in a recent genetically isolated population from the Netherlands. 
Diabetes. 2002;51(3):856-859.
Sex-specific genetic effects and body composition 37
22. Sayed-Tabatabaei FA, van Rijn MJ, Schut AF, et al. Heritability of the function and structure of the 
arterial wall: findings of the Erasmus Rucphen Family (ERF) study. Stroke. 2005;36(11):2351-2356.
23. Santos RL, Zillikens MC, Rivadeneira FR, et al. Heritability of fasting glucose levels in a young 
genetically isolated population. Diabetologia. 2006;49(4):667-672.
24. Wigginton JE, Abecasis GR. PEDSTATS: descriptive statistics, graphics and quality assessment for 
gene mapping data. Bioinformatics. 2005;21(16):3445-3447.
25. Boichard D. PEDIG: a FORTRAN package for pedigree analysis studied for large populations. Pro-
ceeding of the 7th World Congress of Genet Appl Livest Proc. 2002.
26. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum 
Genet. 1998;62(5):1198-1211.
27. Hopper JL, Mathews JD. Extensions to multivariate normal models for pedigree analysis. Ann Hum 
Genet. 1982;46(Pt 4):373-383.
28. Lange K, Boehnke M. Extensions to pedigree analysis. IV. Covariance components models for 
multivariate traits. Am J Med Genet. 1983;14(3):513-524.
29. Falconer D. Introduction to Quantitative Genetics. second edition. ISBN: 0582441951. 1981(second 
edition).
30. Martin LJ, Mahaney MC, Almasy L, et al. Leptin’s sexual dimorphism results from genotype by sex 
interactions mediated by testosterone. Obes Res. 2002;10(1):14-21.
31. Brown LB, Streeten EA, Shuldiner AR, Almasy LA, Peyser PA, Mitchell BD. Assessment of sex-specific 
genetic and environmental effects on bone mineral density. Genet Epidemiol. 2004;27(2):153-161.
32. Martin LJ, Cole SA, Hixson JE, et al. Genotype by smoking interaction for leptin levels in the San 
Antonio Family Heart Study. Genet Epidemiol. 2002;22(2):105-115.
33. Self SG, Liang KY. Asymptomatic properties of maximum likelihood ratio test under nonstandard 
conditions. J Am Stat Assoc. 1987;82:605-610.
34. Pardo LM, MacKay I, Oostra B, van Duijn CM, Aulchenko YS. The effect of genetic drift in a young 
genetically isolated population. Ann Hum Genet. 2005;69(Pt 3):288-295.
35. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era--concepts and misconceptions. Nat 
Rev Genet. 2008;9(4):255-266.

Chapter 3
The role of body mass index, 
insulin and adiponectin in the 
relation between fat distribution 
and bone mineral density
M. Carola Zillikens, André G. Uitterlinden, Johannes P.T.M van Leeuwen, 
Anne L. Berends, Peter Henneman, Ko Willems van Dijk, Ben A. Oostra, 
Cornelia M. van Duijn, Huibert A. P. Pols, Fernando Rivadeneira 
Submitted
40 Chapter 3
AbSTrACT 
Objective Despite the positive association between body mass index (BMI) and bone 
mineral density (BMD) and content (BMC), the role of fat distribution in BMD/BMC 
remains unclear. We examined relationships between BMD/BMC and various measure-
ments of fat distribution and studied the role of BMI, insulin and adiponectin in these 
relations.
Methods Using a cross-sectional investigation of 2631 participants from the Erasmus 
Rucphen Family (ERF) study we studied associations between BMD (using dual-energy 
x-ray absorptiometry (DXA)) at the hip, lumbar spine and total body BMC and fat dis-
tribution by the waist-to-hip ratio (WHR), waist-to-thigh ratio (WTR) and DXA-based 
trunk-to-leg fat ratio and android-to-gynoid fat ratio. Analyses were stratified by gender 
and median age (48.0 years in women and 49.2 in men) and were performed with and 
without adjustment for BMI, fasting insulin and adiponectin. 
results Using linear regression (adjusting for age, height, smoking and use of alcohol) 
most relationships between fat distribution and BMD and BMC were positive, except 
for WTR. After BMI-adjustment, most correlations were negative except for trunk-to-leg 
fat-ratio in both genders. We did not find a consistent influence of age or menopausal 
status. Insulin and adiponectin levels did not explain either positive or negative associa-
tions.
Conclusions Positive associations between android fat distribution and BMD/BMC are 
explained by higher BMI but not by higher insulin and/or lower adiponectin levels. 
Inverse associations after adjustment for BMI suggest that android fat deposition as 
measured by the WHR, WTR and DXA-based android-to-gynoid fat ratio is not beneficial 
and possibly even deleterious for bone. 
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InTrODuCTIOn
Osteoporosis and obesity are important global health problems with increasing preva-
lence. A positive association between body weight or body mass index (BMI) and bone 
mineral density (BMD) has been clearly demonstrated as well as increased fracture risk 
with low BMI 1-3. Possible explanations for higher BMD in heavier people include the 
weight-bearing effect of both fat and lean mass while lean mass is thought to influ-
ence bone through muscle mediated effects of physical exercise. Furthermore, adipose 
tissue might influence BMD through the production of hormones and adipokines by 
adipocytes (e.g., estrogen, leptin, adiponectin, resistin, interleukins) or through an ef-
fect on the secretion of bone-active hormones from the pancreas (e.g., insulin, amylin, 
preptin) 3. There is ongoing controversy about the relative importance of the fat and 
lean components of the body to BMD 3, 4. In postmenopausal women fat mass has been 
shown most consistently to be positively related to BMD, possibly mediated by higher 
estrogen levels. However, several discrepancies can be found in the literature, e.g., fat 
mass being important in young but not in old women and in old but not in young men 5 .
The effect of fat distribution on BMD is far from clear. Adipose tissue is metabolically 
heterogeneous, with differences between visceral and subcutaneous fat for example 
in the production of adipokines and in regulation of steroid hormone metabolism 
6. Android fat deposition (also named abdominal, central, visceral or upper body fat 
distribution) leads to increased risk of chronic diseases like cardiovascular disease and 
type 2 diabetes 7, while larger hip and thigh circumferences in gynoid fat deposition 
are associated with decreased risk of metabolic disease, independently of waist circum-
ference 8, 9. Circumference ratios, especially the waist-to-hip ratio (WHR) but also the 
waist-to-thigh ratio (WTR), have been consistently associated in epidemiological studies 
with metabolic and cardiovascular disease 7, 8. Several physiological factors that are as-
sociated with fat distribution are also associated with BMD. These include age, gender, 
heredity, parity, menopausal status, physical activity, smoking and alcohol consumption 
and hormones such as sex-steroids, glucocorticoids, growth hormones, insulin, leptin 
and adiponectin 3, 10, 11. Studies on the relationship between body fat distribution and 
BMD have yielded conflicting results. In late postmenopausal women from the Study of 
Osteoporotic Fractures (SOF), WHR was found to have no important relationship to BMD 
as compared to weight 12. Heiss et al found that upper body obesity was associated with 
increased BMD 13, possibly due to higher levels of insulin, lower levels of sex-hormone 
binding globulin (SHBG) and higher free sex-steroid levels. Other studies also reported 
positive relations between android fat distribution and BMD 5, 14-18. In contrast, two 
small studies found negative associations between android obesity and BMD or bone 
mineral content (BMC) 19, 20, and this was also seen in pre-pubertal children 21 and HIV 
infected patients 22. Most studies included a small number of subjects and/or were not 
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population based and different techniques were used for measurement of BMD or BMC 
(DXA or peripheral Computed Tomography (CT)) and fat distribution (anthropometry, 
DXA, CT or MRI). Also, the effect of adiposity on the relationship between fat distribution 
and BMD was not always considered. Since, in general, increased obesity is associated 
with increased abdominal fatness, BMI might be a confounder in the relation between 
android obesity and BMD. Despite suggestions that android fat deposition is beneficial 
for bone through higher insulin and/or lower adiponectin levels 11, 13, their role in the 
relation between fat distribution and bone has not been fully explored. 
The aim of the present study was to examine the relationship between various types 
of fat distribution assessment and BMD and BMC in a large number of Caucasian sub-
jects from a genetically isolated population in the Netherlands and to explore potential 
sex and age differences in this relationship as well as the effect of BMI and plasma insulin 
and adiponectin. 
MeThODS 
Study population
This study was carried out within the Erasmus Rucphen Family (ERF) study, a family-
based cohort study that is embedded in the Genetic Research in Isolated Populations 
(GRIP) program in the South West of the Netherlands. The aim of this program was to 
identify genetic risk factors in the development of complex disorders 23-26. 
For the ERF study, twenty-two families that had at least 5 children baptised in the 
community church between 1850-1900 were identified with the help of genealogical 
records. All living descendants of these couples and their spouses were invited to take 
part in the study. Data collection started in June 2002 and was finished in February 2005. 
In this study, we focused on the 2631 participants for whom complete phenotypic, and 
genealogical information was available. The Medical Ethics Committee of Erasmus Medi-
cal Center Rotterdam approved the study. Written informed consent was obtained from 
all participants. 
Data collection
At the research center, located within the community, extensive clinical examinations 
were performed, including the collection of fasting blood samples, anthropometric 
measurements, DXA and personal interviews. A research physician obtained information 
on medical history, medication use, smoking and alcohol use in a personal interview.
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Anthropometric measurements
Height and weight were measured with the participant dressed in light undercloth-
ing. Body mass index (BMI) was calculated from these data (weight (kg)/ height2 (m2)). 
Circumferences of the waist, hip and thigh were measured using a tape measure with 
the participant in standing position without outer garments. Waist circumference was 
measured halfway between the rib cage and the pelvic bone. Hip circumference was 
measured at the maximal circumference of the hips. Thigh circumference was measured 
mid-way between the upper border of the patella and the inguinal fold on the right leg. 
The waist-to-hip ratio (WHR) and waist-to-thigh ratio (WTR) were calculated from these 
measurements.
Dual-energy x-ray absorptiometry (DXA) measurements
DXA scans were performed using a Prodigy total body fan-beam densitometer and 
analyzed with the enCORE 2005 software v.9.3 (DPX, Lunar corporation Madison, WI) as 
described previously 26. BMD was measured at the femoral neck (mean value of left and 
right) and lumbar spine (L1-L4) and BMC at the total body. Total body scans were auto 
analyzed by the software, which employs an algorithm that divides body measurements 
into areas corresponding to head, trunk, arms and legs. 
Total body fat mass (g), lean mass (g), and regional fat mass were obtained from total 
body scans. The trunk region was limited by vertical borders lateral to the ribs, and a 
lower border by the iliac crest and an upper horizontal border below the chin (neck 
cut), above which the head was defined. The arm region was limited by cuts that cross 
the arm sockets, as close to the body as possible and separate the arms and hands from 
the body. The leg region is limited above by the oblique lines passing through the hip 
joint, and cuts that separate the hands and forearms from the legs and a center leg cut 
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1a): sites of the circumference measurements 
1b): regions of trunk fat (T), leg fat (L), “android” and “gynoid” fat assessed by DXA.
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which separates the right and left leg. Additional “android” and “gynoid” regions were 
defined using the software provided by the manufacturer. The “android region” has a 
lower boundary at the pelvis cut and the upper boundary above the pelvis cut by 20% 
of the distance between the pelvis and neck cuts. The lateral boundaries are the arm 
cuts. The “gynoid region” has an upper boundary between the upper part of the greater 
trochanters and a lower boundary defined at a distance equal to twice the height of the 
“android region”. The lateral boundaries are the outer leg cuts. The android and gynoid 
fat mass and android-to-gynoid fat ratio were calculated from these measurements. A 
schematic representation of the trunk, leg, android and gynoid region is shown in Figure 
1B. All analyzes were verified by a trained technician who performed adjustments when 
necessary. For 12 extremely obese subjects (BMI 43.5 – 61.8 kg/m2), total body DXA-scans 
were considered inadequate, since they did not contain all body parts and they were 
therefore excluded from further analysis. Daily quality assurance tests were performed 
with a calibration block supplied by the manufacturer. Repeated measurements on the 
calibration block had coefficients of variation less than 0.5%. In addition a calibration 
aluminum phantom was measured weekly with coefficients of variation less than 0.5%.
In figure 1 the sites of circumference measurements and fat regions by DXA are shown
Laboratory examinations
Fasting plasma insulin was analyzed with the INS-Irma kit of Biosource (cat.#: KIP1254) 
and total plasma adiponectin was analyzed with the Human adiponectin RIA kit (ca.t#: 
HADP-61HK) of Linco Research (St. Charles, MO). All measurements were performed 
conform the manufactures protocol.
Statistical analysis
The associations between fat distribution parameters and BMI, BMD/BMC and plasma 
levels of insulin and adiponectin were studied as partial correlations with correction for 
age. Multivariate linear regression analyses were performed to evaluate the strength 
of the relationship between body fat distribution and BMD and BMC. In the regression 
models, BMD and BMC, which were normally distributed, were used as dependent 
variables. Fat distribution parameters with normal or near normal distribution were 
used untransformed as independent variables, while age, height and lifestyle factors 
(smoking and alcohol history) were also included because of their known association 
with bone and body composition. Smoking of cigarettes was categorized as never, past 
or current. Alcohol use was categorized as no drinking, 1 – 21 units a week or > 21 units 
a week. Additional adjustment for BMI was applied to evaluate its role as a possible con-
founder. To study the effect of plasma insulin and adiponectin, regression analyses were 
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performed with and without adjustment for these hormones. The results of multivariate 
regressions are expressed in standardized regression coefficients. A p-value of <0.05 was 
considered significant. To examine the effect of age, the study population was divided 
by median age (48.0 years for women and 49.2 for men), in order to have equal numbers 
of subjects per group. For women, analyses were repeated stratified by menopausal 
status (premenopausal vs. postmenopausal subjects). All of the statistical analysis was 
done using the statistical package SPSS for Windows, version 15.0.
Table 1. General and body composition characteristics of the study population
  Females Males
Number 1467 1164
Age (years) 47.7 ± 14.2 48.6 ± 14.0
(range) 16.7 – 86.1 17.6 – 84.7
Postmenopausal 673 (45.9)
Height (m) 1.62 ± 0.06 1.75 ± 0.07
Weight (kg) 69.2 ± 12.8 83.0 ± 13.3
Body mass index (kg/m2) 26.4 ± 4.7 27.1 ± 3.9
Waist-to-hip ratio 0.80 ± 0.08 0.94 ± 0.08
Waist-to-thigh ratio 1.62 ± 0.20 1.85 ± 0.20
Android-to-gynoid fat ratio 0.45 ± 0.15 0.71 ± 0.20
Trunk-to-leg fat ratio 1.52 ± 0.46 2.42 ± 0.64
Femoral neck BMD (g/cm2) 0.91 ± 0.13 0.97 ± 0.14
L1-L4 BMD (g/cm2) 1.12 ± 0.16 1.18 ± 1.94
Total body BMC (kg) 2.32 ± 0.67 3.04 ± 0.44
Insulin (μU/ml) (n=2104) 12.8 ± 6.3 13.7 ± 8.8
Adiponectin (mg/L) (n=2104) 12.3 ± 5.8 8.0 ± 4.1
Smoking
Never 420 (28.6) 398 (34.2)
Past 394 (26.9) 375 (32.2)
Current 653 (44.5) 391 (33.6)
Alcohol 
< 1 unit per week 681 (46.4) 221 (19.0)
1-21 units per week 770 (52.5) 834(71.6)
> 21 units per week 16 (1.1) 109 (9.4)
Values are presented as number (percentage) or mean ± standard deviation. 
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reSulTS
Table 1 shows general and body composition characteristics and BMD at the femoral 
neck and lumbar spine and total body BMC of the study population. Mean age was 47.7 
years for women and 48.6 years for men. About 46% of women was postmenopausal. 
As expected, men were taller and had higher values for all fat distribution parameters, 
consistent with men having more android (apple shaped) and women more gynoid 
(pear shaped) fat distribution. Men also had higher values of BMD. Fasting plasma levels 
adiponectin levels were lower in men. 
Table 2 presents partial correlations corrected for age between BMI, the four fat dis-
tribution parameters, BMD/BMC and fasting plasma levels of insulin and adiponectin. 
Regarding the relation between BMI and the fat distribution parameters, in women, the 
highest correlation was found between BMI and android-to-gynoid fat ratio (r = 0.59), 
followed by WHR (r = 0.44) while in men the highest correlation with BMI was found for 
WHR (r = 0.58), followed by android-to-gynoid fat ratio (r = 0.46). Both in women and 
in men, trunk-to-leg fat ratio had the lowest correlations with BMI (r = 0.26 and 0.20 for 
Table 2: Partial correlations coefficients controlled for age between BMI, fat distribution, BMD and 
serum levels of insulin and adiponectina 
 
BMI
Waist-
to- hip 
ratio
Waist-
to-
thigh 
ratio
Android-
to-
gynoid 
fat ratio
Trunk-
to-leg 
fat 
ratio
FN 
BMD
L1-L4 
BMD
Total 
body 
BMC
Insulin
Adipo-
nectin
Females* (n = 1467) →
Males* (n=1164) ↓
BMI 1 0,44 0,3 0,59 0,26 0,28 0,2 0,33 0,47 -0,27
Waist-to-hip ratio 0,58 1 0,84 0,72 0,64 0,1 0.03ns 0.001ns 0,37 -0,36
Waist-to-thigh ratio 0,28 0,74 1 0,67 0,68 0.02ns 0.02ns -0,07 0,32 -0,3
Android-to-gynoid 
fat ratio 0,46 0,68 0,52 1 0,83 0,16 0,1 0,11 0,42 -0,4
Trunk-to-leg fat ratio 0,2 0,48 0,43 0,8 1 0,1 0,11 0,01ns 0,28 -0,35
FN BMD 0,3 0.05ns -0,07 0,09 0,07 1 0,69 0,71 0.05ns -0,1
L1-L4 BMD 0,17 -0.03ns -0,09 0.05ns 0,11 0,61 1 0,7 0.0ns -0,09
Total body BMC 0,25 -0.03ns -0,13 0.0ns 0,04ns 0,66 0,67 1 0.04ns -0,07
Insulin** 0,45 0,34 0,24 0,32 0,17 0,09 0.0ns 0.0ns 1 -0,29
Adiponectin** -0,22 -0,26 -0,13 -0,34 -0,31 -0,13 -0,14 -0,11 -0,18 1
a All correlations are significant at the 0.05 level, except when indicated ns (not significant)
*Females in the upper right corner, males in the lower left corner 
**For plasma levels of insulin and adiponectin n= 1207 for females;n=897 for males
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women and men, respectively). Correlations between the fat distribution parameters 
themselves ranged between 0.43 and 0.84, with the highest correlation between the 
WHR and WTR and between the android-to-gynoid fat ratio and the trunk-to-leg fat ratio. 
Fat distribution parameters were significantly correlated with BMD and BMC at sev-
eral sites and correlations were mostly positive (highest r of 0.16 in females and 0.11 in 
males). Negative correlations were found for waist-to-thigh ratio (in females with total 
body BMC and in males with femoral neck BMD, lumbar spine and total body BMC). 
Fasting levels of plasma insulin were positively correlated with BMI and fat distribu-
tion parameters in both genders and additionally with femoral neck BMD in males.
Fasting plasma levels of adiponectin showed negative correlations with BMI and fat 
distribution. There were also inverse correlations between adiponectin and all BMD/
BMC measurements. 
Table 3 shows the same relationship as in table 2 between the four parameters of fat dis-
tribution and BMD and/or BMC at three sites, expressed as standardized beta-coefficients 
after standard adjustment for age, height, smoking and alcohol intake (model1) and after 
additional adjustment for BMI and plasma insulin and adiponectin. Adjustment for plasma 
insulin (model 2), or plasma adiponectin (model 3) resulted in only minor changes in beta-co-
efficients and p-values. However, after adjustment for BMI (model 4) most relations changed 
and were now negative. Negative relations were most strong for the waist-to-thigh ratio and 
waist-to-hip ratio. For the android-to-gynoid fat ratio negative relations were significant only 
with total body BMC in both genders. For the trunk-to-leg fat ratio there was a small persist-
ing positive relation with lumbar spine BMD after adjustment for BMI. Additional adjustment 
for either insulin (model 5) or adiponectin (model 6) with BMI in the models resulted again 
in only minor changes in beta coefficients. In general, they decreased after adjustment for 
insulin and increased after adjustment for adiponectin. The strongest negative relations were 
seen for the waist-to-thigh ration with total body BMC in males. Beta coefficients (p-values) 
were after BMI adjustment - 0.335 (p=1.5x10-21), after BMI and insulin adjustment - 0.313 
(p=2.7x10-19) and after BMI and adiponectin adjustment - 0.339 (p=3.5x10-22)
Overall, beta-coefficients were more negative in males than in females. 
In Table 4 the relationships between fat distribution and BMD are presented stratified 
by median age in both genders. There were no consistent differences between the age 
groups, although relations of fat distribution parameters with total body BMC appeared 
more positive without adjustment for BMI in younger compared to older women and 
more negative after BMI adjustment in older women.
Outcomes were essentially unchanged when we stratified women by postmenopausal 
status instead of median age and also when we adjusted our analyses in both genders 
for body weight instead of BMI (data not shown).
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The total variation of BMD explained by fat distribution parameters independent of age, 
height, BMI, smoking and alcohol intake was smaller than variation explained by BMI 
independent of age, height, smoking and alcohol intake. 
Variation explained by BMI for femoral neck BMD, lumbar spine BMD and total body 
BMC was respectively, 5.7%, 2.9% and 9.0% in women and 7,8%, 2,4% and 5.0% in men. 
Variation explained by the four fat distribution parameters independent of BMI at 
these sites was for waist-to-hip ratio: 0.0%, 0.2% and 1.3% in women and 1.6%, 2.1% and 
4.0% in men; for the waist-to-thigh ratio: 0.0%, 0.6% and 2.3% in women and 1.8%, 1.8% 
and 4.9% in men; for the android-to-gynoid fat ratio: 0.0%, 0.1% and 1.3% in women and 
0.5%, 0.1% and 1.8% in men. For the trunk-to-leg fat ratio the explained variance was: 
0.2%, 0.5% and 0.0% in women and 0.0%, 0.7% and 0.0% in men, respectively.
Table 4. Relationship between fat distribution and BMD and BMC in males and females stratified by 
median age†
Waist-to-hip ratio waist-to-thigh ratio
android-to-gynoid 
fat ratio
Trunk-to-leg fat 
ratio
A: Without adjustment for bMI
<median 
age
>median 
age
<median 
age
>median 
age
<median 
age
>median 
age
<median 
age
>median 
age
females, n 734 733 734 733 734 733 734 733
Fem Neck BMD + 0.146c + 0.101b + 0.054 + 0.024 + 0.138c + 0.155c + 0.127c + 0.115c
L1-L4 BMD + 0.024 + 0.049 - 0.046 + 0.007 + 0.059 + 0.103b + 0.128c + 0.131c
Total BMC + 0.082b - 0.003 - 0.032 - 0.070a + 0.145c + 0.058 + 0.112c + 0.025
Males, n 582 582 582 582 582 582 582 582
Fem Neck BMD + 0.077 + 0.078 - 0.091a - 0.063 + 0.099a + 0.070 + 0.068 + 0.087a
L1-L4 BMD - 0.031 - 0.010 - 0.164c - 0.066 - 0.025 + 0.070 + 0.072 + 0.154c
Total BMC - 0.019 - 0.064 - 0.171c - 0.179c - 0.019 - 0.038 + 0.051 + 0.036
b: with adjustment for bMI
females
Fem Neck BMD + 0.045 - 0.048 - 0.010 - 0.092a - 0.031 - 0.008 + 0.052 + 0.055
L1-L4 BMD - 0.063 - 0.066 - 0.095a - 0.079a - 0.082 - 0.019 + 0.081a + 0.090a
Total BMC - 0.099 b - 0.180 c - 0.133c - 0.203c - 0.146c - 0.157c - 0.009 - 0.042
Males
Fem Neck BMD - 0.157b - 0.198c - 0.177c - 0.205c - 0.061 - 0.098a + 0.020 + 0.012
L1-L4 BMD - 0.257c - 0.179c - 0.203c - 0.155c - 0.101a - 0.027 + 0.061 + 0.114b
Total BMC - 0.295c - 0.287c - 0.260c - 0.280c - 0.210c - 0.156c + 0.004 - 0.009
†Effect size: standardised Beta coefficients from linear regression adjusted for age, height, smoking and alcohol 
intake. Median age for women: 48.0 years; for men: 49.2 years 
a p< 0.05; b 0.001 < p< 0.01; c p< 0.001
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DISCuSSIOn
In this study we show that positive associations between android fat distribution and 
BMD are explained by higher BMI. Once the effect of BMI is taken into account, android 
fat distribution has no or negative relationships with BMD. We also show that these 
relationships depend on the type of the fat distribution parameter used and the site of 
BMD/BMC measurement and we demonstrate that relations are independent of plasma 
levels of insulin and adiponectin. These observations may largely explain previous 
inconsistent findings of positive, negative or no associations between fat distribution 
and BMD 5, 13-18 and challenge the view that android fat deposition is beneficial for bone 
through higher insulin and/or lower adiponectin levels 11, 13. 
Most of the positive associations we found between BMD and fat distribution are 
explained by increased BMI. After removing the effect of BMI by adjusting for it in the 
multiple regressions, no more positive associations were found except for small but 
significant positive relationships between trunk-to-leg fat ratio and lumbar spine BMD. 
In contrast, several associations became significantly negative with the lowest regres-
sion coefficients for circumference ratios WHR and WTR, followed by android-to-gynoid 
fat ratio, with no negative associations for the trunk-to-leg fat ratio. Thus, despite high 
correlations between the different parameters of fat distribution, there were clear differ-
ences in their relation with BMD but also with BMI. This shows that they do not measure 
the same aspect of fat distribution. Circumference measurements are not only related 
to the amount of adipose tissue but also to size of internal organs (waist circumference), 
and to size of bone and muscle (hip and thigh), the latter especially in men 8, 9. This 
may influence the relation with BMD irrespective of fat distribution. The new DXA-based 
measurement of fat in the abdominal region is theoretically more closely related to vis-
ceral fat than total trunk fat mass, which also contains subcutaneous adipose tissue on 
the thorax, back and breasts. Another advantage of the android-to-gynoid fat ratio over 
the trunk-to-leg fat ratio is that in the latter assessment, gluteal and abdominal fat can 
not be perfectly separated 27. However, neither anthropometry nor DXA can distinguish 
between visceral and subcutaneous fat in the android region, although waist circumfer-
ence as well as trunk fat and abdominal fat in a sub region by DXA show high correlation 
with visceral fat measured by CT or MRI 28-33. 
The only association that remained significantly positive in our study after BMI adjust-
ment was between trunk-to-leg fat ratio and lumbar spine BMD, consistent with findings 
by Douchi et al 15. It is unclear whether this is caused by the fact that the trunk-to-leg fat 
ratio is not a good estimate of fat distribution, or due to an artifact by the DXA measure-
ment, as was observed after simulating changes in trunk fat with lard packets 34. On the 
other hand, we cannot exclude that the observed relationship is real and that (subcu-
taneous) fat in the trunk, as opposed to the legs, produces factors that increase BMD. 
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There were small gender differences in our study, with males showing less posi-
tive (before BMI adjustment) and more negative relationships (after BMI adjustment) 
between fat distribution and BMD or BMC than women. This might be caused by a 
potentially stronger relation in males between hip and thigh circumference and lower 
body muscularity 8, 9, since these differences were most marked for the waist-to-hip and 
waist-to-thigh ratio’s.
We found differences by the site of BMD/BMC measurement. Regression coefficients 
were in general lower for total body BMC than for femoral neck and lumbar spine BMD. 
To our surprise we found no consistent age differences in the relationship between fat 
distribution and BMD/BMC. Considering the strong effect of menopause and age on 
fat distribution and BMD 35, 36, the similarity in their relationships between younger and 
older women is remarkable. 
There are several reasons why it is important to study the relationships between fat 
distribution and BMD and to try to explain previous controversial findings. It is important 
for fracture risk prediction, patient handling and understanding of biological mecha-
nisms. Our study shows that measures of fat distribution explain more of the variation 
in BMD and BMC in men than in women but the effect is relatively small as compared to 
that of weight and BMI. In that respect our data are in agreement with those from the 
Study of Osteoporotic Fractures (SOF) in older women 12 but now extend these findings 
to males and younger subjects. For patient care, it is important to know that android 
obesity does not appear to be beneficial for bone, as was suggested by most previous 
studies. Instead, our data show that especially for males, gynoid fat distribution is better 
than android, possibly in part because it is a marker of greater physical activity with 
greater muscle mass on hips and thighs. Thus, our data comply with and underscore 
the importance of the advice for regular physical exercise that can potentially decrease 
android obesity and also prevents muscle wasting with ageing and increases mechani-
cal loading on the skeleton. Other mediators than physical activity might be considered 
as a possible mechanistic explanation for our findings like glucocorticoids, growth- and 
sex- hormones, leptin and inflammatory adipokines. Our data show that it is unlikely 
that insulin and adiponectin mediate the association. Lastly, technical limitations of the 
DXA technique should be considered in the interpretation of these findings since the 
BMD measurement is influenced by the fat to lean ratio of soft tissues 37.
Given the cross-sectional nature of our study, it is not possible to make causal infer-
ences from associations or to study the relationship of fat distribution with fractures. We 
acknowledge that multiple testing may influence some of the significant findings in our 
study. However, even after applying a Bonferroni correction, that might be too stringent 
considering the high correlation between the fat distribution traits, most correlations 
would remain significant. Considering the consistency of the results across genders, we 
don’t expect multiple testing to play a substantial role in the interpretation of our find-
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ings. Strength of our study is the large population which is not selected on disease and 
which includes both genders with a wide age range and the use of multiple bone sites 
and fat distribution parameters, including a new android-to-gynoid fat ratio by DXA and 
the availability of plasma levels of insulin and adiponectin.
We conclude that positive associations between android fat distribution and BMD are 
explained by higher BMI but not by higher insulin levels and/or lower adiponectin levels. 
Negative associations after adjustment for BMI suggest that android fat deposition as 
measured by the WHR, WTR and android-to-gynoid fat ratio is not beneficial and pos-
sibly even deleterious for bone health. The clinical relevance of these associations needs 
to be shown by studying their relationships with fractures. 
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AbSTrACT
A mildly elevated homocysteine (Hcy) level is a novel and potentially modifiable risk 
factor for age-related osteoporotic fractures. Elevated Hcy levels can have a nutritional 
cause, such as inadequate intake of folate, riboflavin, pyridoxine or cobalamin, which 
serve as cofactors or substrates for the enzymes involved in the Hcy metabolism. We ex-
amined the association between intake of Hcy-related B vitamins (riboflavin, pyridoxine, 
folate and cobalamin) and femoral neck bone mineral density BMD (FN-BMD) and the 
risk of fracture in a large population-based cohort of elderly Caucasians. 
We studied 5304 individuals aged 55 years and over from the Rotterdam Study. 
Dietary intake of nutrients was obtained from food frequency questionnaires. Incident 
non-vertebral fractures were recorded during a mean follow-up period of 7.4 years, and 
vertebral fractures were assessed by X-rays during a mean follow-up period of 6.4 years. 
We observed a small but significant positive association between dietary pyridoxine 
(ß=0.09, p=1x10-8) and riboflavin intake (ß=0.06, p=0.002) and baseline FN-BMD. In addi-
tion, after controlling for gender, age and BMI, pyridoxine intake was inversely correlated 
to fracture risk. As compared to the three lowest quartiles, individuals in the highest 
quartile of age- and energy-adjusted dietary pyridoxine intake had a decreased risk of 
non-vertebral fractures (HR=0.77, 95% CI=0.65-0.92, p=0.005), and fragility fractures 
(HR=0.55, 95% CI=0.40-0.77, p=0.0004). Further adjustments for other dietary B vitamins 
(riboflavin, folate and cobalamin), dietary intake of calcium, vitamin D, A and K, protein 
and energy content, smoking and BMD did not essentially modify these results. 
We conclude that increased dietary riboflavin and pyridoxine intake was associated 
with higher FN-BMD. Furthermore, we found a reduction in risk of fracture in relation to 
dietary pyridoxine intake independent of BMD. These findings highlight the importance 
of considering nutritional factors in epidemiological studies of osteoporosis and frac-
tures.
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InTrODuCTIOn
Osteoporosis is defined as a skeletal disorder characterized by compromised bone 
strength predisposing a person to an increased risk of fracture. Several risk factors have 
been identified for osteoporotic fracture, such as age, low body mass index (BMI) and 
low bone mineral density (BMD). More recently, mildly elevated homocysteine (Hcy) 
concentrations were identified as a novel and potentially modifiable risk factor for age-
related osteoporotic fractures 1,2. 
Hcy is a sulfur-containing amino acid formed from the essential amino acid me-
thionine. Defects in intracellular Hcy metabolism lead to an elevation of plasma Hcy 
concentrations. These metabolic defects can have a genetic cause, i.e., polymorphisms 
in genes involved in the Hcy metabolism. On the other hand, defects in the Hcy metabo-
lism can also have a nutritional cause, such as inadequate intake of folate (vitamin B11), 
riboflavin (vitamin B2), pyridoxine (vitamin B6) or cobalamin (vitamin B12) which serve 
as cofactors or substrates for the enzymes involved in the Hcy metabolism 3,4. It is well 
established that increased plasma Hcy concentrations are associated with low dietary 
intake of riboflavin, folate, cobalamin, and pyridoxine 5-7.
Several epidemiological studies have shown a positive association between folate 
and/or cobalamin status and bone end points. Some have found that higher serum con-
centrations of cobalamin 8-11 or folate 12 are associated with increased BMD, decreased 
bone loss 13, and decreased risk of fracture 9,14. In addition, a randomized, double-blinded 
study in Japanese patients, showed that combined serum cobalamin and folate supple-
mentation was effective in preventing hip fracture presumably by decreasing Hcy con-
centrations 15. This indicates a possible effect of folate and cobalamin on bone strength 
through effects on the Hcy metabolism. There are limited data available on the effect of 
Hcy-related B vitamins on bone end points, especially the risk of fracture. 
We examined the relation between intake of the Hcy-related B vitamins (riboflavin, 
pyridoxine, folate and cobalamin) and BMD and risk of fracture in a large population-
based cohort of individuals aged 55 years and over. 
MATerIAlS AnD MeThODS 
Study population
This study was conducted within the framework of the Rotterdam Study, an ongoing 
prospective population-based cohort study among subjects aged 55 years and over, 
living in Ommoord, a suburb of Rotterdam, the Netherlands. The rationale and design of 
the Rotterdam Study have been described elsewhere 16. Approval of the Medical Ethics 
Committee of the Erasmus University Rotterdam was obtained. From all participants 
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written informed consent was acquired. We studied 5304 subjects who had data avail-
able on dietary intake.
Anthropometric measurements 
Height (cm) and weight (kg) were measured at the initial examination, in standing posi-
tion wearing indoor clothes without shoes. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in centimeters squared (kg/cm2).
Dietary intake 
Dietary intake of vitamins (including riboflavin, pyridoxine, cobalamin folate, vitamin A, 
vitamin K, vitamin D and calcium intake) and use of supplements were assessed using 
validated food intake data obtained from a food frequency questionnaire. A validation 
study comparing this questionnaire with a 2-week food diary demonstrated reproduc-
ible and valid estimates 17,18. For dietary vitamin B intake data were available for 5304 
subjects. Dietary vitamin B intake was adjusted for age and energy intake as described 
elsewhere 19. Persons who reported taking supplements containing vitamins B2 (ribo-
flavin), B6 (pyridoxine), B12 (cobalamin) or B-complex, as well as multivitamins, were 
classified as B vitamin supplement users (n=790).
Potential confounders 
The presence of type 2 diabetes mellitus was defined by the current use of antidiabetic 
medication or by a non-fasting or post-load plasma glucose level above 11.1 mmol per 
liter. Concentrations of serum creatinine were measured with the use of standard 
laboratory procedures. Prevalence of myocardial infarction was defined according to 
the international classification of diseases, 10th revision (ICD-10) 20. Dementia was diag-
nosed with the use of the mini–mental state examination and the geriatric mental state 
schedule 20. The number of falls in the preceding year, and current smoking status were 
assessed with the use of a questionnaire. A lower limb disability index was obtained by 
calculating the mean score of answers to questions concerning rising, walking, bending, 
and getting in and out of a car. The index is represented by a continuous score, ranging 
from 0 to 3, where 0 indicates no impairment and 3 indicates severe impairment 21.
Measurement of Hcy levels
Non-fasting blood samples from 738 subjects at baseline were immediately placed on 
ice and processed within 60 minutes. At baseline, serum samples were kept frozen until 
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Hcy levels were measured. Total Hcy levels were determined as a fluorescence derivate 
with the use of high-pressure liquid chromatography and expressed as micro mol per 
liter (μM/L) 22,23.
Measurement of bone parameters
BMD (in grams per square centimeter) of the hip and lumbar spine (L2-L4) was measured 
by dual-energy x-ray absorptiometry (DXA) using a Lunar DPX- densitometry apparatus 
(DPX-L, Lunar Corp. Madison, WI, USA), under standard protocols. Methods, quality, as-
surance, accuracy, and precision issues of the DXA measurements have been described 
previously 24. To increase the accuracy of BMD measurements on follow-up, the search 
and template tools in the comparison mode were used to position the femoral neck 
region of interest in scans of the same individual. The rate of change in BMD was cal-
culated as the differences between baseline and the second follow-up, with a mean 
follow-up period of 6.5 ± 0.6 (SD) years (n=2422).
Fracture follow-up
Fracture events were obtained from the computerized records of the general practitio-
ners (GPs) in the research area. Research physicians regularly followed participant infor-
mation in the GP’s records outside the research area, and made an independent review 
and encoded of all reported events. Subsequently, a medical expert in the field reviewed 
all coded events for the final classification of diseases, 10th revision (ICD-10)20. Additional 
information on hip fractures was gathered through the Dutch national hospital registra-
tion system. Information on incident non-vertebral fractures has been collected within 
an average follow-up period of 7.4 ± 3.3 (SD) years. For studying incident fractures, all 
fractures which were considered not osteoporotic (fractures caused by cancer and all 
hand, foot, skull, and face fractures) were excluded. We considered separately fragility 
fractures occurring at the hip, pelvis and proximal humerus 25.
Vertebral fracture assessment
Both at baseline (1990-1993) and at the second follow-up visit (between 1997 and 1999) 
radiographs of the thoracolumbar spine were available for 3469 individuals in a mean 
follow-up of 6.4 years. All thoracolumbar radiographs of the follow-up visit were scored 
for the presence of vertebral fracture using the McCloskey/Kanis method, as described 
previously 26. If vertebral fractures were detected, the baseline radiograph was also 
evaluated. If the vertebral fracture was already present at baseline, it was considered 
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to be a baseline prevalent fracture. If it was not present at baseline, the fracture was 
defined to be incident.
Statistical analysis
To examine a relation between dietary intake and BMD, a multivariable linear regression 
analysis was used. In this analysis femoral neck BMD (FN-BMD) and lumbar spine BMD 
(LS-BMD) were used as dependent variables and gender, age, BMI, dietary B (riboflavin, 
pyridoxine, folate, cobalamin) vitamins intake, calcium, vitamin D, K, and A, and energy 
and protein intake were used as covariates. We applied a stepwise multiple regression 
approach to identify the best predictors for baseline BMD. Analysis of variance (ANOVA) 
was used to examine the associations between baseline general characteristics across 
quartiles of pyridoxine intake. Analysis of covariance (ANCOVA) was performed to adjust 
for possible confounders such as BMI, age and important factors related to co-morbidity. 
Variables were log transformed if they did not meet normality assumptions, this was 
the case for Hcy levels and dietary intake of folate and cobalamin. Quartiles of dietary 
pyridoxine intake were created for each gender after adjustment for age and energy by 
using the residual method 19.
Incidence rates for all non-vertebral fractures were calculated by dividing the number 
of incident cases by the total number of fracture-free person-years, and 95% confidence 
intervals (CI) were calculated using the exact Poisson formula. The incidence rate of non-
vertebral fractures was calculated for quartiles of dietary pyridoxine intake (age and 
energy-intake adjusted), taking the quartile with lowest pyridoxine intake as reference 
for the Cox proportional hazards analysis. 
Cox’s proportional hazards regression was used to calculate the hazard ratio (HR) and 
the 95% CI to estimate the relative risk of non-vertebral fractures. Odds ratios (OR) and 
95% CI to assess vertebral fracture risk were estimated using logistic regression. Cox pro-
portional hazards analysis was used to evaluate the contribution of dietary pyridoxine 
intake to mortality, based on a proportional hazards model.
All analyses were adjusted for gender, age and BMI. Subsequently, additional adjust-
ments were made for the following confounders: Dietary B vitamins other than pyridox-
ine (riboflavin, cobalamin and folate), vitamin A and vitamin K intake, protein intake, 
current smoking, type 2 diabetes, serum creatinine, prevalence of myocardial infarction 
at baseline, history of recent falls, lower limb disability, and disability index. 
All analyses were done using the SPSS package version 11 (SPSS, Chicago, IL, USA). 
p-values lower than 0.05 were considered significant. 
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reSulTS
General characteristics of the study population are presented in Table 1. For each of the 
four B vitamins we found a significant association with both FN-BMD and LS-BMD after 
correcting for intake of protein, energy, gender, age and BMI (Table 2). Furthermore, we 
observed that for baseline FN-BMD among the B-vitamins, riboflavin was the strongest 
predictor (ß=0.09, p=1x10-8) and pyridoxine was a good predictor (ß=0.06, p=0.002) 
(Table 3). Gender, age and BMI explained 24% of the variation in FN-BMD. Pyridoxine 
and riboflavin together explained 1% extra variation (data not shown). For LS- BMD we 
found similar results for riboflavin (ß=0.06, p=1x10-5) and pyridoxine (ß=0.06, p=0.002) 
(Table 3). At the lumbar spine, gender and BMI explained 16% of the variation in BMD, 
while pyridoxine and riboflavin together also explained another 1% of the variation (data 
not shown). Age was not a predictor for LS-BMD. Furthermore, in a separate analysis we 
additionally adjusted for age at menopause and parity. These adjustments did not affect 
the results (data not shown).
We investigated whether B vitamin intake was associated with non-vertebral and 
fragility fractures. Only pyridoxine (as a continuous variable) was inversely associated 
Table 1. Baseline characteristics of the study population 
Characteristic Study population
  n=5304  
Age (years) 67.66 ± 7.75 
Height (cm) 167.20 ± 9.20
Weight (kg) 73.63 ± 11.66
Body mass index (kg/m2) 26.33 ± 3.66
Dietary intakes
Riboflavin (mg/day) 1.59 ± 0.56
Pyridoxine (mg/day) 1.63 ± 0.40
Folate (μg/day) 218.60 ± 77.99
Cobalamin (μg/day) 5.26 ± 4.55
Vitamin K (μg/day) 264. 7 ± 127.2
Vitamin A (μg/day) 1090.9 ± 781.6
Vitamin D (μg/day) 1.58 ± 1.01
Calcium (mg/day) 1127.0 ± 401.0
Protein intake (g/day) 81.33 ± 19.50
Energy intake (kJ/day) 8253.5 ± 2106.6
Current smoking (%) 23.2
Femoral neck BMD (g/cm2) 0.87 ± 0.14
Lumbar spine BMD (g/cm2) 1.09 ± 0.20
Data given as mean + SD
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Table 2. Single linear regression analysis between dietary B vitamin intakes and BMD in 5304 men and 
women in the Rotterdam Study
Model 1 Model 2
Dietary B 
vitamins 
intake
FN-BMD LS-BMD FN-BMD LS-BMD
ß† p-value†† ß p-value†† ß p-value†† ß p-value††
Riboflavin 0.082 2.6x10-11 0.058 7x10-6 0.10 7x10-4 0.079 6x10-5
Pyridoxine 0.061 3x10-6 0.041 0.003 0.07 4x10-4 0.069 0.001
Folate 0.043 0.001 0.041 0.002 0.03 0.05 0.04 0.01
Cobalamin 0.039 0.001   0.026 0.049   0.01 0.55   0.01 0.51
Model 1: adjusted for gender, age and BMI.
Model 2: Model 1 plus adjustment for energy intake and protein intake.
FN: femoral neck; LS: lumbar spine.
† Standardized beta coefficients, 
†† Calculated by using linear regression.
Table 3. Multivariable regression analysis of determinants of femoral neck and lumbar spine BMD in 
5304 men and women in the Rotterdam Study
  Starting model
 
Final Model
Variable FN-BMD LS-BMD FN-BMD LS-BMD
  ß† p-value †† ß† p-value†† ß† p-value†† ß† p-value††
Female -0.33 10-112 -0.35 10-116 -0.33 10-112 -0.35 10-116
Age (years) -0.27 10-98 -0.004 0.75 -0.27 10-99 - -
Body mass index (kg/m2) 0.28 10-102 0.25 10-74 0.28 10-102 0.25 10-74
Riboflavin (mg/day) 0.11 10-8 0.08 0.0002 0.09 10-8 0.06 10-5
Pyridoxine (mg/day) 0.07 0.002 0.06 0.01 -0.06 0.002 -0.06 0.002
Energy intake (kJ/day) -0.05 0.01 -0.07 0.002 -0.06 4x10-4 -0.08 10-5
Folate (μg/day) -0.02 0.46 0.01 0.73 - - - -
Vitamin D -0.01 0.88 -0.01 0.42 - - - -
Calcium 0.01 0.68 -0.02 0.29 - - - -
Vitamin A 0.003 0.88 0.003 0.90 - - - -
Vitamin K -0.01 0.53 -0.03 0.07 - - - -
Cobalamin (μg/day) -0.01 0.50 -0.01 0.51 - - - -
Protein intake (g/day) -0.03 0.29 -0.03 0.27 - - - -
† Standardized coefficients beta. †† calculated by using linear regression. FN: femoral neck; LS: lumbar 
spine. In the multivariable linear regression analysis FN-BMD or LS-BMD was used as the dependent 
variable and gender, age, BMI, dietary  B (riboflavin, pyridoxine, folate, cobalamin) vitamins intake, dietary 
intakes of: calcium, vitamin D, K, and A, protein and energy content were used as covariates. In the final 
regression model, only variables significantly and independently associated with FN-BMD (LS-BMD) were 
selected through a stepwise regression method. Adjusted R2 for final model; FN-BMD: (0.25, p<0.001); LS-
BMD: (0.17, p<0.001).
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with non-vertebral, fragility and vertebral fractures (Table 4). Further adjustment for 
other nutritional factors, (including four dietary B vitamins intake (riboflavin, pyridoxine, 
cobalamin, folate) and dietary of vitamin D, calcium, vitamin A and vitamin K intake) and 
baseline FN-BMD or co-morbidity, did not essentially change the result. 
Table 5 shows the comparisons of general characteristics of the study population 
across quartiles of (age and energy adjusted) intake of pyridoxine. There was a signifi-
cant difference in weight, BMI, dietary intake of riboflavin, folate and cobalamin across 
quartiles of dietary pyridoxine intake (p<10-4) (Table 5). Supplemental therapy did not 
differ across quartiles. To avoid confounding by supplement use, we also performed 
the analyses excluding users of supplements but the results remained unchanged (n = 
790, 9.9%) (data not shown). FN-BMD and LS-BMD increased within quartiles of dietary 
pyridoxine intake (p=10-4). Moreover, we observed a significantly reduced bone loss at 
the femoral neck; the latter result remained unchanged after adjustment for baseline 
FN-BMD. 
Comparison of a number of important factors related to co-morbidity across quartiles 
of dietary pyridoxine intake are presented in Table 6. Subjects in the highest quartile of 
Table 4. Association of dietary pyridoxine intake as a continuous variable with risk of fracture in 5304 
men and women in the Rotterdam Study
Types of fracture No. fracture/ Total no (%) ß † Relative Risk (95% CI) p-value††
Non-vertebral
 Model 1 744/5304 (14.0) -0.25 0.78 (0.60-1.00) 0.06
 Model 2 -0.36  0.70 (0.49-1.00) 0.05
 Model 3 -0.45  0.64 (0.42-0.98) 0.04
Fragility      
 Model 1 279/5304 (5.3) -0.54 0.58 (0.38-0.90) 0.02
 Model 2 -0.85 0.43 (0.24-0.77) 0.004
 Model 3 -1.09 0.34 (0.18-0.64) 0.001
Vertebral      
Model 1 328/3003 (6.2) -0.44 0.64 (0.42-0.98) 0.04‡
Model 2 -0.63  0.46 (0.33-1.20)  0.16 ‡
Model 3 -0.64 0.53 (0.27-1.04)  0.06 ‡
Model 1: Adjustment for gender, age, BMI and energy intake
Model 2: Model 1 plus additional adjustments including: dietary intake of riboflavin, cobalamin, folate, 
protein, calcium, vitamin D, vitamin K, vitamin A and co-morbidity status including: prevalence of 
myocardial infarction, type 2 diabetes, dementia, creatinine level, current smoking and recent falling
Model 3: Model 2 plus additional adjustment for FN-BMD for all non-vertebral and fragility fractures, For 
vertebral fractures adjustment for LS-BMD
†  Indicates beta coefficient by unit of milligram per day
†† Calculated by Cox’s proportional hazards regression, 
‡ Calculated by logistic regression
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dietary pyridoxine intake had the lowest percentage of current smoking. The remainder 
of the factors related to co-morbidity did not differ across the quartiles. The results were 
not affected by adjustement for other nutritional factors.
Table 5. General characteristics of age and energy-adjusted pyridoxine quartiles in 5304 men 
and women in the Rotterdam Study
Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
n=1326 n=1325 n=1327 n=1326
Mean pyridoxine (mg/day) 1.30 1.50 1.67 2.03
Male (%) 40.8 40.8 40.8 40.8
Age (year) 67.64 ± 0.21 67.61 ± 0.21 67.96 ± 0.21 67.42 ± 0.21 0.34
Weight (kg) 72.52 ± 0.29 73.60 ± 0.29 74.27 ± 0.29 74.14 ± 0.29 10-7
Height (cm) 167.12 ± 0.17 167.09 ± 0.17 167.42 ± 0.17 167.17 ± 0.17 0.51
BMI (kg/m2) 25.95 ± 0.10 26.35 ± 0.10 26.50 ± 0.10 26.54 ± 0.10 10-7
Riboflavin (mg/day) 1.41 ± 0.01 1.50 ± 0.01 1.61 ± 0.01 1.83 ± 0.01 10-94
Folate (μg/day) †† 177.83 ± 0.07 196.20 ± 0.07 214.42 ± 0.07 252.93 ± 0.07 10-256
Cobalamin (μg/day) †† 4.02 ± 0.07 4.27 ± 0.07 4.41 ± 0.07 5.05 ± 0.07 10-15
Protein intake (g/day) 74.56 ± 0.48 78.29 ± 0.48 81.94 ± 0.48 90.51 ± 0.48 10-126
Femoral neck BMD (g/cm2) 0.853 ± 0.004 0.861 ± 0.004 0.880 ± 0.004 0.879 ± 0.004 10-4
Lumbar spine BMD (g/cm2) 1.074 ± 0.005 1.076 ± 0.005 1.099 ± 0.005 1.106 ± 0.005 10-4
Rate of change FN-BMD 
(g/cm2 per yr)
-0.0067 
± 0.0004
-0.0064 
± 0.0004
-0.0052 
± 0.0004
-0.0055 
± .0004
0.01
Data given as mean ± SE. Adjustment for gender and age.
† Calculated by Analysis of variance (ANCOVA) †† Back log transformed 
Table 6. Comparison of co-morbidity markers by quartiles of dietary pyridoxine intake in 5304 men and 
women in the Rotterdam Study
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value†
n=1326 n=1325 n=1327 n=1326
Mean pyridoxine intake 
(mg/day)
1.30 1.50 1.67 2.03
Co-morbidity 
Dementia 3.5 (47) 3.7 (49) 4.2 (56) 3.2 (42) 0.55
Current smoking 31.0 (401) 23.9 (308) 21.0 (273) 17.7 (230) 0.01
Diabetes 9.5 (126) 10.0 (132) 10.8 (143) 12.1 (160) 0.15
Prevalent MI 13.0 (170) 11.6 (150) 12.3 (160) 12.0 (156) 0.69
Recent fall 14.8 (196) 15.0 (199) 13.1 (174) 13.1 (174) 0.32
Disability index >= 0.5 26.5 (351)  24.0 (318) 24.3 (322)  23.5 (311)  0.33
Data given as percentage (cases) 
†Calculated by Analysis of variance (ANOVA)
B vitamins and BMD and risk of fracture 67
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
2 
4 
6 
8 
1
0 
1
2 
1
4 
1
6 
1
8 
2
0 
HR: 0.77, 95%CI: 0.65-0.92 
p=0.005 
1A. 
In
ci
d
en
ce
 r
at
e 
o
f 
n
o
n
-v
er
te
b
ra
l 
fr
ac
tu
re
 
p
er
 1
0
0
0
 p
er
so
n
-y
ea
rs
 
Numbers of fractures                             176                                          205                                          206                                         157 
Total Number                                        1326                                        1325                                        1327                                       1326 
% of fractures                                        13.3                                         15.5                                         15.5                                        11.8 
      Q1                                           Q2                                           Q3                                          Q4 
 2 
Numbers of fractures                           71                                          83                                           80                                          45 
Total Number                                      1326                                      1325                                       1327                                      1326 
% of fractures                                      5.4                                         6.3                                          6.0                                         3.4 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
HR: 0.55, 95%CI: 0.40-0.77 
p=0.0004 
In
ci
d
en
ce
 r
at
e 
o
f 
fr
ag
il
it
y
 f
ra
ct
u
re
 
p
er
 1
0
0
0
 p
er
so
n
-y
ea
rs
 
      Q1                                        Q2                                           Q3                                        Q4 
1B. 
  89                                  79                                   85                                75 
0.0 
2.0 
4.0 
6.0 
8.0 
10.0 
12.0 
14.0 
Q1 Q2 Q3 Q4 
OR: 0.86, 95%CI: 0.65-1.13 
p=0.27 
P
er
ce
n
ta
g
e 
o
f 
v
er
te
b
ra
l 
fr
ac
tu
re
  
      Q1                                        Q2                                         Q3                                      Q4 
1C. 
Numbers of fractures                            92                                          78                                         84                                        74                       
Total Number                                       750                                        751                                       752                                      750 
% of fractures                                       12.3                                      10.4                                       11.2                                     9.9 
figure 1. Incidence rate of (A) non-vertebral fracture and (B) fragility fracture and (C) percentage of 
vertebral fracture by quartiles of dietary pyridoxine intake.
HR: hazard ratio, CI: confidence interval, Q: quartile. Quartiles of dietary pyridoxine intake.
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figure 1 shows the incidence rate of non-vertebral (A) and fragility (B) fractures, and 
percentage of vertebral fractures (C) by quartiles of dietary pyridoxine intake. The results 
suggest a possible threshold between the fourth and the three remaining quartiles of 
dietary pyridoxine intake. There was a decreased risk of fractures in the highest quartile 
of dietary pyridoxine intake compared with the three remaining quartiles (for incidence 
of non-vertebral fracture HR=0.77, 95%CI=0.65-0.92, p=0.005, for fragility fracture 
HR=0.55, 95%CI=0.40-0.77, p=4x10-4 and for vertebral fracture OR=0.86; 95%CI=0.65-
1.13, p=0.27) after controlling for gender, age and BMI. Further adjustment for other 
dietary B vitamins, protein, energy intake, calcium, vitamin D, A and K intake, co morbid-
ity, and baseline FN-BMD did not alter the results. For the other three B vitamins we 
found no association with fractures (data not shown). 
Since subjects with low vitamin intake might have increased mortality related to 
lifestyle or co-morbidity, we investigated the risk of mortality by quartiles of pyridoxine 
intake (figure 2). Subjects in the lowest quartile had 1.24 times higher risk of mortality 
compared with the three remaining quartiles (95% CI=1.09-1.40, p=0.001). 
Table 7 shows the association between fractures and pyridoxine intake in the subset 
(n=738) of subjects who had Hcy measurements in this subset. Adjustment for Hcy 
levels did not alter the association with fractures.
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figure 2. Risk of mortality by quartiles of dietary pyridoxine intake (highest quartile is reference), Gender 
and age adjusted
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DISCuSSIOn
In this population-based study in elderly individuals, we observed a positive and 
independent relation between dietary intake of riboflavin and pyridoxine with BMD. 
Furthermore, high intake of pyridoxine was associated with a significantly decreased risk 
of fracture. This effect was not modified either by factors related to co-morbidity or by 
dietary intake of other B vitamins (riboflavin, folate, cobalamin), energy, protein, calcium 
and vitamin D. In addition, this effect appears to be independent of FN-BMD. 
Pyridoxine and certain other B vitamins (riboflavin, folate and cobalamin) function 
as cofactors for enzymes that maintain low Hcy levels 27. We hypothesized that high 
intakes of riboflavin, folate, pyridoxine and cobalamin might be related to a lower risk 
of osteoporotic fracture by decreasing Hcy levels. Several biological mechanisms could 
explain how elevated Hcy levels are related to fracture risk. It has been suggested that 
Hcy concentrations may interfere with collagen cross-linking, resulting in poor quality of 
bone and increased susceptibility to fracture 28 . Alternatively, Hcy or related B-vitamins 
could affect the bone cells directly, something that has been suggested by recent stud-
ies of Herrmann et al., who observed direct effects of Hcy on osteoclasts 29.
Among the four studied B vitamins we observed that only higher dietary pyridoxine 
intake was associated with lower risk of fracture. After correcting for Hcy levels, the 
increased risk of fracture at low pyridoxine intake remained unchanged, suggesting that 
the effect of pyridoxine is independent of Hcy levels. However, since Hcy levels were 
available only for a small subgroup of our population and were measured only once, 
we cannot fully address the question whether or not the protective effect of dietary 
pyridoxine on fracture risk is mediated through lowering Hcy or not. The lack of a size-
Table 7. Association of fragility fractures and dietary pyridoxine intake in a subgroup of 738 subjects
with Hcy measurement
Fractures No.fractures/ Total no (%) Relative risk p-value†
Non-vertebral
Model 1 101/739 (13.7) 0.56 (0.30-1.06) 0.08
Model 2 0.59 (0.31-1.13) 0.11
Fragility
Model 1 42/739 (5.7) 0.37 (0.13-1.06) 0.06
Model 2 0.40 (0.13-1.16) 0.09
Vertebral
Model 1 45/428 (6.1) 0.60 (0.24-1.53) 0.29
Model 2 0.71 (0.28-1.79) 0.47
†Calculated by Cox’s proportional hazards regression
Model 1: Gender, age and BMI adjusted
Model 2: Model 1 plus adjustment for Hcy measurement
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able population in which both Hcys and B-vitamins are measured also makes it difficult 
to compare the effect-sizes and/or examine interaction between the two factors with 
respect to their effect on fracture risk. 
The present study confirms earlier findings that gender and BMI are the main de-
terminants of FN-BMD and LS-BMD. Among the four B vitamins, only pyridoxine and 
riboflavin were independent predictors for BMD. This result is not consistent with previ-
ous studies which reported cobalamin 9,13 or folate 12 to be important determinants of 
BMD; however, these studies did not examine the status of riboflavin and pyridoxine. In 
a study by Macdonald et al. 30 a weak but significant association was observed between 
intake of each single dietary B vitamin and BMD; however, most of these associations 
disappeared after adjustment for confounders such as age, height, weight and smoking. 
Because they did not consider all four B vitamins in a multivariate analysis, this casts 
doubt on whether the associations of the B vitamins with BMD were independent of 
each other or not. In contrast, in the present study we examined contributions of all B 
vitamins in a multivariate approach in order to explain the variation in BMD and found 
the effects of both pyridoxine and riboflavin to be independent of each other. 
Little is known about an effect of pyridoxine on bone. Some reports suggest a role for 
this vitamin in maintaining structural integrity of connective tissue. Pyridoxine serves 
as an essential co-factor for lysyl oxidase, a key enzyme for the formation of enzymatic 
cross-links in bone 31. Mice studies showed that pyridoxine deficiency results in a low 
amount of cross-link intermediates and impaired cross-link formation in bone 32. In addi-
tion, a correlation was found between decreased circulating pyridoxine concentrations 
and impaired cross-link formation in bone of human individuals with fracture 33. These 
observations suggest that pyridoxine deficiency may lead to impaired cross-link forma-
tion, resulting in increased bone fragility. 
It is known that pyridoxine acts not only as a cofactor for lysyl oxidase but also as 
cofactor for over 100 enzyme-catalysed reactions in the body, including many involved 
in the synthesis or catabolism of neurotransmitters including gamma-aminobutyrate 
(GABA) 34. Therefore, pyridoxine deficiency could affect the locomotor system and thus 
increase the risk of falling, and thereby increase fracture rates. However, we did not 
observe an effect of pyridoxine intake on the rate of falls, which makes this a less likely 
explanation. 
Because low dietary intake of vitamins may reflect bad dietary habits or compromised 
health, we studied mortality rates across quartiles of dietary pyridoxine intake and 
found an increased risk of mortality in individuals in the lowest quartile. This selective 
mortality might have reduced the contrast in fracture risk between the lowest quartile 
and the highest quartile. Thus, subjects in the lowest quartile of dietary pyridoxine 
intake may have died before a fracture could have occurred. Therefore, the real effect of 
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low pyridoxine intake on fracture risk in the lowest quartile might be even larger than 
that observed in our study. 
The main strengths of the present study are the size of our study population and the 
validated dietary assessment. The study also has some limitations. Because we did not 
have serum levels of B vitamins available to study their relation with BMD and fractures, 
our findings are likely to be biased by self-report. Furthermore, only baseline dietary 
intakes were available, and duration of any possible vitamin B deficiency could not be 
assessed. Nevertheless, in Europe the dietary intakes are relatively stable over time, 
especially among the elderly 35. The validated food frequency test is therefore a good 
measure for long-term assessment of nutrient intake. Using supplement therapy might 
dilute the relation between the quartile of pyridoxine intake with fracture. Nonetheless, 
our results were unchanged after either excluding supplement users at baseline (9.9%) 
from the analysis, or after controlling for B vitamin supplement use, suggesting that it 
is highly unlikely that residual confounding caused by intake of vitamin B supplements 
influenced our results. Although we adjusted for known confounders (such as important 
factors related to co-morbidity and using B vitamin supplements and dietary intake of 
vitamin K, A and, D), we cannot completely exclude that the effect of pyridoxine intake 
on fracture may be a reflection of residual confounding by unknown factors. 
In conclusion, we observed a reduction in the risk of fracture in relation to dietary 
pyridoxine intake. We cannot conclude whether the association between pyridoxine and 
fracture risk is causal. Therefore, performing placebo-controlled trials with pyridoxine 
supplements are needed to elucidate this association. The relative impact of pyridoxine 
intake and Hcy levels and the mechanisms through which these compounds may affect 
the risk of fracture should also be further investigated. 
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AbSTrACT 
background SIRT1 has pleiotropic metabolic functions. We investigated whether SIRT1 
genetic variation is associated with obesity.
Methods In 6,251 elderly subjects from the prospective, population-based Rotterdam 
Study (RS), three Single Nucleotide Polymorphisms (SNPs) in the SIRT1 gene were 
studied in relation with body mass index (BMI) and risk of obesity (BMI > 30kg/m2) and 
prospectively with BMI-change after 6.4 years follow-up. We used cross-sectional data 
from 2,347 participants from the Erasmus Rucphen Family (ERF) study for replication. 
results Minor alleles of rs7895833 (G=20.2%) and rs1467568 (A=36.8%) were associated 
with lower BMI in the RS (p=0.02 and 0.04) and in the replication cohort ERF (p=0.03 and 
0.008) and in studies combined (p=0.002 for both SNPs) with 0.2-0.4 kg/m2 decrease in 
BMI per allele copy. Carriers of these alleles had 13-18% decreased risk of obesity; odds 
ratio (95%CI) for rs7895833 the RS: 0.79 (0.67-0.94), p=0.007; in ERF: 0.93 (0.73-1.19), 
p=0.37 and in the studies combined 0.87 (0.77-0.97), p=0.02; for rs1467568 in the RS: 
0.80 (0.68-0.94), p=0.007; in ERF: 0.85 (0.72-0.99), p=0.04 and in the studies combined: 
0.82 (0.73-0.92), p=0.0009. In the RS, the two variants were also associated with lower 
BMI increase during 6.4 years of follow-up (p=0.01 and 0.08). 
Conclusions Two common variants in SIRT1 are associated with lower BMI in two inde-
pendent Dutch populations. Carriers of these variants have 13-18% decreased risk of 
obesity and gain less weight over time. The availability of SIRT1 stimulators makes these 
findings relevant in light of the growing obesity epidemic.
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InTrODuCTIOn
SIRT1 belongs to the Sirtuin protein family of nicotinamide adenine dinucleotide 
(NAD+)-dependent histone deacetyleases, conserved in evolution from bacteria to 
humans. In lower organisms like yeast, flies, and worms, the silent information regulator 
Sir2 protein is related to longevity 1, 2 and to life span extension after caloric restriction 
3-5. Humans have 7 sirtuins (SIRT1-7) 6 of which SIRT1 has the highest homology to yeast 
Sir2. SIRT1 controls numerous physiological processes and protects cells against stress 
2,7-13. SIRT1 also has an important function in endocrine signaling, specifically in glucose 
and fat metabolism 14-18. Increased hepatic SIRT1 activity enhances gluconeogenesis and 
inhibits glycolysis 15,16. In the pancreas, SIRT1 stimulates insulin secretion in response to 
glucose 17,18. In adipose tissue, SIRT1 interacts with PPARγ to repress its transcriptional 
activity, leading to inhibition of adipogenesis during fasting and activation of lipolysis14. 
This results in fat loss, which is an important component of the effect of caloric restric-
tion on longevity in mammals14. It is not known whether caloric restriction can extend 
lifespan in humans, but clear beneficial effects on cardiovascular risk factors have been 
described 19,20. Fasting leads to up-regulation of SIRT1 in adipose tissue of mice, pigs and 
humans 21-23. Based on findings in lower organisms, it has been hypothesized that stimu-
lation of SIRT1 by agonists may mimic the beneficial effects of caloric restriction in mam-
mals. Resveratrol, a naturally occurring SIRT1 agonist present in red wine and grapes, 
was indeed shown recently to prevent diet-induced obesity and insulin resistance in 
mice and to improve their survival on a high-calorie diet 24,25. If activation of SIRT1 can 
result in loss of body fat without decreasing caloric intake, this could open the door for 
novel treatment and prevention strategies for obesity and related diseases. However, 
in humans, effects of SIRT1 stimulation have not been investigated in vivo and there is 
concern that generalized SIRT1 activation may also have pro-ageing or adverse health 
effects, due to potential pleiotropic and tissue dependent physiological functions 26-29. 
Based on the above findings we hypothesized that genetic variation in SIRT1 may 
influence BMI and the risk of obesity in humans. Previous smaller studies, which have 
examined the relation between variants in SIRT1 and obesity, have led to inconsistent 
findings. A recent case control study of 1.068 obese patients and 313 normal weight 
controls, found a SIRT1 SNP associated to obesity risk. Unexpectedly, male but not 
female carriers of the allele associated with lower obesity risk had increased visceral adi-
posity on CT-scans. This was observed only after adjustment for BMI 30. Another recent 
small study investigating associations of SIRT1 SNPs with metabolic response to lifestyle 
intervention found no association of four SIRT1 SNPs in 917 overweight subjects with 
baseline BMI or with BMI change after 9 months follow-up 31. No population-based stud-
ies with large sample size and replication are available on the association between SIRT1 
genetic variation, BMI, BMI change in time and risk of obesity. We therefore assessed the 
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association of variation in the SIRT1 gene with BMI and the risk of being overweight or 
obese in the large cohort of elderly subjects of the Rotterdam Study (RS). For replication 
we used subjects from a genetically isolated population in the Netherlands, participat-
ing in the Erasmus Rucphen Family (ERF) study. In the RS, we also assessed prospectively 
the relation of SIRT1 variants with BMI change on follow-up. 
MeThODS
The Rotterdam study
The Rotterdam study is a prospective, population-based cohort study among 7,983 
persons aged 55 years and older from a district of Rotterdam, The Netherlands. The 
study was designed to investigate the incidence and determinants of chronic disabling 
diseases. Rationale and design have been described previously 32, 33. Informed consent 
was obtained from each participant, and the Medical Ethics Committee of the Erasmus 
Medical Center Rotterdam approved the study. 
At baseline (1990–1993), all participants were interviewed and underwent extensive 
physical examination. At the second follow-up (1997–1999) these examinations were 
performed according to the same protocol. 
The Erasmus Rucphen Family (ERF) study
This study is a family-based cohort study that is embedded in the Genetic Research in 
Isolated Populations (GRIP) program in the South West of the Netherlands. The aim of 
this program was to identify genetic risk factors in the development of complex disor-
ders 34-36. 
For the ERF study, 22 families that had at least five children baptized in the community 
church between 1850-1900 were identified with the help of genealogical records. All 
living descendants of these couples and their spouses were invited to take part in the 
study. Data collection started in June 2002 and was finished in February 2005. In this 
study, we focused on 2,347 participants for whom complete phenotypic, genotypic and 
genealogical information was available.
The Medical Ethics Committee of Erasmus Medical Center Rotterdam approved of 
both studies and informed consent was obtained from all participants. 
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Measurements
For the two studies identical protocols were used for assembling phenotypic and geno-
typic information. Height (cm) and weight (kg) were measured at the initial examination 
and in the Rotterdam study also at follow-up examinations, in standing position wear-
ing indoor clothes without shoes. Body mass index (BMI) was computed as weight in 
kilograms divided by height in meters squared (kg/m2). 
Genotyping
Three tagging single nucleotide polymorphisms (SNPs) rs7895833, rs1467568 and 
rs497849 were selected from the HapMap database (http://www.hapmap.org) that, 
together with constructed haplotypes, covered 100% of the common (minor allele 
frequency >10%) variation of the SIRT1gene in Caucasians. Genotyping of the SIRT1 
SNPs was performed by Taqman on genomic DNA isolated from peripheral leucocytes 
by standard salting-out procedures. Results were analysed by the ABI Taqman 7900HT 
using the sequence detection system 2.22 software (Applied Biosystems Inc., Foster City, 
CA, USA). To confirm the accuracy of genotyping results, 332 (5%) randomly selected 
samples were re-genotyped with the same method. No inconsistencies were observed. 
All used primers and probes are available on request. 
Statistical Analyses
Hardy-Weinberg equilibrium of the three SIRT1 SNPs was tested with the GENEPOP-
package 37. Subjects were grouped according to genotype for individual SNP alleles, and 
by allele copy number of haplotype alleles. We inferred multimarker haplotypes in the 
Rotterdam study only from these SNPs using the program Phase 38. In the ERF study 
haplotypes were not determined because they could not be inferred with high certainty 
due to the complex pedigree structure. 
Haplotype alleles were numbered in order of decreasing frequency in the population 
(Figure1). Subjects were grouped according to genotype. Genotype groups were based 
on allele copy number (0, 1 and 2, corresponding to non-carriers, heterozygote carriers 
and homozygote carriers, respectively, of the most common haplotype alleles). 
The relation between BMI and SIRT1 genotypes was assessed using linear regression 
analysis, assuming an additive model. The odds ratio of being overweight (BMI > 25 kg/
m2) or obese (BMI > 30 kg/m2) compared to normal weight (BMI = 18.5-25 kg/m2) was 
assessed using logistic regression. The 95% confidence intervals (CIs) of the odds ratios 
(ORs) were calculated as the exponent of the regression coefficient and its standard er-
ror. For the assessment of an association between SIRT1 genotypes and BMI at follow-up 
in the RS we used BMI data of the second follow-up measurement, which was 6.4 + 0.4 
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(mean + SD) years after baseline. Linear regression analysis was also used for the associa-
tion between SIRT1 genotypes and BMI change from baseline to second follow-up. 
In the Rotterdam study, genetic outliers as identified by the IBS clustering analysis 
clustering > 3 standard deviations away from the population mean were removed prior 
to the analyses. Therefore, this population is ethnically homogenous. p-values were cor-
rected by the inflation factor using genomic control method 39. In the Rotterdam study, 
lambda’s (obtained after running genomewide association (GWA) analysis for these 
traits) were small: 1.049, 1.045 and 1.036 for BMI, the risk of overweight and the risk of 
obesity, respectively. 
Since genetic association may be influenced by family relationships we performed 
the analyses in the ERF study with a polygenic model using a variance component ap-
proach with the pedigree information in SOLAR (Sequential Oligogenic Linkage Analysis 
Routine) (http://solar.sfbrgenetics.org). The program takes into account the familial rela-
tionships by estimating heritability from the pedigree data. Subsequently, analyses were 
corrected for residual genomic inflation, which was very small (lambda’s 1.02, values 
obtained from GWAS).
We performed a meta-analysis using fixed effects on the results of the two cohorts 
using the software Review Manager (www.cc-ims.net/RevMan/RevMan5). We also per-
formed meta-analysis for the risk of obesity using results from the Rotterdam and ERF 
studies, together with the published data from the study by Peeters 30 et al. We used the 
rs1467568 and rs7069102 SNPs which are in almost perfect LD (D’=0.99 and r2=0.96) 
to meta-analyse results across studies. All analyses were adjusted for age and sex. The 
statistical analyses were performed using SPSS software, version 15.0 in the RS and with 
SOLAR software, package 2.1.2 in ERF. 
reSulTS
General characteristics
In Table 1, baseline characteristics of the two study populations are presented. In both 
studies a slight majority of participants were females. BMI was 1.1% higher in subjects 
from ERF than in the RS at baseline. 
SIRT1 genotype
figure 1 shows the schematic representation of the SIRT1 locus with the localization 
of the three tagging SNPs and an LD plot of the SNPs (D’ and r2) as well as haplotype 
construction and observed frequencies of the haplotypes in the RS. In the RS, allele and 
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genotype distributions of the three tagging SNPs of SIRT1 follow Hardy Weinberg equi-
librium proportions (P>0.10). LD between the SNPs was high (D’ > 0.8) which enabled us 
to infer multimarker haplotypes in the RS with high confidence. The haplotype frequen-
cies of the four most common haplotypes were 40.9 %, 22.1 %, 20.0% and 16.7%. As 
shown in Figure 1, rs497849 fully tags haplotype 2 and rs7895833 fully tags haplotype 
3. In the ERF study we genotyped the two SNPs showing association with obesity in the 
Table 1. General characteristics of the 2 study populations
  Rotterdam study ERF study
Number 6251 2347
Women (n, %) 3665 (59 %) 1385 (55%)
Age (years) 69.1 ± 8.8 47.5 ± 13.8
range 55.1 – 99.0 17.6 - 85.3
Height (m) 1.67 ± 0.09 1.68 ± 0.09
Weight (kg) 73.2 ± 12.0 75.3 ± 15.4
BMI (kg/m2) baseline 26.3 ± 3.7 26.6 ± 4.4
BMI (kg/m2) follow-up (n ~ 3700) 26.8 ± 3.9
BMI change (kg/m2) follow-up - baseline 0.55 + 1.8
range - 10.0 - +11.0
Values are presented as number (percentage) or mean ± standard deviation. 
BMI: body mass index
figure 1. Schematic representation of the SIRT1 gene with the localization of the 3 tagging SNPs. 
A) LD plot of the SNPs with estimates of r’ in the upper right corner and D’ in the left lower corner. 
B) Haplotype construction and observed frequencies of the haplotypes in the Rotterdam study. 
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RS. These SNPs showed slightly different frequencies between the two studies but were 
also in Hardy Weinberg equilibrium proportions in ERF. 
Relation of SIRT1 variants with BMI
Table 2 shows the relationship of SIRT1 SNPs with BMI in the RS at baseline and at the 
second follow-up examination and the replication data of two SIRT1 SNPs in the ERF 
study. In the RS, two of the three SNPs, rs7895833 and rs1467568, had a significant as-
sociation with BMI at baseline p=0.02 and 0.04 for the two SNPs at baseline, respectively, 
and p=0.02 for both SNPs at the follow-up examination with an allele-dose effect. Car-
riers of the minor alleles of the two SNPS had, on average, 0.2-0.3 kg/m2 decreased BMI 
per allele copy. The third SNP (rs497849) that tags haplotype no. 2 showed no associa-
tion with BMI. Haplotype analysis offered little additional information. For haplotype 1, 
which contains the major alleles for the two SNPs associated with BMI (rs7895833 and 
rs1467568), we observed a significant positive association with BMI that was stronger 
at the second follow-up (Beta=0.273, p=0.008) than at baseline (Beta=0.130, p=0.07). 
Haplotype 4 showed no association with BMI (data not shown). 
Table 2. Associations of SIRT1 genetic variants with BMI in the Rotterdam study (RS) and the ERF study 
MAF*
Difference in BMI
per alle copy 
(kg/m2,SE)
p trend p combined**
rs7895833
RS Baseline 0.20 -0.190 (0.08) 0.02 0.002
RS Follow-up 0.20 -0.291 (0.12) 0.02
ERF study 0.23 -0.350 (0.16) 0.03
rs1467568
RS Baseline 0.37 -0.149 (0.07) 0.04 0.002
RS Follow-up 0.37 -0.238 (0.10) 0.02
ERF study 0.41 -0.372 (0.14) 0.008
rs497849
RS Baseline 0.22 +0.030 (0.08) 0.70
RS Follow-up 0.22 - 0.054 (0.11) 0.62
haplotype 1
RS Baseline 0.41 +0.130 (0.07) 0.07
RS Follow-up 0.41 +0.273 (0.10) 0.008
* MAF: minor allele frequency. Minor allele rs 7895833: G; rs1467568: A; rs497849: A.
**p combined Rotterdam study baseline and ERF study
Analyses adjusted for age, sex, genomic control and in ERF also for family structure
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Similar to the findings in the RS, carriers of the minor alleles of rs7895833 and rs1467568 
had a lower BMI in the ERF study (p=0.03 and 0.008 for the two SNPs, respectively). 
To exclude that associations between the SNPs and BMI were explained by a differ-
ence in body height we also analyzed the relation between the SNPs and height. No 
differences in height were seen between the genotypes (data not shown).
Combined analysis of relation of SIRT1 variants with BMI in two studies
The combined analysis (Table 2) on the outcomes of the two studies RS baseline and ERF 
showed a highly significant association with BMI (p=0.002 for both SNPs).
SIRT1 variants and risk of overweight/obesity
Table 3 A presents the odds ratios (ORs) and 95% CI for the risk of being overweight 
(BMI > 25 kg/m2) compared to normal weight (BMI = 18.5-25 kg/m2) for the two SNPs in 
the SIRT1 gene in the RS at baseline and in the replication cohort of the ERF study. In the 
RS, carriers the minor alleles of rs7895833 had 12% decreased OR of being overweight 
compared to non-carriers of 0.88 (95%CI 0.79 - 0.99), p=0.03. For rs1467568, a similar, yet 
not significant, trend was seen with an OR of 0.91 (95%CI 0.82 - 1.02). Similar results were 
observed in the ERF study, with the strongest and most significant effect for rs1467568. 
At the second follow-up measurement of the RS (n=3,630) the risk of overweight in rela-
tion to SIRT1 was similar to the risk at baseline but did not reach statistical significance 
(for rs7895833: 0.91 (95%CI 0.79-1.05), p=0.21; for rs1467568: 0.90 (95%CI 0.78-1.04), 
p=0.14, data not shown)
In table 3b the odds ratios and 95%CI for the risk of being obese (BMI > 30 kg/m2) 
compared to normal weight (BMI = 18.5-25 kg/m2) are presented for 2 SNPS in the SIRT1 
gene in the two studies. In the RS, both SNPs were associated with the risk of being 
obese. Carriers of minor alleles of the two SNPs had a 20-21% decreased risk with an 
OR for rs7895833 of 0.79 (95%CI 0.67-0.94), p=0.007, and for rs1467568 of 0.80 (95%CI 
0.68-0.94), p=0.007. Similar, trends were seen in the ERF population, only statistically sig-
nificant for rs1467568. At the second follow-up measurement of the RS the association 
with risk of obesity was similar for carriers of the 2 SNPs (OR for rs7895833: 0.78 (95%CI 
0.64-095), p=0.01; for rs1467568: 0.69 (95%CI 0.57-0.84), p=0.0002) (data not shown)
Combined analysis of the risk of overweight/obesity in two studies
Table 3 also presents the data from the meta-analysis of the risk of overweight or obesity 
for the two SNPs in the SIRT1 gene in the Rotterdam study at baseline and the ERF study. 
Carriers of the minor alleles of two SNPs had 9-11% decreased risk of being overweight 
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compared to non-carriers, with OR of 0.91 (95%CI 0.84–0.99), p=0.02 (rs7895833) and 
OR=0.89 (95%CI 0.83-0.97), p=0.005 (rs1467568) with evidence for allele dose-effects (p 
additive model= 0.006 and 3,5x10-6 for rs7895833 and rs1467568, respectively). The risk 
for obesity was decreased by 13-18% (for rs7895833 OR 0.87 (95%CI 0.77-0.97), p=0.02 
and for rs1467568 with OR= 0.82 (95%CI 0.73-0.92), p=0.0009, with allele dose effects (p 
values additive models 0.009 and 0.002 or rs7895833 and rs1467568, respectively). The 
p values for the recessive model were always lower than for the dominant or additive 
models.
Meta analysis with published data
figure 2 shows a forest plot from the meta-analysis of risk of obesity for carriers com-
pared to non-carriers of the A allele of rs1467568 in the Rotterdam and ERF study and 
the C allele of rs7069102 from the study by Peeters et al.30 The A and C alleles of these 
SNPs are in high LD (r2=0.96). The combined odds ratio for the three studies was 0.81 
(95%CI 0.73-0.90), p=0.00007.
Relation of SIRT1 variants with BMI change during follow-up in the Rotterdam 
study
Table 4 presents data from linear regression analysis of change in BMI or body weight 
from baseline to second follow-up for three SNPs in the SIRT1 gene in the RS over a period 
of 6.4 years on average. The two SNPs rs7895833 and rs1467568 that were associated 
with BMI at baseline and follow-up and with the risk of overweight and obesity were 
also associated with BMI change at the second follow-up examination. After adjustment 
 Study name Statistics for each study Odds ratio and 95% CI 
Odds  Lower  Upper  
ratio limit limit p-value 
  Rotterdam study 0.80 0.68 0.94 0.007 
  ERF study 0.85 0.73 0.99 0.04 
  Peeters et al. 0.74 0.57 0.96 0.02 
0.81 0.73 0.90 0.00007 
0,5 1 2 
  Meta-analysis 
Figure 2 
figure 2.
Meta-analysis on the risk of obesity from three studies by SIRT1 genotype for carriers compared to 
noncarriers of the A allele of rs1467568 in the Rotterdam and ERF study and the C allele of rs7069102 from 
the study by Peeters et al 30
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for age and sex the p value for trend was 0.01 for rs7895833, and p=0.08 for rs1467568. 
Adjustment for BMI at baseline did not change these results (data not shown). Findings 
were similar when change of body weight instead of BMI was assessed. 
DISCuSSIOn
In this study we show in two large and independent Dutch Caucasian populations 
that the minor alleles of two common SIRT1 variants are associated with a decreased 
BMI. Carriers of these two common genetic variants had 9-11% decreased risk of being 
overweight and 13-18% decreased risk of being obese compared to non-carriers. In line 
with these findings, we also observed in the Rotterdam study, that carriers of these SIRT1 
variants had a smaller increase of BMI over a 6.4 year follow up period.
Our study is hypothesis driven and based on the known functions of SIRT1 in cell 
cultures and animal studies such as an inhibitory effect of SIRT1 on PPAR gamma in 
adipose tissue14 and a stimulatory effect on peroxisome proliferator-activated receptor 
coactivator-1alpha (PGC-1α) 24, 25. This powerful transcriptional co-activator is regarded 
as a key mediator of many of the known beneficial effects of physical activity on 
skeletal muscle physiology 40. Treatment of mice with resveratrol leads to increased 
mitochondrial biogenesis and increased energy expenditure in mice, possibly by SIRT1 
mediated increase in PGC-1α activity 25. It is also possible that the effects on BMI are 
caused by an influence of SIRT1 on appetite and energy intake, since SIRT1 is highly 
expressed in brain 41. 
Interestingly, SIRT1 has recently been shown to modulate CLOCK-gene expression 42-44 
and it may thus form an intriguing link between sensing of cellular metabolism and the 
circadian clock, which merits further study.
Inhibitory effects of SIRT1 on differentiation of skeletal myoblasts have been shown 
under glucose-restricted conditions in relation with activation of the AMP-activated 
protein kinase (AMPK) 45. Therefore, we cannot exclude that effects on lean mass as well 
as on fat mass explain the relation with BMI that we observed. Further studies are needed 
to investigate the relation between SIRT1 genetic variants and human body composition 
Table 4. Linear regression of change in BMI or weight in the Rotterdam study for 3 SNPs in the SIRT1 gene .
  n beta (SE) p trend* p trend†
rs7895833 3585 -0.126 (0.05) 0.01 0.03
rs1467568 3598 -0.075 (0.04) 0.08 0.13
rs 497849 3622 -0.020 (0.05) 0.69 0.81
*: P trend for BMI change adjusted for age and sex
†: P trend for weight change adjusted for age and sex
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traits and muscle strength. Yet, the strong association with the risk of obesity that we 
found makes a predominant effect on lean mass unlikely since obesity is associated 
more strongly with excess adipose tissue than with excess muscle mass. 
This is the first large population-based study reporting an association between SIRT1 
genetic variation and BMI and obesity in humans with validation in an independent 
population-based cohort. Two recently published genetic studies in humans cor-
roborate our findings. In a Belgian case-control study with 1.068 obese patients and 
313 normal weight controls, carriers of the minor allele of the SNP rs7069102 (which 
is in high LD (r2=0.96) with our SNP rs1467568) had a reduced obesity risk with an OR 
of 0.74 (CI 0.57-0.96, P 0.025) 30. After including their results in a meta-analysis with our 
results the association became more significant and the combined p-value decreased 
from 9x10-4 to 7x10-5. In their study, the variant that was protective against obesity was 
associated with increased visceral obesity as measured by CT-scanning after adjusting 
for BMI in obese male but not female subjects. This unexpected finding may be caused 
by over-adjustment when the decrease in BMI is caused by a decrease in lean as well as 
in fat mass or represent a real sex-specific effect, which needs further investigation. A 
second recent study in 917 overweight German Caucasian subjects found no significant 
change in BMI by SIRT1 genotype, yet we discovered in their data a similar decrease in 
BMI as we found for two SNPs in high LD with ours 31. For carriers of the minor variants 
of rs7069102 (r2=0.96 with rs1467568), BMI was 2.4% lower and for rs730821 (r2=1.0 with 
rs7895833) BMI was 6.1% lower, compared to non-carriers. These differences were not 
significant, possibly because of low power. Recent genome-wide association studies 
(GWAS) have shown that common SNPs contributing to common complex diseases 
have modest effects and require large sample sizes to be discovered 46. The absence of 
SIRT1 among the genome-wide significant new findings in recent GWAS for BMI may 
be explained by the stringent criteria used to correct for multiple testing in GWAS and 
shows the added value of candidate gene analyses.
The strength of our study is the use of two large and independent population based 
cohorts with consistency of findings between studies and between cross-sectional and 
longitudinal analyses. The findings robustly show that SIRT1 variants influence human 
obesity. A limitation of our study is the use of tagging SNPs. The SNPs we selected are 
non-coding and we therefore assume these two variants to be linked with one or more 
functional variants within the SIRT1 gene or its regulatory regions. This will require more 
in depth molecular studies. Future fine-mapping and re-sequencing of the SIRT1 gene 
may detect such functional variants. Further studies into underlying mechanisms and 
body composition are also needed as well as prospective studies on a relation with 
obesity-associated diseases.
The results of our study may have important clinical implications. Obesity has become 
a global epidemic and represents an important risk factor for type 2 diabetes mellitus, 
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hypertension, cardiovascular disease, stroke, some types of cancer and disability. Few, 
if any, effective options for treatment and prevention are available. The findings of 
our study suggest that stimulators of SIRT1 activity may decrease BMI and the risk of 
becoming overweight and obese and may thus provide a valuable new strategy for 
treatment and prevention of obesity and its related diseases. An attractive aspect of our 
findings is that, in contrast to novel genetic findings from GWAS, many data exists on 
SIRT1 biological functions, while in addition several SIRT1 modifiers have already been 
identified. The protective effects of the SIRT1 stimulating flavenoid resveratrol against 
diet-induced obesity in mice may potentially apply to humans as well 25 but its effects 
are not only SIRT1 mediated 47, 48 and low bioavailability is a concern 49. More research 
on pharmacology and possible side effects in humans is necessary for this compound 
as well as for recently developed more potent SIRT1 activators 50. Alternatively, SIRT1 
inhibitors might be of use in cachexia.
In summary, we found that carriers of two common variants in the SIRT1 gene have 
lower BMI, a 13-18% decreased risk of being obese and less BMI gain in time. Together 
with results from recent studies these consistent findings warrant research into a poten-
tial role for SIRT1 activators in prevention and treatment of human obesity. 
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AbSTrACT
SIRT1 protects cells against oxidative stress and ageing. Its activity may be modulated by 
dietary niacin (vitamin B3) intake. We studied the association of SIRT1 genetic variation 
with mortality in subjects with increased oxidative stress (type 2 diabetes and smokers) 
in relation with dietary niacin. In 4573 participants from the Rotterdam Study, includ-
ing 413 subjects with prevalent and 378 with incident type 2 diabetes, 3 SIRT1 tagging 
SNPs were genotyped and all-cause mortality was studied (average follow-up12 years). 
We found no association between SIRT1 variation and mortality in the total population 
and smokers. In subjects with prevalent type 2 diabetes, homozygous carriers of the 
most common SIRT1 haplotype 1 had 1.5 times (95%CI 1.1-2.1) increased mortality risk 
compared to noncarriers. This risk further increased among smokers and with low niacin 
intake. In the lowest tertile of niacin intake, mortality risk was increased 2.3 (1.1-4.9) and 
5.7 (2.5-13.1) times for heterozygous and homozygous carriers of haplotype 1. Subjects 
with incident diabetes showed similar findings but only when they smoked. We con-
clude that in subjects with type 2 diabetes, SIRT1 genetic variation influences survival in 
interaction with dietary niacin and smoking. Correction of niacin deficiency and SIRT1 
modulators may prolong life of patients with diabetes. 
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InTrODuCTIOn
The silent information regulator Sir2 (an NAD+-dependent histone deacetylase) protein 
is related to longevity in lower organisms like yeast, flies, and worms 1, 2. Sir2 has also 
been implicated in life span extension during caloric restriction in these organisms 3-5. 
The protein is highly conserved across species and humans have 7 sirtuins (SIRT1-7) 6. 
Mammalian SIRT1 is most homologous to yeast Sir2 and has been studied most exten-
sively. SIRT1 may protect cells against oxidative and genotoxic stress by binding to and 
deacetylating a large number of substrates, such as tumor suppressor p53 and forkhead 
transcription factors FOXO’s 2. Accordingly, SIRT1 plays a protective role in many cell 
types under various conditions of increased stress 7-13. By regulating other transcription 
factors, SIRT1 is also involved in glucose and fat metabolism 14-18. 
During the deacetylation reaction, SIRT1 consumes NAD+ and produces nicotinamide 
that is a potent SIRT1 inhibitor 7, 19. SIRT1 activity can thus be modulated by pathways 
that influence NAD+, and/or nicotinamide levels 9, 20-22. Nicotinamide and its acid form, 
nicotinic acid, are together known as vitamin B3 or niacin. Both serve as a precursor for 
the generation of cellular NAD+, while only nicotinamide inhibits SIRT1 activity. 
Only a few human genetic association studies on SIRT1 have been published so far. 
Variation in the SIRT1 gene was not associated with longevity in a case-control study 
comparing long-lived individuals with younger subjects 23 and all-cause mortality was 
not influenced by SIRT1 genetic variation in the Leiden 85-Plus study 24. Among healthy 
non-diabetic offspring of type 2 diabetic patients, carriers of SIRT1 polymorphisms had 
increased whole body energy expenditure 25. 
In light of the role of SIRT1 in protection against oxidative stress, we hypothesized that 
a chronic increase in oxidative stress is required to observe an association of genetic 
variation of SIRT1. Diabetes and smoking are well-known conditions with increased oxi-
dative stress. Moreover, hyperglycemia in diabetes leads to activation of the DNA repair 
enzyme Poly (ADP-ribose) polymerase-1 (PARP-1), which also uses NAD+ and produces 
nicotinamide and thus could reduce SIRT1 activity 12, 26-28. SIRT1 expression in diabetes 
may also be decreased due to redox imbalance leading to a lower NAD+ to NADH ra-
tio29. In endothelial progenitor cells (EPCs), SIRT1 expression and activity was reduced 
by treatment with high glucose and SIRT1 was found to be a critical modulator of EPC 
dysfunction during alteration of glucose metabolism 30. Cigarette smoke was shown to 
decrease SIRT1 levels and activity in rat lungs, possibly by oxidative stress 31 and SIRT1 
levels are reduced in macrophages and lungs of smokers and patients with chronic ob-
structive pulmonary disease (COPD) 32. Hence, in subjects with diabetes and in smokers 
SIRT1 expression and/or activity may be decreased while there is a high need for SIRT1 
protection against oxidative stress. 
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In the large cohort of elderly subjects in the Rotterdam study we assessed the associa-
tion of variation in the SIRT1 gene with mortality in persons with type 2 diabetes mellitus 
and in cigarette smokers, according to dietary niacin intake.
reSeArCh DeSIGn AnD MeThODS
The Rotterdam Study
The Rotterdam Study is a prospective, population-based cohort study of 7,983 persons 
aged 55 years and older from a district of Rotterdam, The Netherlands. The study was 
designed to investigate the incidence and determinants of chronic disabling diseases. 
Rationale and design have been described previously 33, 34. Informed consent was ob-
tained from each participant, and the Medical Ethics Committee of the Erasmus Medical 
Center Rotterdam approved the study. 
At baseline (1990–1993), all participants were interviewed and subsequently under-
went extensive physical examination. Three follow-up examinations following to the 
same protocol took place in 1993–1994, 1997–1999, and 2002–2004. In addition, the 
cohort has been continuously monitored for major disease outcomes and mortality 
through computerized linkage of the study database to general practitioners’ medi-
cal files. Procedures on follow-up of all-cause mortality and coding of cardiovascular 
disease (CVD) mortality was described previously 35. Follow up data on overall mortality 
were available until September 1, 2006. Cardiovascular disease-specific mortality was 
based on data until January 1, 2004. 
Assessment of diabetes mellitus type 2
Prevalent diabetes was defined as use of anti-diabetic medication, and/or abnormal 
non-fasting glucose, and/or an abnormal oral glucose tolerance test (OGTT). A Non-
fasting or post-load glucose level of 11.1 mmol/L or over was considered abnormal.
During follow-up, incident cases of diabetes were diagnosed by use of information 
from the general practitioners, the pharmacies’ databases, and our follow-up examina-
tions. Based on guidelines of the American Diabetes Association and WHO we defined 
incident diabetes as follows: fasting plasma glucose level >= 7.0 mmol/l and/or random 
(non-fasting) plasma glucose level >= 11.1 mmol/l and/or use of oral anti-diabetic 
medication and/or use of insulin (but not type 1 diabetes) and/or treatment by diet and 
registered by a general practitioner as having diabetes. 
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Assessment of dietary variables and covariates
At baseline, dietary intake was assessed through an interview by a trained dietician, 
using an extensive, validated semi-quantitative food-frequency questionnaire (SFFQ) 36. 
The amounts of food and drink intake indicated on the SFFQ were converted to en-
ergy intake and nutrient intake by means of the computerized Dutch Food Composition 
Table. For the current study, we used data on dietary intake of niacin (vitamin B3) (in mg/
day), pyridoxine (vitamin B6), riboflavin (vitamin B2), vitamin C and E and total energy 
intake (in kcal/day), total protein intake (g/day), as well as data on use of B vitamin 
and multivitamin supplements. Dietary niacin intake was analyzed using the residual 
method to obtain sex-specific age- and energy-adjusted tertiles 37. At baseline, smoking 
status was assessed during the interview and subjects were classified as current smokers 
or non-smokers of cigarettes.
Measurements
Height (cm) and weight (kg) were measured at the initial examination, in standing 
position wearing indoor clothes without shoes. Body mass index (BMI) was computed 
as weight in kilograms divided by height in meters squared (kg/m2). Two standardized 
blood pressure measurements were taken by using a random zero sphygmomanometer, 
with the participant in sitting position, and averaged. Serum total cholesterol level was 
determined by an enzymatic procedure 38. 
Genotyping
Three tagging single nucleotide polymorphisms (SNPs) were selected from the HapMap 
database (http://www.hapmap.org) that covered most of the common (minor allele 
frequency >10%) variation of the SIRT1 gene in Caucasians: rs7895833, rs1467568 and 
rs497849. Genotyping of the SIRT1 SNPs was performed by Taqman on genomic DNA 
isolated from peripheral leucocytes by standard salting-out procedures. The PCR reac-
tion mixture included 2 ng of genomic DNA in a 2 ml volume and the following reagents: 
FAM and VIC probes (200 nM), primers (0.9 uM), 2x Taqman PCR master mix (ABgene, Ep-
som, UK). Reagents were dispensed in a 384-well plate using the Deerac Equator NS808 
(Deerac Fluidics, Dublin, Ireland). PCR cycling reaction were performed in 384 wells PCR 
plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster City, CA, USA) and 
consisted of initial denaturation for 15 minutes at 95° C, and 40 cycles with denaturation 
of 15 seconds at 95° C and annealing and extension for 60 seconds at 60° C. Results were 
analysed by the ABI Taqman 7900HT using the sequence detection system 2.22 software 
(Applied Biosystems Inc., Foster City, CA, USA). To confirm the accuracy of genotyping 
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results, 332 (5%) randomly selected samples were re-genotyped with the same method. 
No inconsistencies were observed. All used primers and probes are available on request. 
Population for analysis
The study sample for the current study comprised 4573 independently living partici-
pants, with complete dietary data and genotyping information. A total of 1067 of these 
subjects were smokers at baseline, while 413 subjects had diabetes mellitus at baseline 
(prevalent diabetes) and 378 subjects developed diabetes mellitus at follow up (incident 
diabetes). Only subjects with minimal follow-up time of one year after the diagnosis of 
type 2 diabetes were studied to avoid interference from mortality due to underlying co-
morbid conditions. Of the subjects with prevalent diabetes 97 were smokers at baseline 
and of those with incident diabetes 96.
Statistical Analyses
Hardy-Weinberg equilibrium of the SIRT1 SNPs was tested with the GENEPOP-package 
39. We inferred 4 common (frequencies > 10%) multimarker haplotypes from these SNPs 
using the program Phase 40. Haplotype alleles were numbered in order of decreasing 
frequency in the population (Figure 1). Subjects were grouped according to genotype. 
Groups were based on allele copy number (0, 1 and 2, corresponding to non-carriers, 
heterozygote carriers and homozygote carriers, respectively, of the most common 
haplotype alleles). 
Cumulative survival was determined with Cox proportional hazards analyses. The 95% 
confidence intervals (CIs) of the hazard ratios (HRs) were calculated as the exponent 
of the regression coefficient and its standard error. The analyses were adjusted for 
age and sex and BMI. We performed separate analyses in subjects with prevalent and 
incident diabetes to test for consistency. Additional analyses were performed in tertiles 
of age- and energy adjusted intake of niacin. A relationship between intake of niacin 
and intake of protein and vitamin B2, B6, C and E was tested using partial correlations 
with adjustment for age, gender and energy intake. The data were reanalyzed after 
exclusion of users of B vitamin and multivitamin supplements (n = 540). We tested for 
statistical interaction between SIRT1 haplotypes and smoking status and between SIRT1 
haplotypes and niacin intake in tertiles by adding multiplicative interaction terms to 
the model. A p-value of 0.05 was considered significant in all of the analyses. We chose 
not to make any corrections for multiple testing since the main hypothesis of increased 
oxidative stress being necessary for an effect of SIRT1 on mortality was tested in several 
subgroups of increased oxidative stress with the objective of showing consistency. The 
statistical analyses were performed using SPSS software, version 11.0. 
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reSulTS
General characteristics
In Table 1, baseline characteristics of the study population are presented for the total 
population and for subjects with prevalent and incident type 2 diabetes. The subjects 
with prevalent diabetes were 3 years older at baseline and had a higher prevalence 
of myocardial infarction compared to the total population and subjects with incident 
diabetes. Mean (SD) follow up time was 12.0 (3.8), 10.5 (4.3) and 13.0 (2.5) for the total 
population and the subjects with prevalent and incident diabetes, respectively. The 
diagnosis of incident type 2 diabetes was made after a mean (SD) follow up time of 6.5 
(2.8) years.
Dietary niacin (vitamin B3) intake was not different between subjects with and without 
type 2 diabetes. Since it was significantly associated with age, gender, and energy intake 
we adjusted niacin intake for these variables. Niacin intake was also significantly corre-
lated with other B-vitamins, especially with vitamin B6 (partial r = 0.57, p< 0.001) as well 
as with intake of protein, vitamin C and BMI (partial r = 0.52, 0.16 and 0.12, respectively, 
p values < 0.001), but not with the intake of vitamin E or with smoking (data not shown). 
We performed all analyses of niacin intake in sex-specific age- and energy-adjusted 
tertiles. Mean ± SD intake of niacin in the lowest, middle and highest tertile was 12.8 + 
3.1, 15.5 + 2.8 and 19.8 + 5.0 mg per day, respectively. 
Table 1. Baseline characteristics of the study population
Total population  
Prevalent 
diabetesa   Incident diabetesb
n 4573 413 378
Age, years 67.6 (7.7) 70.7 (7.6) 67.0 (6.8)
Women, (n, %) 2665 (58) 242 (58.5) 207 (54.8)
BMI, kg/m2 26.3 (3.6) 27.0 (4.0) 28.3 (3.8)
Intake of energy, kcal/day 1976 (504) 1944 (465) 1933 (473)
Intake of proteins, g/day 81.4 (19.4) 83.4 (19.9) 81.7 (18.1)
Intake of niacin, mg/dayc 16.1 (4.7) 16.0 (4.6) 16.0 (4.3)
Use of B vitamin or multivitamin (n, %) 540 (11.8) 49 (11.9) 41 (10.8)
Current smoking (n, %) 1067 (23.3) 97 (23.5) 87 (23.0)
Prevalent myocardial infarction (n, %) 556 (12.2) 76 (18.4) 49 (13.0)
data are mean (SD) or number (percentage)
a Type 2 diabetes at baseline;
b Type 2 diabetes on follow-up
c The U.S. RDA for niacin is 20 milligrams per day.
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SIRT1 genotype
Allele and genotype distributions of the three tagging SNPs of SIRT1 follow Hardy Wein-
berg equilibrium proportions in all groups (p>0.10). LD between the SNPs was high (D’ > 
0.8) which enabled us to infer multimarker haplotypes with high confidence. The haplo-
type frequencies of the four most common haplotypes were 40.9 %, 22.1 %, 20.0% and 
16.7% (Figure 1). As shown in figure 1, rs497849 fully tags haplotype 2 and rs7895833 
fully tags haplotype 3. Haplotype 1 represents the major alleles of the three SNPs. Figure 
1 shows the schematic representation of the SIRT1 gene with the localization of the 3 
tagging SNPs and an LD plot of the SNPs (D’ and r’) as well as haplotype construction and 
observed frequencies of the haplotypes.
All-cause mortality by SIRT1 genotype
No association was found between any of the four SIRT1 haplotypes and all-cause mortal-
ity in the total population or in the group of smokers (data not shown). The mortality risk 
according to the number of copies of the most frequent haplotype 1 is shown in Table 
2. Homozygosity for haplotype 1 increased all-cause mortality by 50% in subjects with 
prevalent type 2 diabetes (diabetes at baseline) (HR=1.5, 95% CI, 1.1-2.1). The smokers 
figure 1.
Schematic representation of the SIRT1 gene with the localisation of the 3 tagging SNPs. 
A) LD plot of the SNPs with estimates of r’ in the upper right corner and D’ in the left lower corner. 
B) Haplotype construction and observed frequencies of the haplotypes in the current study. 
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among them had a higher risk estimate of 2.2 (95% CI, 1.0-4.7), but the interaction term 
between SIRT1 haplotype 1 and smoking was not significant. In subjects with incident 
diabetes (diabetes on follow-up), significant excess mortality was also present among 
those who smoked (HR for heterozygotes: 2.2 (95% CI, 1.0-4.9); for homozygotes: 3.0 
(95% CI, 1.1-8.2)) with a significant interaction between SIRT1 haplotypes 1 and smoking 
(p=0.008). All analyses were adjusted for age, gender, and BMI at baseline. 
Effect of dietary niacin intake
We repeated the analyses in sex-specific age- and energy-adjusted tertiles of niacin 
intake. In the total population, SIRT1 haplotype 1 was not associated with mortality 
in any of the 3 tertiles of niacin intake. Table 3 summarizes the results for the lowest 
tertile of dietary niacin. Looking at the smokers in general, we found 50% increase in the 
mortality risk (95% CI, 1.1-2.1) in the lowest tertile of niacin intake that was significant for 
heterozygotes and for carriers versus noncarriers of haplotype 1.
Table 2. Risk of mortality by SIRT1 haplotype 1 in the total population, in smokers and in subjects with 
diabetes 
 
no. of
Person-years
no. of 
Deaths
hr
(95%CI)
no. of
Person-years
no. of 
Deaths
hr 
(95%CI)
Total population (n:4573) Current smokers (n:1067)
0a 18,984 611 1 (Reference) 4,490 151 1 (Reference)
1 27,152 862 1.0 (0.9-1.1) 6,445 240 1.1 (0.9-1.4)
2 8,815 276 1.0 (0.9-1.2) 2,083 73 1.1 (0.8-1.5)
Prevalent diabetesb (n:413) Incident diabetesc (n:378)
0a 1,548 79 1 (Reference) 1,585 40 1 (Reference)
1 2,001 109 1.1 (0.8-1.5) 2,600 79 1.0 (0.7-1.4)
2 806 56 1.5 (1.1-2.2)* 735 16 0.8 (0.4-1.4)
Prevalent diabetes non-smoking (316) Prevalent diabetes smoking (n:97)
0a 1,220 64 1 (Reference) 331 15 1 (Reference)
1 1,534 82 1.0 (0.7-1.4) 459 27 1.7 (0.9-3.3)
2 592 40 1.4 (0.9-2.0) 214 16 2.2 (1.0-4.7)*
Incident diabetes non-smoking (291) Incident diabetes smoking (n: 87)
0a 1,192 31 1 (Reference) 393 9 1 (Reference)
1 2,086 53 0.8 (0.5-1.2) 508 26 2.2 (1.0-4.9)
2 559 9 0.5 (0.2-1.1) 176 7 3.0 (1.1-8.2)*
All analyses adjusted for sex and age and BMI
a 0, 1 and 2 denote number of copies of haplotype 1
b Type 2 diabetes at baseline 
c Type 2 diabetes on follow-up
* P trend: p< 0.05
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In subjects with prevalent diabetes, a significant interaction was observed between 
niacin intake in tertiles and SIRT1 haplotype 1 (p=0.003). In the lowest tertile of niacin 
intake, the subjects with prevalent diabetes had a 2.3 (95% CI, 1.1- 4.9) times increased 
risk of mortality when they were heterozygous for haplotype 1 and a 5.7 (95% CI, 2.5-
13.1) times increased risk when they were homozygous (p for trend = 0.00002). The 
smokers among them tended to have a higher point estimate than the non-smokers 
but confidence intervals were very wide as a result of the low numbers (HR:10.7, 95% 
CI,1.0-110 for heterozygous carriers who smoke). 
When we examined the three SNPs individually, we observed decreased mortality risk 
for carriers of the minor alleles for all three SNPs in subjects with prevalent diabetes 
and low niacin intake, most marked for rs1467568 and rs7895833 (data not shown). The 
effects were stronger (and in opposite direction) for carriers of haplotype 1.
figure 2 shows a Kaplan-Meier curve with the mortality of the persons with prevalent 
type 2 diabetes in the lowest tertile of niacin intake according to SIRT1 haplotype 1 
Table 3. Risk of mortality by SIRT1 haplotype 1 in the lowest tertile of niacin intake in the total 
population, in smokers, and in subjects with diabetes
 
no. of
Person Years
no. of 
Deaths
hr
(95%CI)
no. of
Person Years
no. of 
Deaths
hr 
(95%CI)
Total population (n:1524) Current smokers (n:367)
0a 6,324 193 1 (Reference) 1,648 52 1 (Reference)
1 9,068 306 1.1 (0.9-1.3) 2,189 95 1.5 (1.1-2.1)
2 2,844 82 1.1 (0.8-1.4) 666 24 1.5 (0.9-2.5) *
Prevalent diabetesb: (n: 110) Incident diabetesc (n:121)
0a 413 9 1 (Reference) 529 14 1 (Reference)
1 583 30 2.3 (1.1- 4.9) 800 26 1.1 (0.8-2.2)
2 199 19 5.7 (2.5-13.1)*** 204 8 1.9 (0.8-4.7)
Prevalent diabetes non-smoking (n:84) Prevalent diabetes smoking (n:26)
0a 313 8 1 (Reference) 102 1 1 (Reference)
1 456 24 1.8 (0.8-4.0) 124 6 10.7 (1.0-111)
2 118 14 5.6 (2.2-14.2)** 80 5 9.9 (0.7-133)
Incident diabetes non-smoking (n:90) Incident diabetes smoking (n:31)
0a 403 11 1 (Reference) 127 3 1 (Reference)
1 616 13 0.7 (0.3-1.7) 181 13 4.9 (1.3-19.4)
2 145 5 1.5 (0.5-4.6) 59 3 3.1 (0.6-16.3)
All analyses adjusted for sex and age and BMI
a 0, 1 and 2 denote number of copies of haplotype 1
b Type 2 diabetes at baseline
c Type 2 diabetes on follow-up
* P trend: p< 0.05,** P trend < 0.001, ***P trend: <0.0001
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genotype. In the middle and highest tertile of niacin intake no excess mortality was 
found in relation to SIRT1 haplotype 1 (figure 3). 
In subjects with incident diabetes, the risk of mortality was not significantly higher for 
carriers of SIRT1 haplotype 1 in the lowest niacin tertile, although there was a trend in 
the same direction as for the subjects with prevalent diabetes (Table 3). However, when 
they smoked the risk of mortality was also significantly higher in the lowest tertile of 
niacin intake (HR for heterozygotes: 4.9 (95% CI,1.3-19.4), for homozygotes: 3.1 (95% CI, 
0.6 –16.3), for carriers compared to noncarriers: 4.3 (95% CI, 1.2-15.6)). 
Figure 2 
figure 2. 
Kaplan-Meier curve of mortality in subjects with prevalent diabetes in the lowest tertile of niacin intake by 
SIRT1 haplotype 1 genotype.
figure 3. 
Kaplan-Meier curve of mortality in subjects with prevalent diabetes in the middle and highest tertile of 
niacin intake by SIRT1 haplotype 1 genotype.
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The results were not substantially different after adjusting for other risk factors of 
cardiovascular disease (blood pressure and cholesterol level) and for intake of protein 
and other vitamins (B6, E and C) and when niacin containing supplement users were 
excluded from the analyses (data not shown). 
Cardiovascular mortality
The homozygous carriers of SIRT1 haplotype 1 with prevalent diabetes had 1.9 times 
higher cardiovascular disease mortality risk than noncarriers (95% CI, 1.1-3.2). We also 
found a significant interaction (p=0.02) in the persons with prevalent type 2 diabetes 
between niacin intake in tertiles and SIRT1 haplotype 1 for cardiovascular mortality. 
In the lowest tertile of niacin intake, the HR was 2.0 for heterozygous carriers (95% CI, 
0.4-9.9) and 9.7 for homozygous carriers (95% CI, 2.8-45) compared with noncarriers, p 
trend =0.0004.
DISCuSSIOn
In this prospective population-based study, subjects with prevalent type 2 diabetes had 
a 50% higher risk of all-cause mortality and in particular cardiovascular mortality when 
they were homozygous carriers of the most common SIRT1 haplotype 1 compared to 
noncarriers. This risk further increased among smokers and in those with low dietary 
niacin intake. In the lowest tertile of niacin intake, they had a 2.3 and 5.7 times increased 
risk of death when they were heterozygous or homozygous for SIRT1 haplotype 1, 
respectively. In the subjects with incident type 2 diabetes, we also found higher mortal-
ity for carriers of this haplotype but only for the smokers among them, with a further 
increase of the risk in the lowest tertile of niacin intake. The absence of an association 
with mortality in the total population is in line with data from two previous studies 
23, 24 and supports our hypothesis that increased oxidative stress may be necessary to 
show an effect of genetic variation in SIRT1 on mortality. Diabetes duration can strongly 
influence the outcome of genetic studies of complications of diabetes 41. Therefore, we 
decided to study prevalent and incident cases separately and use incident cases to show 
consistency of our findings. The results suggest that even in incident cases, with shorter 
duration of diabetes by definition, a detectable effect from the SIRT1 haplotype 1 risk 
allele can be observed when they are exposed to an additional source of oxidative stress 
like smoking of cigarettes. From our data we cannot conclude whether differences in 
mortality by the SIRT1 haplotype 1 were associated with increased or decreased SIRT1 
activity. Based on the known cell-protective data in animals and in vitro studies, our 
results would predict that carriers of the SIRT1 haplotype 1 had reduced SIRT1 activity, 
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influencing survival only under adverse circumstances. In the Leiden 85-Plus study (24) 
heterozygous carriers of the rs3758391 minor allele had lower cardiovascular mortality 
risk, although this was considered not significant because multiple end-points were 
tested in this study. Since this SNP is in high LD with SNP rs1467568 (r’ 0.96) this finding 
is in line with the decreased mortality risk that we found in the subjects with diabetes 
and low niacin intake carrying the minor allele of rs1467568 and the increased mortality 
risk for carriers of haplotype 1. 
We studied the effect of dietary niacin intake because of its potential involvement in 
SIRT1 enzymatic activity, as a precursor of NAD+ that SIRT1 needs, while nicotinamide is 
a strong inhibitor of SIRT1 activity. We found effects of SIRT1 genotype on mortality only 
in the lowest tertile of niacin intake. In theory, this could be explained by a decreased 
inhibition of SIRT1 by low nicotinamide intake. A more likely explanation is that low 
niacin intake further reduced SIRT1 activity due to lower NAD+ production. This might 
be particularly relevant when NAD+ is used by the DNA repair enzyme Poly (ADP-ribose) 
polymerase-1 (PARP-1). Increased activation of this enzyme due to high oxidative stress 
in diabetes is considered an important factor in the pathogenesis of endothelial dys-
function and other diabetic complications 27. 
Alternatively, an overall lower dietary anti-oxidant content in the lowest tertile of nia-
cin intake might explain the effects we found, although our findings did not disappear 
after adjustment for the vitamins with anti-oxidant properties associated with niacin 
intake (vitamin B6 and C). Good sources of niacin are meat (especially liver and heart), 
fish, nuts and some fruits and vegetables and coffee. Although protein intake was as-
sociated with niacin intake, adjustment for it did not influence the mortality data. 
Methodological strengths of this study include the prospective design with validated 
dietary assessments and virtually complete follow up with a large number of person-
years. Among the methodological constraints of our study are the limited statistical 
power to perform stratified analyses and the possibility of misclassification of nutrient 
intake inherent to food frequency questionnaires. This might however only be expected 
to weaken a true interaction between dietary intake and genotype. Only baseline dietary 
intakes were available and dietary intake may not necessarily correspond to actual levels 
of B vitamins. Unfortunately current methods of assessing niacin status by measurement 
of blood nicotinamide or urinary excretion of niacin metabolites are considered unsat-
isfactory 42. Nevertheless, dietary intakes are quite stable in Europe, especially among 
elderly 43 and so a single validated food frequency test is considered as a good measure 
for long-term assessment of nutrient intake. 
Although our results are very consistent, we cannot exclude population specific fac-
tors that were unaccounted for and this makes replication in other diabetes populations 
necessary. The findings may have important clinical implications. First, that niacin defi-
ciency appears undesirable in subjects with type 2 diabetes and may require correction, 
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especially in carriers of SIRT1 haplotype 1. Second, that smoking seems extra deleterious 
for carriers of SIRT1 haplotype 1 with type 2 diabetes. Last, the findings suggest that high 
mortality in a disease that has reached epidemic proportions worldwide may potentially 
be modified by actions that interfere with SIRT1 activity and do justify further investi-
gations into SIRT1 stimulators like resveratrol on morbidity and mortality in patients 
with diabetes. This flavenoid, present in red wine and grapes, was recently shown to 
prevent diet-induced obesity and insulin resistance in mice and improve survival in mice 
on a high-calorie diet 25, 44. It also protected endothelial cells in rats against cigarette 
smoking-induced oxidative effects, most likely in a SIRT1 dependent way 45. Resveratrol, 
however, also has many SIRT1 independent effects and it has low bioavailability 46. Novel 
and more potent activators of SIRT1 were recently identified, that improve glucose ho-
meostasis of insulin-resistant animals 47. Whether these compounds have therapeutic 
potential in situations with reduced SIRT1 expression and/or activity and increased 
oxidative stress like diabetes and smoking can be studied once data on pharmacology 
and safety in humans are available.
In summary, in subjects with type 2 diabetes SIRT1 genetic variation influences sur-
vival in interaction with dietary niacin intake and cigarette smoking, most likely through 
an effect on cardiovascular mortality. Correction of niacin deficiency and modulators of 
SIRT1 activity may increase survival of patients with diabetes. 
AbbrevIATIOnS
BMI, Body mass index; LD, Linkage Disequilibrium; (PARP-1), Poly (ADP-ribose) poly-
merase-1; NAD+, Nicotinamide Adenine Dinucleotide; SIRT, Silent Information Regulator 
Two; SNP, Single Nucleotide Polymorphism.
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AbSTrACT
background Variation in the SIRT1 gene has been associated with body mass index 
(BMI) and risk of obesity. Since dietary factors may influence SIRT1 activity we studied 
gene-diet interaction on BMI at the SIRT1 locus.
Methods In 4,575 elderly men and women of the prospective, population-based Rotter-
dam Study (RS), the effect of SIRT1 genetic variants was studied on BMI in relation with 
dietary intake of energy, fat, calcium, milk, antioxidant vitamins and niacin as precursor 
for NAD+. We used cross-sectional data from 2,566 participants from the Erasmus Ruc-
phen Family (ERF) study for replication of findings with milk intake. 
results There was no difference in energy and fat intake by SIRT1 genotypes. Significant 
associations of the SIRT1 genetic variants with BMI were found in the lowest tertiles of 
intake of energy, fat and vitamins and in the highest tertile of calcium and milk intake. 
Interaction terms with the SIRT1variants were significant for intake of vitamin E (p=0.06, 
0.005 and 0.0005 for rs7895833, rs1467568 and haplotype 1, respectively) and calcium 
(p=0.02, 0.01 and 0.13 for rs7895833, rs1467568 and haplotype 1, respectively). In ERF, 
we found associations between the two SNPs rs7895833, rs1467568 and BMI in the high-
est tertiles of milk intake. 
Conclusions Dietary intake of anti-oxidants, especially Vitamin E, and of calcium and 
milk modify the associations of SIRT1 variants with BMI. These data support that gene-
diet interactions influence BMI. Additional replication of our findings and further in 
depth studies of specific dietary patterns that modify SIRT1 may lead to clinical studies 
with dietary modification of SIRT1 to influence obesity.
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InTrODuCTIOn
Obesity has become a global epidemic and represents an important risk factor for 
many diseases such as type 2 diabetes mellitus, hypertension, cardiovascular disease, 
stroke, some types of cancer and disability. The growing prevalence of obesity is most 
likely driven by increasing caloric intake and decreasing energy expenditure by physical 
activity, but individual susceptibility varies widely and is strongly influenced by genetic 
factors. Twin, adoption and family studies have shown that between 40 and 80% of inter-
individual variation of body mass index (BMI) is heritable 1-3. A lot of genetic association 
studies on obesity traits have been published but only a few have been consistently 
re plicated 4, 5. Early genome-wide association studies (GWAS), identified both FTO and 
MC4R as genes related to BMI 6, 7. Several new loci have been identified in three recent 
obesity related GWAS studies 8-10. Collectively, these variants explain only a small propor-
tion of the genetic influence of obesity 8-10. It is possible that interactions between genes 
and between genes and environmental factors such as diet and physical activity explain 
part of the so far unexplained genetic variance of complex traits like BMI. We recently 
demonstrated that genetic variation in the SIRT1 gene is associated with BMI and risk of 
obesity (Zillikens et al, manuscript under review). SIRT1 belongs to the Sirtuin protein 
family of nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetyleases. 
In lower organisms like yeast, flies, and worms, the silent information regulator Sir2 
protein is related to longevity 11, 12 and to life span extension after caloric restriction 13-15. 
The closest Sir2 human homologue SIRT1 controls numerous physiological processes, 
protects cells against stress, such as oxidative stress 16-18 and has an important func-
tion in endocrine signaling, specifically in glucose and fat metabolism 19-22. The NAD+ 
dependence of SIRT1 links it activity to the metabolic state of an organism. Thus we 
hypothesized that dietary factors that regulate SIRT1 could modify the association of 
SIRT1 genetic variants with BMI. Fasting leads to up-regulation of SIRT1 in adipose tissue 
of mice, pigs and humans 23-25 and the SIRT1 stimulator resveratrol protects mice against 
a high-fat diet 26, 27. NAD+ is synthesized from the precursors nicotinic acid and nicotin-
amide, collectively known as niacin or vitamin B3 while a small part of cellular niacin is 
formed de novo from the amino-acid tryptophan 28. Recently, a newly discovered NAD+ 
precursor in milk called nicotinamide riboside was found to stimulate SIRT1 activity, 29, 30. 
Thus, intake of precursors of NAD+ may influence SIRT1 activity.
Moreover, since SIRT1 protects cells under conditions of oxidative stress and is also 
regulated itself by oxidative stress 31, we hypothesized that SIRT1 function is influenced 
by dietary intake of anti-oxidants. Based on these potential influences of dietary fac-
tors on SIRT1, we investigated in the large cohort of elderly subjects of the Rotterdam 
study (RS) whether interaction between SIRT1 genetic variation and diet influences 
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BMI. Specifically, we studied a relation with dietary intake of energy, fat, calcium, milk, 
antioxidant vitamins (beta-carotene, vitamin C and E) and niacin. 
To replicate findings of milk consumption we used data from subjects from a genetically 
isolated population in the Netherlands, participating in the Erasmus Rucphen Family 
(ERF) study. 
MeThODS
The Rotterdam Study
The Rotterdam study is a prospective, population-based cohort study among 7,983 
persons aged 55 years and older from a district of Rotterdam, The Netherlands. The 
study was designed to investigate the incidence and determinants of chronic disabling 
diseases. Rationale and design have been described previously 32, 33. Informed consent 
was obtained from each participant, and the Medical Ethics Committee of the Erasmus 
Medical Center Rotterdam approved the study. At baseline (1990–1993), all participants 
were interviewed and subsequently underwent extensive physical examination. Three 
follow-up examinations following to the same protocol took place in 1993–1994, 
1997–1999, and 2002–2004
The Erasmus Rucphen Family (ERF) study
This study is a family-based cohort study that is embedded in the Genetic Research in 
Isolated Populations (GRIP) program in the South West of the Netherlands. The aim of 
this program was to identify genetic risk factors in the development of complex disor-
ders 34-36. 
For the ERF study, 22 families that had at least five children baptized in the community 
church between 1850-1900 were identified with the help of genealogical records. All 
living descendants of these couples and their spouses were invited to take part in the 
study. Data collection started in June 2002 and was finished in February 2005. In this 
study, we focused on 2,566 participants for whom complete phenotypic, genotypic and 
genealogical information was available.
The Medical Ethics Committee of Erasmus Medical Center Rotterdam approved of 
both studies and informed consent was obtained from all participants. 
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Assessment of dietary variables
In the Rotterdam study dietary intake was assessed at baseline, through an interview 
by a trained dietician, using an extensive, validated semi-quantitative food-frequency 
questionnaire (SFFQ) 37. 
The amounts of food and drink intake indicated on the SFFQ were converted to 
energy intake and nutrient intake by means of the computerized Dutch Food Composi-
tion Table. For the current study, we used data on dietary intake of energy (in kcal/day), 
macronutrients (fat, protein and carbohydrates in g/day), calcium, milk and the vitamins 
beta-carotene (vitamin A), vitamin C and vitamin E and niacin (vitamin B3) (in mg/day). 
Also at baseline, we recorded data on the use of vitamin supplements. Dietary intake 
was analyzed using the residual method to obtain sex-specific energy-adjusted tertiles 
and when intake was associated with age we used age- and energy-adjusted tertiles 38. 
Tertiles of sex-specific energy intake were created with and without adjustment for body 
weight. In ERF, participating subjects were asked in a home questionnaire for the current 
average amount of glasses of milk they drink per day. Since no information was obtained 
on total caloric intake, sex-specific tertiles of milk intake were constructed after adjust-
ment for body weight.
Measurements
For the two studies identical protocols were used for assembling phenotypic and ge-
notypic information. Height (cm) and weight (kg) were measured in standing position 
wearing indoor clothes without shoes. Body mass index (BMI) was computed as weight 
in kilograms divided by height in meters squared (kg/m2). 
Genotyping
Three tagging single nucleotide polymorphisms (SNPs) rs7895833, rs1467568 and 
rs497849 were selected from the HapMap database (http://www.hapmap.org) as 
described previously 39. Together with constructed haplotypes, they covered 100% of 
the common (minor allele frequency >10%) variation of the SIRT1gene in Caucasians. 
Genotyping of the SIRT1 SNPs was performed by Taqman as described earlier 39. For the 
current study, data were analysed for the 2 SNPs (rs7895833, rs1467568) and the most 
common haplotype 1, which were associated previously with BMI and risk of obesity 
(Zillikens et al, Manuscript under review).
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Statistical Analyses
Hardy-Weinberg equilibrium of the two SIRT1 SNPs was tested with the GENEPOP-
package 40. Subjects were grouped by genotype for individual SNP alleles, and by allele 
copy number of haplotype 1. In the Rotterdam study, multimarker haplotypes were 
inferred from the three SNPs using the program Phase 41. figure 1 (chapter 6 page 100) 
shows the schematic representation of the SIRT1 locus with the localization of the three 
tagging SNPs and an LD plot of the SNPs (r’ and R2) as well as haplotype construction 
and observed frequencies of the haplotypes in the RS. As described earlier (Zillikens 
et al, manuscript under review), in the Rotterdam study, allele and genotype distribu-
tions of the three tagging SNPs of SIRT1 follow Hardy Weinberg equilibrium proportions 
(p>0.10). LD between the SNPs was high (D’ > 0.8) which enabled us to infer multimarker 
haplotypes in the Rotterdam study with high confidence. The haplotype frequencies of 
the four most common haplotypes were 40.9 %, 22.1 %, 20.0% and 16.7%. In the ERF 
study only the two SNPs (rs7895833 and rs1467568) were genotyped that previously 
showed association with BMI in the RS (Zillikens et al, manuscript under review). These 
SNPs showed slightly different frequencies between the two studies but were also in 
Hardy Weinberg equilibrium proportions in ERF. In the ERF study haplotypes were not 
determined because they could not be inferred with high certainty due to the complex 
pedigree structure. 
The relation between BMI and SIRT1 genotypes was assessed using linear regression 
analysis, assuming an additive model. In the ERF study, the p values were corrected by the 
inflation factor using genomic control method because of the familial relationships 42. 
We tested for statistical interaction between SIRT1 variants and nutrient intake in tertiles 
by adding multiplicative interaction terms to the model. All analyses were adjusted for 
age and sex. The statistical analyses were performed using SPSS software, version 15.0. A 
p value of < 0.05 was considered statistically significant, while we considered Bonferroni 
correction for multiple testing of 8 independent dietary variables and 3 genetic variants 
(significant p values below 0.002). This correction might be too stringent for the current 
study since our genetic and dietary variables are not totally independent. 
reSulTS
General characteristics
In Table 1, baseline characteristics of the two study populations are presented. In both 
studies a slight majority of participants was female. BMI was 1.5% higher in subjects 
from ERF than in the RS at baseline. For the subjects of the Rotterdam study, dietary 
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intakes of energy and fat and micronutrients are presented. For the subjects from the 
ERF study only intake of milk is presented. 
Effect of intake of vitamin supplements on the association of SIRT1 variants with 
BMI
Table 2 shows the relationship between the two SIRT1 SNPs rs7895833 and rs1467568 
and haplotype 1 and BMI in the Rotterdam study. For the current sample of 4,575 subjects 
with complete dietary and genotype information the association between SIRT1 genetic 
variation and BMI was significant only for haplotype 1 (p= 0.03) with carriers having 
higher BMI. For rs7895833 and rs1467568 the relations were of borderline significance 
in this smaller sample of the original study with carriers of the minor alleles having lower 
BMI than non-carriers. Effect sizes were stronger and p values were lower for all three 
SIRT1 variants when the analysis was limited to the non-users of vitamin supplements. 
Among the users of vitamin supplements (n = 775) there was no association between 
SIRT1 variants and BMI. 
Table 1. General and body composition characteristics of the 2 study populations
  Rotterdam study ERF study
Number 4,575 2,566
Women (n, %) 3191 (59.1 %) 1321 (55.5%)
Age (years) 67.7 ± 7.8 48.3 ± 14.2
range 55.0 – 94.5 16.7 - 86.1
Height (m) 1.67 ± 9.2 1.68 ± 9.4
Weight (kg) 73.6 ± 11.7 75.3 ± 14.8
BMI (kg/m2) 26.3 ± 3.7 26.7 ± 4.4
Users of vitamin supplements (n,%) 775 (17%) NA
Energy intake (kJ/day) 8259 + 2110 NA
Energy intake (kcal/day) 1974 + 504 NA
Fat intake (g/day) 80.6 ± 27.4 NA
Betacarotene intake(mg/day) 2.71 ± 1.66 NA
Vitamin C intake(mg/day) 120.7 ± 54.2 NA
Vitamin E intake(mg/day) 13.8 ± 6.2 NA
Niacin intake (mg/day) 16.3 ± 4.7 NA
Calcium intake (mg/day) 1127 ± 395 NA
Milk intake (ml/day) 397 ± 254 254 ± 278
Data are mean + SD or numbers (percentage).
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Intake of energy and macronutrients by SIRT1 variants
Table 3 shows mean intake of energy and of macronutrients by SIRT1 genotype in the 
Rotterdam study. There were no significant differences in dietary intake of energy, fat, 
proteins and carbohydrates by SIRT1 genotype. Most importantly, carriers of the geno-
type with the lowest BMI (carriers of the minor alleles of rs7895833 and rs1467568 and 
non-carriers of haplotype 1) did not have decreased intake of energy or fat. Also, when 
intakes of macronutrients were adjusted for energy intake (and when energy intake was 
adjusted for body weight) there were no significant differences in intake between the 
SIRT1 variants. 
Table 2. BMI by SIRT1 genotype in all subjects and stratified by use of vitamin supplements in the 
Rotterdam study
genotype beta (SE) p trend
rs7895833 AA AG GG
all subjects No. 2,898 1,489 188
BMI 26.4 (0.07) 26.2 (0.09) 26.2 (0.26) -0.126 (0.09) 0.18
non-users of supplements No. 2414 1219 167
BMI 26.5(0.07) 26.2 (0.10) 26.2 (0.27)) -0.206 (0.10) 0.04
users of supplements No. 484 270 21
BMI 26.0 (0.17) 26.3 (0.23) 26.6 (0.83) +0.312 (0.25) 0.22
rs1467568 GG GA AA
all subjects No. 1,826 2,230 619
BMI 26.5 (0.08) 26.2 (0.08) 26.3(0.14) -0.122(0.08) 0.12
non-users of supplements No. 1,525 1,754 521
BMI 26.5 (0.08) 26.2 (0.09) 26.3(0.15) -0.156 (0.08) 0.06
users of supplements No. 309 392 102
BMI 26.1 (0.22) 26.1 (0.20) 26.3 (0.39) +0.053 (0.20) 0.80
haplotype 1 0 copies 1 copy 2 copies
all subjects No. 1,587 2,242 746
BMI 26.3 (0.09) 26.3 (0.08) 26.7 (0.13) +0.167 (0.08) 0.03
non-users of supplements No. 1308 1863 746
BMI 26.2 (1.0) 26.3 (0.08) 26.7 (0.14) +0.205 (0.08) 0.01
users of supplements No. 279 379 117
BMI 26.2 (0.23) 26.1 (0.20) 26.2 (0.35) -0.039 (0.20) 0.85
BMI: mean (SE), adjusted for age and sex
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Correlations between dietary components
In table 4 the spearman correlation coefficients are presented between the different 
dietary components under investigation in the current study.
As expected, intake of energy correlated strongly with intake of carbohydrates, fat 
and proteins (spearman’s rho > 0.73). Energy intake correlated significantly with intake 
of all vitamins. There were modest correlations between intake of the 4 vitamins, with 
the highest correlation coefficient between intake of niacin and vitamin E (rho = 0.33) 
and the lowest between vitamin C and niacin (rho = 0.17) and between vitamin C and 
vitamin E (rho = 0.17). After adjustment for energy intake, vitamin intakes were also 
correlated with each other except for intake of vitamin E with niacin intake (data not 
shown). Intake of total calcium and milk were highly correlated (rho = 0.80). 
Table 3. Intake of macronutrients by SIRT1 genotype in the Rotterdam study
genotype p model 1 p model 2
rs7895833 AA AG GG
No. 2,898 1,489 188
Energy intake (KJ/day) 8259 (35.0) 8254 (48.8) 8294 (137) 0.96
Fat intake (Grams/day) 80.5 (0.47) 80.6 (0.67) 80.1 (1.88) 0.96 0.59
Protein intake (Grams/day) 81.4 (0.34) 81.4(0.47) 80.3 (1.33) 0.72 0.39
Carbohydrate intake (Grams/day) 212.0 (1.08) 212.4 (1.51) 218.5 (4.25) 0.34 0.10
rs1467568 GG GA AA
No. 1,826 2,230 619
Energy intake (Kcal/day) 8271 (44.0) 8234 (40.8) 8310(75.6) 0.63
Fat intake (Grams/day) 80.6 (0.60) 80.2 (0.56) 81.3 (1.04) 0.63 0.93
Protein intake (Grams/day) 81.7 (0.42) 81.0 (0.39) 81.6 (0.73) 0.71 0.60
Carbohydrate intake (Grams/day) 212.6 (1.36) 211.8 (1.26) 214.2 (2.34) 0.65 0.93
haplotype 1 0 copies 1 copy 2 copies
No. 1,587 2,242 746
Energy intake (Kcal/day) 8265(47.2) 8228 (39.7) 8339 (68.9) 0.37
Fat intake (Grams/day) 80.6 (0.65) 80.2 (0.54) 81.5 (0.94) 0.51 1.00
Protein intake (Grams/day) 81.5 (0.46) 80.8 (0.38) 82.5 (0.69) 0.05 0.08
Carbohydrate intake (Grams/day) 213.7 (1.46) 211.2 (1.23) 213.6 (2.13) 0.35 0.30
data are mean (SE)
model 1: adjusted for age and sex 
model 2: adjusted for age, sex and energy intake; energy intake adjusted for age, sex and weight
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Effect of dietary intake on the relation between SIRT1 variants and BMI
Table 5 shows the relationship in the Rotterdam study between the SIRT1 haplotype1 
and BMI in tertiles of intake of energy, fat, vitamins and calcium and milk. Results for 
the two SNPs, rs7895833 and rs1467568, were similar but less pronounced and are 
presented in Supplementary Table 1. 
For sex-specific tertiles of energy intake (adjusted for age and body weight) we ob-
served an association between SIRT1 haplotype 1 and BMI only in the lowest tertile (p 
trend = 0.03) In the highest two tertiles there was no association between SIRT1 variants 
and BMI. For fat intake (adjusted for age and energy intake), we also observed an asso-
ciation between haplotype 1 and BMI only in the lowest tertile (p trend = 0.03). Again, no 
associations were seen in the highest two tertiles. For all four vitamins (beta-carotene, 
vitamin C, vitamin E and niacin) similar trends were seen with significant associations 
only in the lowest sex-specific tertiles of age- and energy adjusted intake. These effects 
were most pronounced for vitamin E with the strongest effect for haplotype 1 (beta 
0.685 + 0.14, p trend = 1x 10-6). In this lowest tertile, BMI was 26.1, 26.2 and 27.7 kg/m2 for 
non-carriers, heterozygous and homozygous carriers of haplotype 1, respectively, while 
in the highest tertile of vitamin E intake BMI was similar across genotype groups. In 
contrast, for calcium and milk intake significant associations between SIRT 1 haplotype 
1 and BMI were seen only in the highest tertiles. In the highest tertile of calcium intake 
BMI was and 26.2, 26.5 and 27.2 kg/m2 for non-carriers, heterozygous and homozygous 
carriers of haplotype 1, respectively (beta 0.460 + 0.13, p trend = 5 x 10-4) while in the 
lowest tertile BMI was not significantly different. Interaction terms between the SIRT1 
haplotype 1 and tertiles of nutrient intake were significant for vitamin E only (p= 0.0005). 
Table 4. Spearman’s correlations between intake of dietary components in 4,575 subjects from the 
Rotterdam study 
 
Energy Carbo-
hydrates
Fat Protein Beta-
carotene 
Vitamin 
C 
Vitamin 
E 
Niacin Calcium Milk
Energy 1,00 0,80 0,86 0,70 0,14 0,11 0,54 0,59 0,36 0,22
Carbohydrates   1,00 0,52 0,51 0,12 0,18 0,40 0,36 0,33 0,25
Fat     1,00 0,57 0,08 0,00ns 0,57 0,48 0,25 0,12
Protein       1,00 0,25 0,20 0,36 0,74 0,67 0,45
Betacarotene         1,00 0,35 0,19 0,25 0,22 0,10
Vitamin C           1,00 0,17 0,17 0,23 0,11
Vitamin E             1,00 0,33 0,19 0,07
Niacin               1,00 0,22 0,05
Calcium                 1,00 0,80
Milk                   1,00
All correlations significant at the p= 0.01 level except for ns: not significant
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Table 5. BMI by SIRT1 haplotype 1 in tertiles of dietary intake in the Rotterdam study
  BMI*   beta (SE)   p
Overall 0/1/2& 
energy adjusted for age and weight
Tertile 1 26.7 (0.09) 26.5/26.8/27.1   + 0.269 (0.14)   0.03
Tertile 2 26.3 (0.09) 26.4/26.1/26.6 + 0.017(0.14) 0.19
Tertile 3 26.0 (0.09) 25.9/25.9/26.4   + 0.197 (0.12)   0.11
fat adjusted for age and energy intake
Tertile 1 26.1 (0.09) 25.9/26.1/26.6   + 0.312 (0.13)   0.02
Tertile 2 26.4 (0.09) 26.3/26.4/26.6 + 0.152 (0.13) 0.25
Tertile 3 26.5 (0.09) 26.6/26.3/26.8   + 0.031 (0.14)   0.82
betacarotene adjusted for age and energy intake
Tertile 1 26.1 (0.09) 25.9/26.0/26.7   + 0.355 (0.13)   0.007
Tertile 2 26.3 (0.09) 26.2/26.4/26.5 + 0.164 (0.14) 0.23
Tertile 3 26.6 (0.09) 26.7/26.4/26.8   - 0.01 (0.13)   0.97
vitamine C adjusted for age and energy intake
Tertile 1 26.1 (0.09) 25.9/26.0/26.5   + 0.293 (0.14)   0.03
Tertile 2 26.3 (0.09) 26.3/26.2/26.9 + 0.199 (0.14) 0.14
Tertile 3 26.6 (0.09) 26.5/26.6/26.6   + 0.028 (0.13)   0.82
vitamin e adjusted for energy intake
Tertile 1 26.4 (0.09) 26.1/26.2/27.7   + 0.685 (0.14)   0.000001
Tertile 2 26.4 (0.09) 26.6/26.3/26.2 - 0.184 (0.13) 0.16
Tertile 3 26.2 (0.09) 26.1/26.2/26.1   + 0.017 (0.13)   0.90
niacin adjusted age and energy intake
Tertile 1 25.8 (0.09) 25.7/25.8/26.2   + 0.221 (0.13)   0.10
Tertile 2 26.4 (0.09) 26.2/26.3/26.7 + 0.236 (0.13) 0.07
Tertile 3 26.8 (0.09) 26.8/26.6/27.0   + 0.038 (0.14)   0.81
Calcium adjusted for age and energy
Tertile 1 26.1 (0.09) 26.0/26.0/26.4   + 0.178 (0.13)   0.18
Tertile 2 26.4 (0.09) 26.5/26.3/26.4 - 0.125 (0.14) 0.36
Tertile 3 26.5 (0.09) 26.2/26.5/27.2   + 0.460 (0.13)   0.0005
Milk adjusted for age and energy intake
Tertile 1 26.2 (0.09) 26.2/26.1/26.4   - 0.072 (0.13)   0.59
Tertile 2 26.5 (0.09) 26.6/26.5/26.6 + 0.000 (0.14) 1.00
Tertile 3 26.2 (0.09) 26.0/26.2/26.9   + 0.430 (0.13)   0.001
*BMI mean + SE, data adjusted for age and sex. & 0/1/2 copies of haplotype 1
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Interaction terms between the SIRT1 genetic variants and calcium intake were significant 
only for the two SNPs (p= 0.02, 0.01 and 0.13 for rs7895833, rs1467568 and haplotype 1, 
respectively, data not shown).
Irrespective of genotypes, BMI in tertiles of intake were not significantly different for 
vitamin E and milk. For energy intake BMI decreased with increasing tertiles while for fat 
and the other vitamins BMI increased.
Effect of milk intake on the relation between SIRT1 variants and BMI in the 
Rotterdam and ERF study
Relationships between SIRT1 genetic variants and BMI in tertiles of milk intake for the 
two SNPS rs7895833, rs1467568 in the Rotterdam study and in ERF are shown in table 
6. In ERF, sex-specific tertiles for milk intake were created with adjustment for age and 
weight, since no data on caloric intake were available. In the Rotterdam study, associa-
tions between rs7895833, rs1467568 and BMI were significantly negative in the third ter-
tile of milk intake only (p= 0.01 and 0.007 for the two SNPs, respectively). In ERF, negative 
associations were observed for rs7895833 in relation with BMI in the second and third 
tertile that was significant in the second tertile only (p trend = 0.008). For rs1467568 the 
same pattern was seen with significant inverse associations in the second (p trend = 
0.002) and third (p trend = 0.03) tertile.
Table 6. BMI by two SIRT1 SNPs in tertiles of milk intake in the Rotterdam study and the ERF study
  BMI beta (SE) p   BMI beta (SE) p
rs7895833     rs1467568    
Overall* AA/AG/GG GG/GA/AA
rotterdam study: Milk adjusted for age and energy intake
Tertile 1 26.2 (0.09) 26.2/26.1/26.0 - 0.082 (0.16) 0.61 26.1/26.2/26.2 - 0.100 (0.13) 0.46
Tertile 2 26.5 (0.09) 26.5/26.6/26.7 - 0.083 (0.16) 0.61 26.7/26.4/26.5 - 0.116 (0.14) 0.40
Tertile 3 26.2 (0.09) 26.4/25.9/26.0 - 0.408 (0.16) 0.01 26.6/26.0/26.1 - 0.360 (0.13) 0.007
erf: Milk adjusted for age and weight
Tertile 1 26.9 (0.16) 26.7/26.9/28.1 + 0.421 (0.27) 0.12 26.8/26.7/27.5 + 0.286 (0.29) 0.21
Tertile 2 26.5 (0.16) 26.8/26.5/24.7 - 0.690 (0.26) 0.008 26.9/26.7/25.4 - 0.667 (0.22) 0.002
Tertile 3 26.7 (0.16) 26.8/26.8/25.7 - 0.250 (0.27) 0.36 27.3/26.5/26.4 - 0.494 (0.23) 0.03
*Data are mean + SE, adjusted for age and sex
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DISCuSSIOn
SIRT1 is a plausible candidate gene for obesity, based on numerous functions in me-
tabolism. We recently demonstrated an association of two SIRT1 SNPs and the most 
common haplotype 1 with BMI in two independent Dutch populations. In the current 
study we investigated a potential gene-diet interaction, based on known regulators of 
SIRT1. In the Rotterdam study, we found that the effects of the SIRT1 variants on BMI 
were only seen in the lowest tertiles of intake of energy, fat and the three antioxidant 
vitamins and niacin, while, in contrast, for calcium and milk intake effects were only seen 
in the highest tertile. 
At first sight it appears exciting that we found an effect of SIRT1 haplotype 1 on BMI 
with low intake of energy per kg body weight, as Sirtuins are regarded as potential 
mediators of caloric restriction on increased life span in lower organisms 13-15. However, 
other explanations for this finding are possible. We did not find that subjects with the 
lowest intake of energy per kg body weight had the lowest BMI. In fact, BMI decreased 
with increasing caloric intake. This could suggest that subjects with low energy intake 
for body weight may represent those with low physical activity. Moreover, it is known 
that there may be selective underreporting of dietary intake in persons with higher BMI 
43. Even though subjects were excluded when dieticians considered dietary information 
unreliable, e.g. with unrealistic values of caloric intake for body weight, we cannot ex-
clude that selective underreporting in subjects in the lowest tertile of energy intake plays 
a role in our findings. For the effects of fat, vitamins, calcium and milk, underreporting 
is less likely a confounder since we adjusted intake of these nutrients for energy intake. 
The largest effects were seen with vitamin E and calcium intake and interaction terms 
for these nutrients with haplotype 1 were the only significant ones. This suggests that 
intake of vitamin E or calcium or other compounds in milk are the true modifiers of SIRT1 
but other associated dietary or lifestyle factors may very well underlie these interactions. 
It is also possible that the findings are chance findings. After applying a Bonferroni cor-
rection for testing three genetic variants and 8 dietary traits, which may be too stringent 
because the traits are not totally independent, only the interaction between haplotype 
1 and vitamin E intake remained significant.
Interestingly, we observed that the strength of the relationship between SIRT1 genetic 
variants and BMI increased after excluding subjects reporting use of supplements with 
the vitamins under investigation. In users of supplements there was not even a trend 
for a similar effect on BMI for the genetic variants. This supports that our findings of an 
association in the lowest tertiles of vitamin intakes are genuine. 
No studies have so far found, an interaction between vitamin E and SIRT1 except for 
one, in which vitamin E prevented a decrease in SIRT1 expression in the hippocampus 
and cerebral cortex in rodents caused by a high fat diet 44. The interaction between SIRT1 
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and vitamin E, that we found, needs further study. It could indeed be due to antioxidant 
function of vitamin E although there is debate about its anti-oxidant effects in vivo 45. 
Recent discoveries of vitamin E, as a regulator of enzymes and gene activity 45 are also 
important to consider as an explanation for its interaction with SIRT1. A recent paper 
found that vitamin C and E supplements inhibited exercise induced beneficial effects on 
insulin sensitivity in healthy young men, by preventing the promotion of endogenous 
antioxidant defense capacity trough peroxisome proliferator-activated receptor-gamma 
(PPARg) and PPARg- co-activators PGC1α and PGC1β 46. Since SIRT1 expression in muscle 
is increased by physical exercise 47 and SIRT1 influences PPARg and PGC1α, a potential 
role of SIRT1 on these exercise induced metabolic effects should be explored. Vitamin 
E is abundant in foods such as nuts, seeds, vegetable oils and green leafy vegetables. 
High intake of vitamin E may thus also represent a healthy diet or an otherwise healthy 
lifestyle.
We also found effects of SIRT1 with high intake of calcium and milk. This observation 
also needs further validation, although similar findings in the ERF study in the highest 
tertiles of self-reported milk intake adjusted for body weight lend support to the find-
ings in the Rotterdam study. It is possible that these findings are related to nicotinamide 
riboside, a SIRT1 stimulator found in milk 29, 30. There is evidence for a role of dietary 
calcium in human body weight regulation possibly by suppression of 1,25 (OH)2 vitamin 
D (calcitriol) 48, 49, although there is debate about the underlying mechanisms and the 
clinical relevance 50. We did not observe decreased BMI independent of SIRT1 genotype 
with higher intake of milk in the Rotterdam study nor in the ERF study but the interac-
tion of SIRT1 genetic variants with calcium and milk intake on BMI merits further studies 
on potential role for dairy products or nicotinamide riboside supplementation on body 
weight through SIRT1 stimulation. 
It is not yet clear how SIRT1 influences BMI but potential mechanisms include a repres-
sive effect on PPARγ, central effects through satiety, increased energy expenditure or 
effects by modification of Clock genes. Our finding that energy intake did not differ be-
tween genotypes makes it unlikely that appetite plays a role in the association between 
SIRT1 and BMI. However, we cannot exclude that small differences in caloric intake can 
be found in large-scale studies. Our results are not in line with findings of decreased 
food intake in transgenic mice with moderate over expression of SIRT1 51.
Limitations of our study are the possibility of misclassification of nutrient intake in-
herent to food frequency questionnaires, the lack of data on functionality of the SIRT1 
SNPS and the lack of replication in other cohorts with validated information of dietary 
intake. The results of this study, while preliminary, are important because they high-
light that gene-diet interaction may influence BMI and the risk of obesity and strongly 
support further research on SIRT1 gene-diet interaction in larger populations. This will 
require meta-analysis of data from multiple studies within international consortia after 
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standardization of different methods used to assess dietary intake. Gene-environment 
interactions may explain part of the so-called “dark matter” in heritability where so far 
variation in genes explain only a few percent of the heritability of traits and diseases 52. 
They may also underlie heterogeneity in large-scale meta-analyses of genome-wide as-
sociation studies if dietary habits differ between study populations. It is of great impor-
tance to uncover such interactions in the growing epidemic of obesity. Knowledge on 
gene-diet interaction may modify dietary advice, potentially in the future personalized 
and based on genotype. This is preferable to new and costly medication with potential 
side effects, especially when used on large scale. However, more research is needed 
before any personalized dietary advice can be used in clinical practice.
We conclude that associations between SIRT1 genetic variants and BMI are not ex-
plained by differences in caloric intake. Dietary intake of antioxidants, especially vitamin 
E, and of calcium and milk modify the associations of SIRT1 variants with BMI. These 
data further support evidence that gene-diet interactions influence complex traits like 
BMI. Replication of our findings and further study of specific dietary factors that can 
modify SIRT1 can pave the way for prospective studies on dietary modification of SIRT1 
to influence obesity.
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AbSTrACT
Central abdominal fat is a strong risk factor for diabetes and cardiovascular disease. To 
identify common variants influencing central abdominal fat, we conducted a two-stage 
genome-wide association analysis for waist circumference (WC). In total, three loci 
reached genome-wide significance. In stage 1, 31,373 individuals of Caucasian descent 
from eight cohort studies confirmed the role of FTO and MC4R and identified one novel 
locus associated with WC in the neurexin 3 gene (NRXN3 [rs10146997, p= 6.4 x 10-7]). 
The association with NRXN3 was confirmed in Stage 2 by combining stage 1 results with 
those from 38,641 participants in the GIANT consortium (p= 0.009 in GIANT only, p= 
5.3 x 10-8 for combined analysis, n=70,014). Mean WC increase per copy of G allele was 
0.0498 z-score units (0.65 cm). This SNP was also associated with body mass index (BMI) 
(p= 7.4 x 10-6, 0.024 z-score units [0.10 kg/m2] per copy of the G allele) and the risk of obe-
sity (odds ratio 1.13, 95% CI 1.07-1.19; p=3.2 x 10-5 per copy of the G allele). The NRXN3 
gene has been previously implicated in addiction and reward behavior, lending further 
evidence that common forms of obesity may be a central nervous system-mediated 
disorder. Our findings establish that common variants in NRXN3 are associated with WC, 
BMI, and obesity. 
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InTrODuCTIOn
Body mass index (BMI) is a commonly used measure of overall adiposity. However, spe-
cific fat depots may confer differential metabolic risk. In particular, central abdominal 
fat, as measured by waist circumference (WC), may be more strongly associated with 
the development of metabolic risk factors and cardiovascular disease as compared 
with BMI 1-4. Therefore, understanding the pathogenesis of central fat distribution may 
provide further insight into the relationship between adiposity, cardiometabolic risk, 
and cardiovascular disease.
Both genetic and environmental factors have been linked to obesity 5. Heritability 
estimates for BMI and WC range from 30 to 70% in family and twin studies 6, and mul-
tiple quantitative trait loci and candidate genes have been mapped to genes for central 
adiposity 5. Despite strong evidence for an underlying genetic component, genes for 
obesity-related traits, particularly central obesity, have been difficult to identify and 
replicate. 
Early genome-wide association studies (GWAS) identified both FTO and MC4R as genes 
related to BMI and WC 7-10. Many new loci have been identified in recent obesity related 
GWAS studies 11-13. However, collectively these variants explain only a small proportion of 
the variation in adiposity 7-13. In addition, no GWAS exist exclusively to identify genes for 
central fat. Thus, to identify new variants, we carried out a large-scale meta-analysis of 
GWAS from eight studies to detect variants associated with central body fat distribution. 
MeThODS
Study Samples
Participants for the current analysis were drawn from 8 cohort studies, including the 
Age, Gene/Environment Susceptibility-Reykjavik Study (AGES- Reykjavik Study), the 
Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study 
(CHS), the European Special Population Network consortium (EUROSPAN), the Family 
Heart Study, the Framingham Heart Study, Old Order Amish (OOA), and the Rotterdam 
Study (RS). These groups comprise the CHARGE (Cohorts for Heart and Aging Research 
in Genome Epidemiology) Consortium. All participants provided informed consent. Lo-
cal ethical committees at each institution approved the individual study protocols. The 
online supplement contains details regarding all participating cohorts.
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Imputation and Statistical Analysis
Common to all analyses were use of the raw WC measures and the assumption of an 
additive model; study specific details follow. Each study reported an effect allele, which 
was meta-analyzed consistently across all studies. Results are currently presented rela-
tive to the minor G allele for the NRXN3 SNP. In all studies except CHS, MACH (version 
1.0.15 in Family Heart, Framingham, EUROSPAN and RS; version 1.0.16 in ARIC and AGES) 
was used to impute all autosomal SNPs on the HapMap, using the publicly available 
phased haplotypes (release 22, build 36, CEU population) as a reference panel. In CHS, 
the program BIMBAM was used 14. Details are provided in Supplementary Table S1 re-
garding covariates and trait creation.
In ARIC, Framingham, and RS, sex- and either cohort-specific or study center-specific 
residuals were created after adjustment for age, age-squared, and smoking status. In 
CHS and Family Heart, linear regression models were used to adjust for age, age-squared, 
sex, smoking, and study center. In AGES, linear regression models using PLINK v1.04 15 
were used to adjust for age, age-squared, sex, and smoking. In the OOA the measured 
genotype mixed effects model was used adjusting for age, age-squared, sex and family 
structure based on the complete 14-generation pedigree as implemented in ITSNBN 
16. Framingham employed the linear mixed effect model for continuous traits and the 
generalized estimating equations for dichotomous traits in R 17 to account for family 
relatedness. In RS, linear regression models were run using MACH2QTL 18. In ARIC and 
EUROSPAN, all regression models were run using the ProbABEL package from the ABEL 
set of programs 19 and in EUROSPAN genomic control 20 was used to correct standard 
errors of the effect estimates for relatedness among individuals. The Family Heart Study 
determined the effect of each SNP using linear mixed effects models to account for the 
siblings present in the data using SAS®. 
Principal components calculated using EIGENSTRAT 21 were adjusted for in the indi-
vidual studies when significant in order to account for population substructure.
Meta-analysis
A weighted z-score approach was used to conduct meta-analyses with METAL (www.
sph.umich.edu/csg/abecasis/metal/). Genomic control correction was applied to each 
study prior to  the full meta-analysis. p-values less than 4.4 x 10-7 were considered 
genome-wide significant 22.
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In Silico Exchange with the GIANT Consortium
In stage 2 of our study, we conducted an in silico exchange of the results from 48 SNPs 
with the GIANT consortium. To create our list of SNPs to exchange, we first selected the 
top 34 SNPs from independent loci (defined as SNPs with R2<0.2) from our meta-analysis 
of WC, excluding SNPs in known loci for adiposity. An additional 14 SNPs of independent 
loci with a p-value<1.0 x 10-5 from a secondary list that focused on SNPs for WC with 
corresponding BMI p-values > 0.01 were also included in an attempt to isolate genes 
that might be specifically associated with central fat deposition. Our a priori threshold 
for replication was a p-value<0.001 (0.05/48 SNPs) and/or reaching genome-wide 
significance in a combined meta-analysis. CHARGE and GIANT results were then meta-
analyzed using METAL.
reSulTS
Table 1 presents descriptive statistics across the 8 cohorts providing data for the meta-
analysis. We had a total sample size of 31,373 individuals of Caucasian descent. Partici-
pants were mostly middle-aged with ages ranging from a mean of 45 to 76 years of age. 
Table 1. Descriptive statistics across the eight cohorts.
Cohort N Age (years) % Women
Current 
smokers (%)
Waist Circ (cm) BMI (kg/m2)
AGES 3172 76.4 (5.4) 58.0 (1840) 12.7 (402) 100.7 (12.1)* 27.1 (4.4)
ARIC 8097 54.3 (5.7) 52.8 (4276) 25.2 (2036) 96.2 (13.4) 27.0 (4.9)
CHS 3213 72.3 (5.4) 60.0 (1942) 11.0 (354) 93.6 (12.6) 26.4 (4.3)
Family Heart Study 855 55.6 (11.0) 51.5 (440) 11.9 (101) 98.6 (13.6) 27.8 (5.1)
Framingham Heart 
Study 7115 45.2 (10.9) 52.7 (3750) 18.8 (1338) 91.4 (15.0) 26.0 (5.1)
Old Order Amish 1134 49.6 (16.8) 48.4 (549) 9.4 (106) 88.5 (11.4) 27.0 (4.7)
Rotterdam Study 5471 69.0 (8.8) 58.6 (3205) 23.0 (1258) 90.6 (11.2) 26.3 (3.7)
EUROSPAN 
Consortium  
ERF (Dutch) 1239 48.3 (14.7) 60.1 (744) 43.6 (540) 87.0 (13.7) 26.7 (4.7)
CROATIAN 784 56.5 (15.3) 58.6 (459) 27.7 (217) 95.9 (11.8) 27.3 (4.3)
MICROS (South 
Tyrolean) 293 46.3 (15.6) 59.7 (175) 45.3 (125) 88.5 (13.3) 25.4 (5.4)
Data provided as mean (standard deviation) for continuous and % (n) for dichotomous data.
*N=3,167 for WC by tape measure; mean (SD) of WC measured by computed tomography is 125.9(14.0) 
cm
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Supplementary Figure S1 (Supplementary material available at the PLoS Genetics 
website) shows the genome-wide association results for WC in the stage 1 CHARGE only 
analysis. The top SNPs for WC were in the FTO and MC4R genes (Supplementary Table 
S3). Supplementary Figure S2 shows the QQ plot for our results excluding SNPs in FTO 
and MC4R. For FTO, the top SNP was rs1558902 (p= 4.6 x 10-19). For MC4R, the top SNP 
was rs489693 (p= 3.5 x 10-7). The top results excluding SNPs in FTO and MC4R from our 
stage 1 meta-analysis are shown in Table 2 along with the stage 2 in silico replication 
results from the GIANT consortium; additional meta-analysis results from CHARGE are 
presented in Supplementary Table S3. The lowest p-value on our list, for SNP rs10146997 
in the NRXN3 gene, had a stage 1 meta-analysis p-value of 6.4 x10-7 and was confirmed in 
38,641 participants from the GIANT consortium with a p-value of 0.009 and a combined 
p-value of 5.3 x 10-8. The NRXN3 SNP was derived from the list of SNPs associated with WC 
irrespective of association with BMI. None of the other SNPs that were exchanged were 
confirmed in GIANT. We do note that while rs10857809 (proxy for rs10857810) in the 
FAM40A gene had a p-value of 0.003 in GIANT, the results were not direction-consistent 
with CHARGE and therefore did not replicate in the combined analysis. 
Table 2. Top 48 SNPs exchanged with the GIANT Consortium, GIANT p-values, and the combined results
Marker Chromosome Position
CHARGE 
pvalue 
GIANT 
pvalue*
COMBINED 
pvalue
Nearest 
Gene**
rs10146997 14 79014915 6.4E-07 0.009 5.3E-08 NRXN3
rs981113 5 75556684 9.8E-07 0.55 3.4E-03 SV2C
rs7338657 13 62299289 1.1E-06 0.75 4.4E-04 PCDH20
rs6714750 2 136499639 1.9E-06 0.48 2.9E-03 DARS
rs1555967 6 51267954 1.9E-06 0.07 3.3E-06 PKHD1
rs4701252 5 21814911 2.5E-06 0.45 2.3E-06 CDH12
rs4420638 19 50114786 3.6E-06 0.80 3.8E-04 APOC1
rs2365642 1 199501709 4.1E-06 0.79 3.4E-03 PKP1
rs17008958 3 71838178 4.5E-06 0.18 5.7E-05 EIF4E3
rs7932813 11 7664857 4.6E-06 0.09 5.0E-06 OVCH2
rs569406 9 77219165 4.7E-06 0.54 3.7E-04 OSTF1
rs6837818 4 168112 5.2E-06 0.81 1.1E-03 ZNF718
rs17537900 13 42593449 7.3E-06 0.07 2.9E-03 DNAJC15
rs17476669 2 50579975 7.9E-06 0.27 1.1E-04 NRXN1
rs11857639 15 71424825 8.0E-06 0.94 3.8E-04 HCN4
rs3758063 8 87754664 1.2E-05 0.76 5.4E-03 CNGB3
rs804569 20 22099652 1.4E-05 0.29 1.7E-04 FOXA2
rs13002346 2 133761936 1.6E-05 0.78 1.9E-03 NAP5
rs7138803 12 48533735 1.6E-05 0.01 8.0E-07 BCDIN3D
rs17201502 12 48571829 1.7E-05 0.02 4.2E-06 FAIM2
rs154168 5 107078981 1.7E-05 0.86 2.0E-03 EFNA5
rs1324618 9 121107783 1.8E-05 0.62 0.01 DBC1
rs1553754 17 43918706 2.0E-05 0.05 1.2E-05 HOXB1
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figure 1 presents the genomic region for SNP rs10146997 (intronic) in NRXN3. Table 3 
shows detailed results of rs10146997 in the NRXN3 gene by contributing CHARGE study 
and corresponding results appear in the forest plot in Supplementary Figure S3; there 
was no evidence for heterogeneity across the Stage 1 studies (p=0.64). The minor allele 
(G) frequency (MAF) for rs10146997 in our sample ranged from 0.14 in the OOA to 0.24 
in the Croatians; the frequency of the NRXN3 SNP G allele is 0.275, 1.0, 1.0, and 0.35, in 
Hapmap CEPH, Han Chinese, Japanese, and Yoruba populations, respectively. This SNP 
was genotyped in AGES, CHS, Family Heart Study, Rotterdam and all EUROSPAN stud-
ies, and imputation scores for the other studies indicated very high quality. Overall, per 
copy of the G allele, mean WC was increased 0.0498 z-score units (0.65 cm). Beta coef-
ficients (in z-score units) were consistently positive in all samples except the ERF study 
(β=-0.0098; p= 0.86), which is most likely due to chance. Due to overlap in participants 
Table 2. continued
Marker Chromosome Position
CHARGE 
pvalue 
GIANT 
pvalue*
COMBINED 
pvalue
Nearest 
Gene**
rs12971184 18 32134683 2.1E-05 0.43 0.03 FHOD3
rs253414 5 74992273 2.3E-05 0.47 8.0E-04 C5orf37
rs309193 19 52317155 2.4E-05 0.20 1.8E-04 C19orf7
rs12457723 18 27981438 2.4E-05 0.14 0.08 RNF138
rs8006194 14 88980606 2.5E-05 0.63 0.01 FOXN3
rs10172766 2 205587746 3.0E-05 0.30 0.01 PARD3B
rs11096633 2 20067535 3.1E-05 0.47 5.2E-04 MATN3
rs8049894 16 75371885 3.1E-05 0.67 1.9E-03 CNTNAP4
rs12148445 15 34703950 3.1E-05 0.60 0.01 C15orf41
rs9829637 3 135638752 3.5E-05 0.10 4.9E-05 ANAPC13
rs7666149 4 41017949 3.7E-05 0.06 2.1E-05 LIMCH1
rs13421140 2 1753016 4.2E-05 0.97 6.1E-03 MYT1L
rs4238692 16 82149934 5.8E-05 0.14 1.4E-04 CDH13
rs17833967 12 13846345 6.0E-05 0.46 1.2E-03 GRIN2B
rs1532206 3 99153367 6.2E-05 0.89 9.2E-03 MINA
rs6723108 2 135196450 6.2E-05 0.27 4.4E-04 TMEM163
rs12704232 7 85640166 7.4E-05 0.61 0.05 GRM3
rs12377679 9 128437576 8.0E-05 0.12 1.1E-04 LMX1B
rs1017643 6 156835825 9.5E-05 0.04 2.6E-05 ARID1B
rs6485438 11 43643194 1.3E-04 0.09 9.7E-05 HSD17B12
rs7116632 11 129452949 1.9E-04 0.74 0.04 APLP2
rs422988 1 4718977 2.4E-04 0.62 3.5E-03 AJAP1
rs5771623 22 47415000 2.9E-04 0.07 0.28 FAM19A5
rs6728666 2 216894986 5.3E-04 0.76 0.02 MARCH4
rs10857810*** 1 110403320 1.8E-04 .003 0.97 FAM40A
*GIANT sample size is 38,641.
**Nearest reference is bolded if SNP is within the reference gene
***GIANT SNP is proxy rs10857809 (r2=0.92)
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Table 3. Results per copy of the G allele for rs10146997 by contributing study; beta coefficients expressed 
as z-scores 
Cohort N MAF (G)
Imputation 
Quality Score
Beta 
Coefficient
SE p-value
AGES 3170 0.21 Genotyped 0.058 0.031 0.06
ARIC 8097 0.22 0.98 0.032 0.019 0.12
CHS 3213 0.21 Genotyped 0.103 0.030 0.00048
Family Heart Study 855 0.21 Genotyped 0.003 0.055 0.65
Framingham Heart Study 7115 0.20 1.00 0.068 0.022 0.0019
Old Order Amish 1097* 0.14 0.87 0.049 0.073 0.33
Rotterdam Study 5471 0.21 Genotyped 0.042 0.024 0.08
EUROSPAN Consortium  
ERF (Dutch) 1241 0.20 Genotyped -0.010 0.052 0.86
Croatia 784 0.24 Genotyped 0.039 0.059 0.52
MICROS (South Tyrolean) 293 0.17 Genotyped 0.057 0.101 0.60
Meta-analysis results 31373 0.21 N/A 0.0498 0.010 6.4 x10-7 
SE=standard error; MAF=minor allele frequency
*Sample size reduced from 1134 because smokers excluded due to the low smoking prevalence
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figure 1.  Regional Association Plot for rs10146997 on chromosome 14 in the stage 1 CHARGE-only 
analysis.  The scheme is black for strong linkage disequilibrium (LD; r2 ≥0.8), dark grey for moderate LD (r2 
≥0.5 and < 0.8), light grey for weak LD (r2 ≥0.2 and < 0.5) and white for limited or no LD (r2 < 0.2). 
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from the Framingham Heart Study and ARIC with those from the Family Heart Study, the 
CHARGE meta-analysis was re-run for the NRXN3 SNP without the Family Heart Study; 
results were essentially unchanged (p= 6.6 x 10-7). Individual study-specific results for 
rs10146997 from the studies comprising the GIANT consortium can be found in Supple-
mentary Table S2. 
Within CHARGE we also observed an association of rs10146997 with BMI (p=7.4 x 10-6). 
Overall, per copy of the G allele, mean BMI was increased 0.024 z-score units per G allele 
(0.10 kg/m2). When WC was additionally adjusted for BMI, the signal was completely at-
tenuated (0.0065 z-score units per G allele; p= 0.32). The association of rs10146997 with 
WC was similar in women and men and in older and younger individuals (Table 4). After 
excluding smoking from the covariate adjustment list, results were essentially similar. 
Per copy of the G allele, the odds ratio of having high WC (≥88 cm in women; ≥102 cm 
in men) was 1.07 (95% CI 1.02-1.11; Table 4). Similarly, the odds ratio of obesity was 1.13 
(95% CI 1.07-1.19). 
We calculated a risk score of FTO (rs9939609), MC4R (rs17782313), and NRXN3 with 
possible scores ranging from 0-6 risk alleles (figure 2). Across this range, mean WC 
increased from 92.4 cm among those with 0 risk alleles, to 95.7 cm among those with 4 
Table 4. CHARGE consortium secondary analysis results per copy of the G allele for rs10146997 in 31373 
individuals; beta coefficients expressed as z-scores 
beta Coefficient Se p-value
Overall 0.0498 0.010 6.4 x10-7 
Overall without adjusting for smoking 0.0460 0.010 5.6 x10-6
Sex stratification  
Women 0.0500 0.014 4.7 x10-4
Men 0.0427 0.013 0.001
Age stratification  
<55 years 0.0520 0.017 0.002
55+ years 0.0560 0.013 7.4 x10-6
  Odds ratio 95% CI p-value
WC category*  
High WC (women ≥88 cm, men ≥102 cm) 1.07 1.02-1.11 0.003
BMI categories**  
Overweight (BMI 25 to <30) 1.03 0.98-1.07 0.250
Obese (BMI ≥ 30) 1.13 1.07-1.19 3.2 x10-5
*Referent = normal WC category (women <88 cm; men <102 cm)
**Referent = normal weight category (BMI 18.5-<25 kg/m2)
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or more risk alleles. To put our findings in perspective, per copy of the effect allele the 
NRXN3 SNP resulted in a WC difference of 0.65 cm; FTO 0.73 cm, and MC4R 0.37 cm.
CHARGE consortium meta-analysis results for BMI can be found in Supplementary 
Table S4; Manhattan and QQ plots can be found in Supplementary Figure S4 and Supple-
mentary Figure S5, respectively.
DISCuSSIOn
In a discovery sample of more than 30,000 individuals from several cohort studies, we 
identified a novel locus in the NRXN3 gene associated with WC. In combination with 
data from the GIANT consortium, the p-value for this finding exceeded our pre-defined 
threshold for genome-wide statistical significance. This SNP was also significantly associ-
ated with BMI and obesity. This gene has previously been associated with addiction and 
reward behavior, and is a compelling biologic candidate for obesity. We also confirmed 
the significant associations with FTO and MC4R that have previously been reported with 
BMI and WC. 
Although our genome-wide scan was performed for WC, the NRXN3 SNP was also sig-
nificantly associated with BMI. In secondary analyses, the signal for WC was attenuated 
after additionally adjusting for BMI, suggesting that this locus is most likely involved in 
overall adiposity and not specific to central fat deposition. Similar observations have 
been made for FTO 10 and MC4R 7, highlighting the inter-dependence between different 
measures of adiposity and the importance of performing GWAS on multiple adiposity-
related traits.
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figure 2.  Mean waist circumference by number of risk alleles for FTO, MC4R, and NRXN3.  Bars represent 
standard errors.  The panel on the left represents the distribution of risk alleles in the overall sample.
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The small magnitude of the effect size of the NRXN3 variant on WC is consistent with 
what has previously been reported for FTO and MC4R. These findings highlight the need 
for large sample sizes in order to facilitate continued gene discovery for obesity-related 
traits. In particular, genes that emerge for waist circumference will most likely be genes 
for overall adiposity because of the strong correlation between the two measurements 
22. More specific measures of visceral abdominal fat depots may make it possible to 
isolate genes involved in regional body composition.
NRXN3 is part of a family of central nervous adhesion molecules and is highly expressed 
in the central nervous system. Prior studies of NRNX3 point towards an important role 
in alcohol dependence, cocaine addiction, and illegal substance abuse 23-26. In addition, 
opioid dependence has been linked to the chromosome 14q region 23. In mice, NRXN3 
beta expression was observed in the globus pallidus when exposed to cocaine 24. Many 
of the neuronal pathways in these sub-cortical regions of the brain in which NRXN3 is 
expressed are involved with learning and reward training 25.
Obesity and addiction may share common neurologic underpinnings 26. Other well-
replicated obesity loci, including MC4R, have also been shown to be associated with 
centrally-mediated phenomena including binge eating behavior 11,12,27. Studies in mice 
indicate that FTO expression is particularly pronounced in regions of the brain known to 
regulate energy balance 28, and recent data suggest that variants in the FTO gene may 
regulate food intake and selection 29.
Additional research is needed to understand the association of rs10146997 with the 
NRXN3 gene and to identify a causal variant. Since there are no other genes within a 
distance of more than several hundred kilobases of this SNP, it is unlikely that a different 
gene accounts for this finding. A search of publically available databases 30-31 did not 
identify an association between SNPs in NRXN3 and gene expression. 
A relationship between WC and causal variants in the NRXN3 gene may have clinical 
implications. Obesity is a multifactorial trait that results from a complex interaction 
between genes and environment. The identification of an association between obesity 
and variants in a gene that has been associated with substance abuse suggests that fur-
ther exploration of the role of this gene in vulnerability to addiction to food substances 
should be undertaken. 
The strengths of this work include the large discovery sample size. The effect size 
was small, and achieving conventional levels of genome-wide significance required 
combining data from more than 70,000 participants in two large consortia. Although 
the confirmation with the GIANT consortium is promising, the joint p-value based on 
more than 70,000 participants achieved only borderline genome-wide significance. Our 
findings warrant the need for further replication in other ethnic groups. 
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We identified a SNP at a novel locus in the NRXN3 gene associated with WC. This gene 
has previously been implicated in addiction and reward behavior, lending further sup-
port to the concept that obesity, in part, is a centrally-mediated disorder.
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AbSTrACT
Bone mineral density (BMD) is a heritable complex trait used in the clinical diagnosis 
of osteoporosis and the assessment of fracture risk. We performed meta-analysis of 
five genome-wide association studies of femoral neck and lumbar spine BMD in 19,195 
subjects of Northern European descent. We identified 20 loci reaching genome-wide 
significance (GWS; p<5x10-8), of which 13 map to new regions including 1p31.3 (GPR177), 
2p21 (SPTBN1), 3p22 (CTNNB1), 4q21.1 (MEPE), 5q14 (MEF2C), 7p14 (STARD3NL), 7q21.3 
(FLJ42280), 11p11.2 (LRP4; ARHGAP1; F2), 11p14.1 (DCDC5), 11p15 (SOX6), 16q24 (FOXL1), 
17q21 (HDAC5) and 17q12 (CRHR1). The meta-analysis also confirmed at GWS level, 
seven known BMD loci on 1p36 (ZBTB40), 6q25 (ESR1), 8q24 (TNFRSF11B), 11q13.4 (LRP5), 
12q13 (SP7), 13q14 (TNFSF11), and 18q21 (TNFRSF11A). The numerous SNPs associated 
with BMD map to genes in signaling pathways with relevance to bone metabolism, and 
highlight the complex genetic architecture underlying osteoporosis and BMD variation.
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InTrODuCTIOn
Osteoporosis is a condition characterized by reduced bone mass and microarchitec-
tural deterioration of bone tissue, leading to loss of bone strength and increased risk 
of fracture. Osteoporosis increases in incidence with age, and is a major health threat 
to hundreds of millions of elderly individuals worldwide. Linkage analysis in monogenic 
bone disorders like Osteoporosis-Pseudoglioma syndrome, sclerosteosis, high bone 
mass syndrome and Paget’s disease, have yielded major advances in recent years and 
highlighted the importance of the Wnt signaling1 and the RANK/RANKL/Opg pathways 
in the regulation of bone mass and bone turnover2. Linkage studies for the common 
form of osteoporosis have had limited success however3. As with other complex dis-
eases, most of the candidate gene association studies in osteoporosis have produced 
conflicting results with limited replication4 mostly due to small sample sizes5. However, 
large-studies of major candidate gene polymorphisms within the sufficiently powered 
setting of the GENOMOS consortium, have been successful in obtaining consistent evi-
dence of association between some genetic variants, BMD and fracture6-10. Concurrently, 
genome-wide association studies (GWAS), which perform a hypothesis-free search for 
genetic determinants,11 have already been successful in identifying 10 loci associated 
at a genome-wide significance (GWS) level with BMD12,13. Four of these loci involve 
members of the Wnt and RANK/RANKL/Opg signaling pathways highlighting their role in 
monogenic forms as well as the common form of osteoporosis.
BMD is used in clinical practice for the diagnosis of osteoporosis and in the assessment 
of fracture risk14. BMD is usually measured at the hip (femoral neck) and lumbar spine, 
which are common sites of fracture. However, BMD measurements at different skeletal 
sites are predictive of fracture in general because of their high correlation (r2~0.60).15 
From a genetic perspective, BMD at both spine and hip is a complex, but highly heritable 
trait (h2~0.60-0.80)16. As shown for human height17-19, dozens and possibly hundreds of 
loci with small effects can be expected to influence the variation in BMD. Detection and 
reliable documentation of these loci of weak effects requires studies with comprehen-
sive coverage of the genome and very large sample sizes. Here, we report the findings 
of a large-scale meta-analysis of 19,195 adult individuals from five GWAS on BMD of the 
lumbar spine (LS) and the femoral neck (FN), within the setting of the GEnetic Factors of 
OSteoporosis (GEFOS) consortium. 
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MeThODS
Study population
The GEnetic Factors of Osteoporosis (GEFOS) consortium is a coalition of teams of in-
vestigators working on the genetics of osteoporosis. The current meta-analysis incorpo-
rated 19,195 individuals of Northern European ancestry derived from five GWAS on BMD 
of the lumbar spine (LS-BMD) and the femoral neck (FN-BMD) including: the Rotterdam 
Study (RS, n=4,987), Erasmus Rucphen Family Study (ERF, n=1,228), Twins UK Study (TUK, 
n=2,734), deCODE Genetics Study (dCG, n=6,743) and the Framingham Osteoporosis Study 
(FOS, n=3503). All studies were approved by institutional ethics review committees at 
the relevant organizations and all participants provided written informed consent. The 
Rotterdam Study (RS) is a prospective population-based cohort study of chronic dis-
abling conditions in Dutch elderly individuals age 55 years and over (http://www.epib.
nl/ergo.htm).50,51 The Erasmus Rucphen Family (ERF) study is a family-based study of a 
genetic isolate in the South West Netherlands to identify genetic risk factors for complex 
disorders.52 The Twins UK (TUK) study is a population-based sample of twins from the 
UK studying the hereditary basis of a wide variety of age-related traits and diseases 
(http:/www.twinsUK.ac.uk).53 The Icelandic deCODE Genetics (dCG) study comprises a 
population-based sample to identify the genetic basis of complex diseases.13 The Fram-
ingham Osteoporosis Study (FOS) is embedded in the Framingham Heart Study (FHS), 
a community-based, longitudinal, prospective cohort comprising three generations of 
individuals in multigenerational pedigrees and additional unrelated individuals (http://
www.framinghamheartstudy.org/). Individuals of “Generation 1” include those first 
examined in 194854, “Generation 2” includes those examined at the first cycle from 1971 
to 197555, and “Generation 3” includes those examined at the first cycle beginning in 
2002-2005.56 For these analyses, 812 members of the Generation 1 cohort (22.6% of the 
sample) and 2783 (77.4%) of the Generation 2 cohort who had BMD measured as part of 
the FOS were included.
Bone mineral density and anthropometric measurements
BMD was measured in all cohorts at the lumbar spine (either at L1–L4 or L2-L4) and 
femoral neck using dual-energy X-ray absorptiometry following standard manufacturer 
protocols (GE-Lunar Corporation, Madison, WI or Hologic Incorporated, Bedford, MA) 
see Supplementary Table 1 for details. All DXA and anthropometric measurements were 
performed in the RS at the baseline visit baseline between 1991-1992, in ERF between 
2002-2003, in TUK at the latest follow-up, dCG at the baseline visit and in FOS Generation 
1 between 1992-1997, and Generation 2 between 1996-2001. 
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Phenotype modeling
The overall strategy involved linear regression to adjust BMD measurements for effects 
of age, weight, sex and study using standardized residuals with mean 0 and standard de-
viation 1 in the genotype-phenotype association testing. Such residuals were obtained 
by regressing within each study the raw BMD measurements on age and weight (and 
principal components in FOS to adjust for population substructure using Eigenstrat57) in 
sex-specific models. Thus, in studies including both men and women the data for each 
gender are included as separate estimates in the meta-analysis.
Genotyping
The five GWAS were genotyped using the Illumina Infinium HumanHap550 Beadchip 
(RS), the Illumina Infinium HumanHap300 or HumanCNV370 Beadchip (ERF, TUK & dCG) 
or the Affymetrix Dual NspI/StyI GeneChip 2x250K with 50K gene-centered MIP set (FOS), 
all according to manufacturer’s protocols and quality control standards. The exclusion/
filtering criteria for individuals and SNPs are described in Supplementary Tables 2-3. 
Genotype imputation
Imputation was used to evaluate associations for the same SNPs across study popula-
tions using scans from different genotyping platforms. Genotypes were imputed for all 
polymorphic SNPs oriented to the positive strand from phased autosomal chromosomes 
of the HapMap CEU Phase II panel (release 22, build 36)58. Hidden Markov Model-based 
algorithms were used to infer unobserved genotypes probabilistically as implemented 
in either MACH59 or IMPUTE60. Imputation quality control metrics from MACH and IM-
PUTE were used. Detailed descriptions of quality control and imputation procedures are 
summarized for all studies in Supplementary Table 3. We performed technical validation 
of the imputed genotypes in an independent set of 880 individuals of Icelandic origin 
using Centaurus (Nanogen)61 discrimination assays, for the top associated hits that 
reached GWS for the first time in this study (Supplementary Table 10).
Genotype-phenotype association testing 62
Each study performed genome-wide association for BMD using sex-specific, age- and 
weight-adjusted standardized residuals analyzed under an additive (per allele) genetic 
model. Analysis of imputed genotype data accounted for uncertainty in each genotype 
prediction by utilizing either the dosage information from MACH or the genotype prob-
abilities from IMPUTE. Studies used MACH2QTL59, which uses genotype dosage value 
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(0 – 2, continuous) as a predictor in a linear regression framework, SNPTEST60, Merlin63 or 
the linear mixed effects model of the Kinship64 and ProABEL65 packages in R66 to account 
for relatedness (Supplementary Table 3). The genomic control method20 was used to 
correct the standard error by the square root of the genomic inflation factor (lambda): 
SEcorrected =SE * √λ , which is equivalent to the proposed correction of the Chi2-statistic by 
lambda. Genomic inflation factors for the studies are presented on Supplementary Table 
3. Overall meta-analysis genomic control inflation factors were calculated as described 
previously.67 Genomic inflation factors scaled to a standard size (1000 individuals) to 
calibrate for the effect of sample size on λ67, showed residual genomic inflation was 
negligible (λLSBMD1000=1.005 and λFN-BMD1000=1.004).
Meta-analysis
The minor allele from HapMap CEU genotypes was used to define the coded allele in 
all analyses, regardless of frequency in individual cohorts. All meta-analysis calculations 
were done using the METAL21 software package applying inverse-variance methodology 
assuming fixed effects with Cochran’s Q and I2 metrics used to quantify between-study 
heterogeneity. We also calculated the summary results by random effects using STATA 
software68 for those markers associated at GWS level with Cochran’s Q p-value < 0.05 
and/or I2 estimates > 50%, reflecting large heterogeneity beyond chance. Random ef-
fects models also incorporate in the calculations the between-study heterogeneity, and 
estimate the average genetic effect from the population of genetic effects that may differ 
in different studies. In the absence of between-study heterogeneity fixed and random 
effects calculations give identical results. We declared results genome-wide significant 
at α=5x10-8 after adjusting for all common variant tests in the human genome22,23. To test 
for BMD site specificity we estimated the effect difference (∆β) as βfemoralneck – βlumbarspine , the 
SE of the mean difference (∆SEM) as sqrt(SEfemoralneck
2 + SElumbarspine
2) and the Z-statistic as 
∆β/∆SEM from which the p-values were computed. 
eQTL analysis in human osteoblast (HOb)
SNPs from new loci associated with BMD at the genome-wide significance (GWS) level 
were tested for association with cis-allelic expression of neighboring gene transcripts, 
in primary human osteoblasts (HOb) derived from 95 unrelated Swedish donors. De-
tailed cell culture methods have been described previously69. Expression profiling was 
performed using the Illumina HumRef-8 BeadChips according to the manufacturer 
protocol. Genotyping for genotype-expression association was performed using the 
Illumina HumanHap 550k Duo chip. Individuals with low genotyping rate and SNPs 
showing significant deviation from Hardy-Weinberg equilibrium (P< 0.05) were ex-
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cluded. Similarly low frequency (MAF<0.05) SNPs and SNPs with high rates of missing 
data were excluded. The association of the expression levels was focused on cis-acting 
genetic variants, defined as being within 250kb window flanking the gene, using a 
linear regression model implemented in the PLINK70 software package with age and sex 
as covariates. SNPs included on the Illumina 550K chip were assessed for expression 
cis-associations directly. In addition, all genotyped SNPs included on the Illumina chip 
that were in strong LD (defined as D´≥0.8) and mapping ± 50kb from the GWS hit were 
included in the association study. To test for a significant enrichment of functional SNPs 
(i.e., SNPs associated with gene expression in HObs at p<0.05) among the candidate 
SNPs, a Chi2- statistic was obtained to test whether observed associations were different 
from expected associations in the expression data set beyond chance. Expected values 
(7.1%) were based on the proportion of SNPs with p<0.05 seen in the HOb gene expres-
sion data set and in a random selection of 1200 SNPs associated with both LS- and FN-
BMD at P>0.90, MAF>0.20, and present in the Illumina HumanHap550 array (assessed as 
negative controls for association with HOb expression). 
Combined effect of associated loci
Within the setting of the prospective population-based Rotterdam Study the combined 
effect of all 20 BMD loci was studied by classifying subjects according to the number of 
BMD decreasing (risk) alleles. This was based on 15 lumbar spine and 10 femoral neck 
BMD loci as follows: 
Lumbar spine (15 SNPs) => rs7524102 [ZBTB40], rs1430742 [GPR177], rs11898505 
[SPTBN1], rs1471403 [MEPE], rs2504063 [ESR1], rs1524058 [STARD3NL], rs4729260 
[FLJ42280], rs2062377 [TNFRSF11B], rs16921914 [DCDC5], rs599083 [LRP5], rs2016266 
[SP7], rs9533090 [TNFSF11], rs10048146 [FOXC2], rs9303521 [CRHR1] and rs884205 [TN-
FRSF11A]. 
Femoral neck (10 SNPs) => (rs6426749 [ZBTB40], rs2566755 [GPR177], rs87938 
[CTNNB1], rs1366594 [MEF2C], rs2941740 [ESR1], rs7781370 [FLJ42280], rs11995824 
[TNFRSF11B], rs7117858 [SOX6], rs7932354 [ARHGAP1], and rs228769 [HDAC5]). The 
mean BMD for each risk allele-count group was determined, and at the extremes of the 
distribution counts were pooled into the nearest risk allele-count group of size >100 
individuals. The approximate BMD difference in g/cm2 was obtained by multiplying in 
each group the mean Z-score LS-BMD by 0.18 g/cm2 and the mean Z-score FN-BMD by 
0.13 g/cm2 (the SDs of BMD in the Rotterdam study). The allele score was obtained by di-
viding the number of “BMD decreasing alleles” by the total number of alleles. Also within 
the setting of the prospective population-based Rotterdam Study, we determined the 
risk for vertebral and non-vertebral fracture for the combined allelic scores constructed 
for all the top hits associated at a genome-wide significantly level with BMD. Risk ratio 
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(RR) estimates were obtained from logistic regression (vertebral fractures) and Cox-
proportional hazards (incident non-vertebral fractures) models adjusted for sex, age 
and weight. To determine the fraction of fracture risk explained by BMD, we applied 
the following formula: [lnRRunadjusted- lnRRBMDadjusted]/ lnRRunadjusted. Methods describing the 
fracture datasets have been published previously71,72. In summary, thoracolumbar ra-
diographs of the spine were obtained in 3308 (genotyped) individuals who survived on 
average 6.4 ± 0.4 (SD) years and were scored for presence of vertebral fractures (n=329) 
using the McCloskey/Kanis method73. Record of the incident non-vertebral fractures 
(n=900) occurring between the baseline visit from 1990 through 1993 until January 1, 
2002, was obtained from the computerized records of general practitioners and hospital 
registries for 5974 genotyped individuals followed on average 8.2 ± 2.7 (SD) years after 
the baseline visit.
reSulTS
Samples, genotyping and (meta) analysis of genome-wide scans
The five study populations included the Rotterdam Study (RS, n=4,987), Erasmus Ruc-
phen Family Study (ERF, n=1,228), Twins UK Study (TUK, n=2,734), deCODE Genetics 
Study (dCG, n=6,743) and the Framingham Osteoporosis Study (FOS, n=3,503). The age 
of participants ranged from 18 to 96 years. All studies had a majority of women (range 
57-88%) in their samples with TUK including women only. Additional characteristics of 
the study populations and subject exclusion criteria are presented in Supplementary 
Tables 1 and 2, respectively (www.nature.com/ng/index.html).
BMD loci identification
Association results (corrected by the genomic control method20) of all HapMap CEU 
imputed SNPs passing quality-control (QC) criteria in each study (Supplementary Table 
3), were meta-analyzed using METAL21. We declared results genome-wide significant 
at α=5x10-8 after adjusting for all common variant tests in the human genome22,23. We 
investigated if there was an excess of significant associations by comparing the test sta-
tistics to those expected under the null distribution using inter quantile-quantile (QQ) 
plots (corrected for overall meta-analysis genomic control λLS-BMD=1.09 and λFN-BMD=1.08). 
As observed in figure 1, strong (and not early) deviation of the observed statistics from 
the null distribution was observed for both BMD traits, corresponding to an excess of 
significant and likely true associations. Excluding all SNPs within 500 Kb of the SNPs 
associated at a GWS level and correction for overall meta-analysis genomic control, still 
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left many SNPs associated with BMD more than expected by chance alone. This suggests 
that among many false positives appearing at less stringent statistical thresholds, ad-
ditional truly associated BMD variants may exist.
The meta-analysis identified 467 SNPs from 20 genomic loci exceeding the GWS 
threshold of association with the BMD traits (figure 2). Of these, 15 loci associated 
with LS-BMD (Supplementary Tables 4A and 5A) and 10 with FN-BMD (Supplementary 
figure 1. Quantile-Quantile (Q-Q) plots for: A. Lumbar Spine BMD and b. Femoral Neck BMD; comparing 
additive model statistics to those expected under the null distribution using fixed-effects for all analyzed 
HapMap CEU imputed SNPs passing quality-control (QC) criteria in the studies (upper lines), and after 
exclusion of all genome-wide significant and correlated (r2>0.1) SNPs (lower lines). 
A.
b.
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Table 1. Top genome-wide significant markers of the 20 loci associated at GWS with lumbar spine and/or femoral 
neck BMD
Marker Information lumbar spine bMD lumbar spine bMD lumbar spine bMD femoral neck bMD Site Specificity
effect estimate  (in SD) heterogeneity effect estimate  (in SD) heterogeneity h o : β lS = β fn
locus SnP A1*/A2 freQ* Type Closest 
Gene
Distance 
(kb)
beta Se P-value OMA-GC 
P-value
Q P-value I 2 beta Se P-value OMA-GC 
P-value
Q P-value I 2 Q P-value
novel loci associated with bMD at GWS level
1p31.3 rs1430742 T/C 0.79 I GPR177 44.0 0.105 0.014 2.6e-13 2.5e-12 0.26 21 0.100 0.014 1.8e-12 1.2e-11 0.75 0 0.82
rs2566755 T/C 0.79 G GPR177 44.3 0.104 0.014 3.3e-13 3.1e-12 0.27 20 0.100 0.014 1.7e-12 1.1e-11 0.76 0 0.83
3p22 rs87938 A/G 0.45 G CTNNB1 103.3 -0.043 0.012 1.7E-04 3.1E-04 0.24 23 -0.070 0.011 8.1e-10 3.4e-09 0.14 34.5 0.10
5q14 rs1366594 A/C 0.55 G MEF2C 197.0 0.005 0.012 0.65 0.66 NC NC -0.085 0.011 1.3e-13 1.1e-12 0.62 0 3.2E-08
7p14 rs1524058 T/C 0.40 I STARD3NL 81.7 -0.070 0.012 1.1e-09 5.2e-09 0.18 30 -0.038 0.011 8.9E-04 1.4E-03 0.05 48 0.05
7q21.3 rs4729260 C/G 0.68 I FLJ42280 14.9 -0.081 0.013 1.7e-10 9.5e-10 0.14 35 -0.085 0.012 9.4e-12 5.4e-11 0.77 0 0.82
rs7781370 T/C 0.34 I FLJ42280 0.7 -0.074 0.012 1.1e-09 5.5e-09 0.12 37 -0.083 0.012 4.7e-12 2.9e-11 0.68 0 0.60
11p14.1 rs16921914 A/G 0.27 G DCDC5 61.6 0.077 0.013 2.3e-09 1.0e-08 0.52 0 0.038 0.013 0.003 0.005 NC NC 0.03
11p15 rs7117858 A/G 0.80 G SOX6 297.3 -0.042 0.014 0.004 0.005 NC NC 0.088 0.014 6.4e-10 2.7e-09 0.70 0 1.5E-10
16q24 rs10048146 A/G 0.81 G FOXL1 95.4 -0.093 0.016 1.7e-08 6.0E-08 0.21 28 -0.085 0.016 1.7E-07 4.9E-07 0.96 0 0.73
17q12 rs9303521 T/G 0.46 G CRHR1 56.5 -0.068 0.012 1.4e-08 5.0E-08 0.05 49 -0.055 0.012 3.6E-06 8.3E-06 0.07 45 0.46
Suggestive loci now associated with bMD at GWS level 
2p21 rs11898505 A/G 0.34 G SPTBN1 1.1 0.067 0.012 1.6e-08 6.3E-08 0.39 6 0.027 0.012 0.02 0.03 NC NC 0.02
4q21.1 rs1471403 T/C 0.34 G MEPE 7.3 0.068 0.012 1.5e-08 5.7E-08 0.18 30 0.059 0.012 7.8E-07 2.0E-06 0.56 0 0.58
11p11.2 rs7932354 T/C 0.29 I ARHGAP1 0.1 0.056 0.013 1.1E-05 2.4E-05 0.61 0 0.073 0.012 4.0e-09 1.5e-08 0.68 0 0.32
17q21 rs228769 C/G 0.80 I HDAC5 7.8 0.067 0.014 4.0E-06 1.0E-05 0.87 0 0.081 0.014 1.7e-08 5.8E-08 0.94 0 0.49
known loci associated with bMD at GWS level
1p36 rs7524102 A/G 0.83 G ZBTB40 79.9 0.094 0.015 3.2e-10 1.7e-09 0.27 19.5 0.079 0.015 8.8e-08 2.6E-07 0.64 0 0.48
rs6426749 C/G 0.17 I ZBTB40 66.9 0.107 0.017 7.6e-10 3.8e-09 0.74 0 0.082 0.015 4.8e-08 1.5E-07 0.64 0 0.26
6q25 rs2504063 A/G 0.40 G ESR1 38.0 -0.078 0.012 6.1e-11 3.7e-10 0.03 52.7 -0.066 0.012 3.0e-08 9.6E-08 0.84 0 0.45
rs2941740 A/G 0.57 I C6orf97 67.3 0.070 0.012 2.0e-09 9.3e-09 0.01 59.0 0.073 0.012 2.0e-10 9.1e-10 0.02 57.2 0.84
8q24 rs2062377 A/T 0.56 I TNFRSF11B 43.0 0.094 0.012 3.5e-16 5.7e-15 0.31 15.4 0.062 0.011 5.4E-08 1.7E-07 0.61 0 0.05
rs11995824 C/G 0.45 I TNFRSF11B 48.3 -0.093 0.012 1.1e-15 1.6e-14 0.24 22.3 -0.066 0.011 7.1e-09 2.6e-08 0.48 0 0.10
11q13.4 rs599083 T/G 0.69 G LRP5 24.4 -0.067 0.012 4.7e-08 1.7E-07 0.50 0 -0.047 0.012 9.7E-05 0.0002 0.76 0 0.25
12q13 rs2016266 A/G 0.68 G SP7 1.6 0.070 0.012 1.3e-08 5.2E-08 0.93 0 0.046 0.012 1.9E-04 0.0003 0.81 0 0.16
13q14 rs9533090 T/C 0.50 I AKAP11 54.0 -0.120 0.012 5.4e-25 4.6e-23 0.02 57.1 -0.041 0.011 3.9E-04 0.0006 0.39 5.7 1.1E-06
18q21 rs884205 A/C 0.27 I TNFRSF11A 1.4 -0.078 0.0136 9.4e-09 3.8e-08 0.90 0 -0.039 0.013 0.004 0.005 NC NC 0.04
Type SNP : G=Genotyped (at least in 1 study) I=Imputed
Distance : to coding region
Bold: P<5x10-8
OMA-GC : overall meta-analysis genomic control
NC : Not calculated: P>0.001
Q P-value: Q-statistic P-value
Twenty bone mineral density loci identified by meta-analysis of GWAS 153
Table 1. Top genome-wide significant markers of the 20 loci associated at GWS with lumbar spine and/or femoral 
neck BMD
Marker Information lumbar spine bMD lumbar spine bMD lumbar spine bMD femoral neck bMD Site Specificity
effect estimate  (in SD) heterogeneity effect estimate  (in SD) heterogeneity h o : β lS = β fn
locus SnP A1*/A2 freQ* Type Closest 
Gene
Distance 
(kb)
beta Se P-value OMA-GC 
P-value
Q P-value I 2 beta Se P-value OMA-GC 
P-value
Q P-value I 2 Q P-value
novel loci associated with bMD at GWS level
1p31.3 rs1430742 T/C 0.79 I GPR177 44.0 0.105 0.014 2.6e-13 2.5e-12 0.26 21 0.100 0.014 1.8e-12 1.2e-11 0.75 0 0.82
rs2566755 T/C 0.79 G GPR177 44.3 0.104 0.014 3.3e-13 3.1e-12 0.27 20 0.100 0.014 1.7e-12 1.1e-11 0.76 0 0.83
3p22 rs87938 A/G 0.45 G CTNNB1 103.3 -0.043 0.012 1.7E-04 3.1E-04 0.24 23 -0.070 0.011 8.1e-10 3.4e-09 0.14 34.5 0.10
5q14 rs1366594 A/C 0.55 G MEF2C 197.0 0.005 0.012 0.65 0.66 NC NC -0.085 0.011 1.3e-13 1.1e-12 0.62 0 3.2E-08
7p14 rs1524058 T/C 0.40 I STARD3NL 81.7 -0.070 0.012 1.1e-09 5.2e-09 0.18 30 -0.038 0.011 8.9E-04 1.4E-03 0.05 48 0.05
7q21.3 rs4729260 C/G 0.68 I FLJ42280 14.9 -0.081 0.013 1.7e-10 9.5e-10 0.14 35 -0.085 0.012 9.4e-12 5.4e-11 0.77 0 0.82
rs7781370 T/C 0.34 I FLJ42280 0.7 -0.074 0.012 1.1e-09 5.5e-09 0.12 37 -0.083 0.012 4.7e-12 2.9e-11 0.68 0 0.60
11p14.1 rs16921914 A/G 0.27 G DCDC5 61.6 0.077 0.013 2.3e-09 1.0e-08 0.52 0 0.038 0.013 0.003 0.005 NC NC 0.03
11p15 rs7117858 A/G 0.80 G SOX6 297.3 -0.042 0.014 0.004 0.005 NC NC 0.088 0.014 6.4e-10 2.7e-09 0.70 0 1.5E-10
16q24 rs10048146 A/G 0.81 G FOXL1 95.4 -0.093 0.016 1.7e-08 6.0E-08 0.21 28 -0.085 0.016 1.7E-07 4.9E-07 0.96 0 0.73
17q12 rs9303521 T/G 0.46 G CRHR1 56.5 -0.068 0.012 1.4e-08 5.0E-08 0.05 49 -0.055 0.012 3.6E-06 8.3E-06 0.07 45 0.46
Suggestive loci now associated with bMD at GWS level 
2p21 rs11898505 A/G 0.34 G SPTBN1 1.1 0.067 0.012 1.6e-08 6.3E-08 0.39 6 0.027 0.012 0.02 0.03 NC NC 0.02
4q21.1 rs1471403 T/C 0.34 G MEPE 7.3 0.068 0.012 1.5e-08 5.7E-08 0.18 30 0.059 0.012 7.8E-07 2.0E-06 0.56 0 0.58
11p11.2 rs7932354 T/C 0.29 I ARHGAP1 0.1 0.056 0.013 1.1E-05 2.4E-05 0.61 0 0.073 0.012 4.0e-09 1.5e-08 0.68 0 0.32
17q21 rs228769 C/G 0.80 I HDAC5 7.8 0.067 0.014 4.0E-06 1.0E-05 0.87 0 0.081 0.014 1.7e-08 5.8E-08 0.94 0 0.49
known loci associated with bMD at GWS level
1p36 rs7524102 A/G 0.83 G ZBTB40 79.9 0.094 0.015 3.2e-10 1.7e-09 0.27 19.5 0.079 0.015 8.8e-08 2.6E-07 0.64 0 0.48
rs6426749 C/G 0.17 I ZBTB40 66.9 0.107 0.017 7.6e-10 3.8e-09 0.74 0 0.082 0.015 4.8e-08 1.5E-07 0.64 0 0.26
6q25 rs2504063 A/G 0.40 G ESR1 38.0 -0.078 0.012 6.1e-11 3.7e-10 0.03 52.7 -0.066 0.012 3.0e-08 9.6E-08 0.84 0 0.45
rs2941740 A/G 0.57 I C6orf97 67.3 0.070 0.012 2.0e-09 9.3e-09 0.01 59.0 0.073 0.012 2.0e-10 9.1e-10 0.02 57.2 0.84
8q24 rs2062377 A/T 0.56 I TNFRSF11B 43.0 0.094 0.012 3.5e-16 5.7e-15 0.31 15.4 0.062 0.011 5.4E-08 1.7E-07 0.61 0 0.05
rs11995824 C/G 0.45 I TNFRSF11B 48.3 -0.093 0.012 1.1e-15 1.6e-14 0.24 22.3 -0.066 0.011 7.1e-09 2.6e-08 0.48 0 0.10
11q13.4 rs599083 T/G 0.69 G LRP5 24.4 -0.067 0.012 4.7e-08 1.7E-07 0.50 0 -0.047 0.012 9.7E-05 0.0002 0.76 0 0.25
12q13 rs2016266 A/G 0.68 G SP7 1.6 0.070 0.012 1.3e-08 5.2E-08 0.93 0 0.046 0.012 1.9E-04 0.0003 0.81 0 0.16
13q14 rs9533090 T/C 0.50 I AKAP11 54.0 -0.120 0.012 5.4e-25 4.6e-23 0.02 57.1 -0.041 0.011 3.9E-04 0.0006 0.39 5.7 1.1E-06
18q21 rs884205 A/C 0.27 I TNFRSF11A 1.4 -0.078 0.0136 9.4e-09 3.8e-08 0.90 0 -0.039 0.013 0.004 0.005 NC NC 0.04
Type SNP : G=Genotyped (at least in 1 study) I=Imputed
Distance : to coding region
Bold: P<5x10-8
OMA-GC : overall meta-analysis genomic control
NC : Not calculated: P>0.001
Q P-value: Q-statistic P-value
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Tables 4B and 5B); five of these loci were associated with both skeletal sites. The effect 
sizes and significance of the top SNPs from the 20 regions containing markers associ-
ated with LS- and FN-BMD at GWS are presented in Table 1. Applying correction for 
overall- meta-analysis genomic control resulted in five of the 20 loci not to be GWS (with 
7.1x10-7<P<5.0x10-8). For most markers heterogeneity was not very large or statistically 
significant. 
Despite the correlation between LS- and FN-BMD measurements, site-specific ef-
fects were observed. Seven of the 20 loci showed evidence for skeletal site-specificity 
(P<0.05), three of which displayed strong evidence for site-specificity (P<1x10-6). This 
site-specificity is to be expected given the differences in heritability and that the genetic 
figure 2. Manhattan plots displaying novel and previously reported (known) loci associated at genome-
wide significant level (GWS) with Lumbar Spine BMD (top) and Femoral Neck BMD (bottom) for all 
2,543,686 HapMap CEU-imputed SNPs analyzed using fixed-effects. The 13 new GWS loci are in bold and 
underlined type.  
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correlation (or fraction of “shared” heritability) between the measurements is consider-
ably less than 1 (Supplementary Table 6). 
Genes in associated regions and their function
Of the 20 BMD loci identified in this genome scan at a GWS level, seven have been 
reported previously as GWS13,24, whereas the remaining 13 have not. Of these 13 loci 
not previously associated with BMD at a GWS level, four were suggestively associated in 
previous reports (12,13), whereas nine are novel loci. In Supplementary Table 7 we present 
a summary of relevant gene annotations including related pathways, monogenic syn-
dromes, knockout mouse models, and additional functional details of the genes most 
likely to be underlying the associated signals in these 13 loci.
Novel loci associated with BMD at GWS level
There are nine loci displaying novel associations with BMD for which we present Forest 
plots of effects (figure 3) and regional association plots (Supplementary Figure 1) from 
the top SNPs.
1p31.3 locus [GRP177]
Two common SNPs (MAF=0.21) in complete pair wise LD (rs1430742 and rs2566755) 
were associated at a GWS level with both FN- and LS-BMD. Both top SNPs are located 
within an intronic region of the G protein-coupled receptor 177 (GPR177, also named 
WNTLESS homologue) gene. GPR177 is part of the highly evolutionary conserved Wnt 
signaling pathway,25 involved in bone cell differentiation and development. The gene 
has been shown to be positive regulator of the I-kappaB kinase/NF-kappaB cascade, part 
of the RANK system. Cross-talk between the NF-kB and the mitogen-activated protein 
kinase (MAPK) pathway has been indicated by the identification of several overlapping 
genes expressed in both pathways, including several G protein-coupled receptors26. 
3p22 locus [CTNNB1]
The rs87939 SNP (MAF=0.45) located 103 Kb upstream of the catenin (cadherin-associat-
ed protein), beta 1 (CTNNB1) gene on chromosome 3 was associated at a GWS level with 
FN-BMD. CTNNB1 is integral to the Wnt signaling pathway, and as such, is an excellent 
candidate for BMD regulation, considering that Wnt signaling controls the process of 
bone resorption by (negative) regulation of Opg (TNFRS11B) expression in osteoblasts27.
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5q14 locus[MEF2C]
The rs1366594 top SNP (MAF=0.45) displayed skeletal site-specificity being associated 
with FN-BMD only, together with other 60 GWS markers at this locus. The SNP is located 
197 Kb upstream of the MADS box transcription enhancer factor 2, polypeptide C (MEF2C) 
gene with no other known annotation within the large LD block. MEF2C is a transcrip-
tion factor highly expressed in muscle which allows transcriptional cross-talk between 
theCa2+/calmodulin-dependent kinase (CaMK) and mitogen-activated protein kinase 
(MAPK) signaling pathways by signal-dependent dissociation from histone deacetylases 
(HDACs). MEF2C interacts with HDAC4 and HDAC5 (see below 17q21 region), resulting in 
repression of the transcriptional activity of MEF2C. Potthoff et al. showed in mice that 
HDACs selectively degraded by the proteasome enables MEF2C to activate the slow 
myofiber gene program, resulting in enhanced endurance during physical exercise28. 
7p14-p13 locus[STARD3NL] 
The rs1524058 SNP (MAF=0.40) located on the short arm of chromosome 7 is 81 Kb 
upstream of the STARD3 n-terminal like (STARD3NL) gene, a cholesterol endosomal trans-
porter, was associated at a GWS level with LS-BMD but less strongly with FN-BMD. Very 
figure 3. Forest Plots for the top SNPs for each of the 9 novel loci: A. 1p31.3, b. 3p22, C. 5q14,  D. 7p14, 
e. 7q21.3, f. 11p15, G. 11p14.1, h. 16q24, I. 17q12. Squares represent effect estimate and 95%CI for each 
study, and the diamonds are summary effect. Measurements units are in BMD standard deviations (SD).
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recently, a study on Asian individuals29 identified a SNP in this 7p14 region consistently 
associated with BMD measurements of the radius, tibia and heel (lowest P=1.4x10-7). Yet, 
the rs1721400 SNP was not associated with either LS- or FN- BMD in our study (P>0.05). 
The rs1721400 marker (mapping close to SFRP4) is in very low LD with our top SNP 
rs1524058 in HapMap individuals of European descent (r2=0.015, D’=0.194), while LD 
between markers is considerably higher in Chinese or Japanese individuals (r2=0.230, 
D’=0.931). Thus, an underlying signal common to both Europeans and Asians may be 
still be captured by these SNPs considering the differences in LD across populations. 
7q21.3 locus[FLJ42280]
Several SNPs are GWS in this region, with the two top SNPs being in moderate pair wise 
LD (r2=0.36; D’=0.84) and associated at GWS with both LS- and FN-BMD. The SNPs are 
located within (rs4729260) and just upstream (rs7781370) of FLJ42280, a hypothetical 
protein of unknown function. There are several genes within the ~480 kb LD stretch 
region, of which the split hand/foot malformation (ectrodactyly) type 1 (SHFM1) is the 
closest gene (87-185 kb away).
11p15 locus[SOX6] 
The rs7117858 SNP (MAF=0.20) was associated at GWS level with FN-BMD only, display-
ing strong evidence for skeletal site-specificity. The SNP is located 297kb upstream from 
the SRY (sex determining region Y)-box(SOX6) gene, which is a transcription factor of 
the SOX gene family defined by a conserved high mobility group (HMG) DNA-binding 
domain. The gene is expressed in a wide variety of tissues, most abundantly in skeletal 
muscle. Sox6 knock-out mice exhibit early lethality due to cardiac insufficiency and pres-
ent with mild skeletal abnormalities affecting size and mineralization of endochondral 
elements30. Other SOX-family genes regulate RUNX2-mediated differentiation of mesen-
chymal cells during endochondral ossification (skeletogenesis)31.
11p14.1 locus[DCDC5;DCDC1]
The rs16921914 SNP (MAF=0.27) is the only marker in the 11p14.1 region associ-
ated with LS-BMD at a GWS level.  All other associated SNPs are in moderate LD with 
rs16921914 (r2<0.70) and display less strong associations (P>1x10-7). The SNP is located 
62 kb downstream of the doublecortin domain containing 1 (DCDC1) and 73 kbupstream 
of the DCDC5genes. Doublecortin domains are highly conserved elements which serve 
as protein-interaction platforms32. Mutations in members of this protein superfamily 
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are linked to several neurogenetic diseases and to our knowledge are not expressed in 
bone. 
16q24.3 locus[FOXC2; fOXl1] 
The rs10048146 SNP (MAF=0.19) was associated with LS-BMD (-0.09 and is located on 
the subtelomeric region of chromosome 16, about 95Kb downstream from a cluster of 
small (1 Kb) genes of the “forkhead” (or winged helix) gene family. The genes are mainly 
expressed in the gastrointestinal mucosa (FOXL1) or are involved in adipocyte metabo-
lism and early stage chondrogenic differentiation (FOXC2). FOXC2 stimulates osteoblast 
differentiation of mesenchymal cells through activation of canonical Wnt-beta-catenin 
signals33 while FOXC2 expression has been shown to occur via bone morphogenetic 
proteins34. Skeletal defects of the spine have been reported in FOXC2 mouse knockout 
models35 and recently, deletions and inactivating mutations affecting the FOX gene 
cluster have been identified as causing severe malformations of the VACTER type in 
humans, which include vertebral malformations.36
17q12-q22 [CRHR1]
The rs9303521 SNP (MAF=0.46) on chromosome 17 was associated with LS-BMD and 
is located 56 Kb from the corticotrophin-releasing factor receptor (CRHR1) gene. Among 
other genes in this LD region, MAP3K14 is another candidate potentially involved in 
bone-active pathways, particularly through the activation of NF-kappa-B. 
SuGGeSTIve lOCI nOW ASSOCIATeD WITh bMD AT GWS level
Four BMD loci which now reach for the first time a GWS level were “suggestively” associ-
ated with BMD in previous reports12,13. We present Forest plots of effects (figure 4) and 
regional association plots (Supplementary Figure 2) from these SNPs. 
2p21 locus [SPTBN1]
The rs11898505 (MAF=0.34) on chromosome 2 is intronic to the spectrin, beta, non-
erythrocytic 1 (SPTBN1) gene which encodes a major cytoskeletal scaffolding protein, 
and was associated with LS-BMD. The same SNP was previously shown to be associated 
with BMD and fractures, even though it did not reach GWS level for BMD in the same 
study.13 In mice, disruption of beta-spectrin isoforms (Elf ) leads to the disruption of TGF-
beta signaling by Smad proteins37. 
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4q21.1 locus[MEPE]
The 4q21.1 region contains a cluster of structurally and phylogenetically related genes 
encoding matricellular phosphoglycoproteins with function in bone formation and 
growth38. The top associated rs1471403 SNP (MAF=0.34) is located 7 Kb 3’ to the matrix, 
extracellular, phosphoglycoprotein (MEPE) gene (also known as osteoblast/osteocyte 
factor 45), 42 Kb to the integrin-binding sialoprotein (IBSP) gene and 122 Kb 5’ to the 
secreted phosphoprotein 1 (SPP1) gene, also known as osteopontin. IBSP and SPP1 are 
highly expressed in osteoblasts, osteoclasts and hypertrophic chondrocytes. MEPE is 
predominantly expressed by osteocytes in human bone, playing an inhibitory role in 
bone formation. All three genes display diverse skeletal phenotypes in mice knock out 
(KO) models.  MEPE (Of45) KO show increased bone mass and inhibition of age-related 
bone loss39, IBSP KO show high trabecular bone density with low bone turnover but 
respond to bone loss caused by disuse40 and the SPP1 KO have high trabecular bone 
mass and is resistant to bone loss41. Previously, a non-synonymous SNP in the IBSP gene 
(rs1054627, G195Q) in moderate LD with  (r2=0.2, D’=0.8) was reported as suggestively 
associated with hip BMD.12
11p11.2 locus[ARHGAP1;LRP4]
At the 11p11.2 region a large LD block extends the region withholding several genes, 
including C11orf49, LRP4, CKAP5, F2, ZN408 and ARHGAP1 among others. Two fully cor-
figure 4. Forest Plots for the top SNPs for each of the 4 loci attaining GWS for the first time in this study: 
A. 2p21, b. 4q21.1, C. 11p11.2,  D. 17q21. Squares represent effect estimate and 95%CI for each study, and 
diamonds are summary effect estimates. Measurements units are in BMD standard deviations (SD).
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related SNPs (r2=1;MAF=0.29) including rs7932354, which lies in the promoter region of 
the Rho GTPase activating protein 1 (ARHGAP1) gene; and rs2070852, located in intron 5 
of the coagulation factor II  (F2) gene were associated with FN-BMD at GWS level. Other 
correlated SNPs in the region (r2 between 0.2 and 0.8) were previously suggestively as-
sociated with hip BMD and attributed to the LRP4 gene13.  ARHGAP1, a ubiquitous factor 
composing one of the GTPase activating proteins that represses RhoA, is another good 
candidate. RhoA is a small G-protein of the Rho family that regulates cell morphology via 
actin- cytoskeleton reorganization and which is thought to be a potential commitment 
switch in the differentiation of mesenchymal stem cells to osteoblasts42. In addition, data 
from ARHGAP1 KO mouse models show a strong skeletal phenotype, including a 3-fold 
reduction in BMD, decreased cortical thickness and bone fragility in older animals43.
17q21 locus [HDAC5;C17orf53]
The 17q21 region contains more than 30 genes in 1 Mb surrounding the top rs228769 
SNP (MAF=0.20) which is located 8 Kb upstream of thehistone deacetylase 5 (HDAC5) and 
26 kb upstream of the C17orf53 genes. A non synonymous SNP in the C17orf53 gene, 
rs227584 (T126P), moderately correlated to rs228769 (r2=0.64) was found associated 
with hip BMD, albeit not at GWS level12. These SNPs likely represent the same signal. 
HDAC5 is a class histone deacetylase II (homologous to yeast Hda1), ubiquitously ex-
pressed and responsible for the deacetylation of lysine residues on the N-terminal part 
of the core histones (H2A, H2B, H3 and H4). Histone acetylation and deacetylation plays 
an important role in transcriptional regulation,cell cycle progression and developmental 
events, particularly for myocyte differentiation44.  In undifferentiated myoblasts, HDAC5 
is present in the nucleus where it binds to the myocyte enhancer MEF2C (see above) 
to repress transcription and detain muscle maturation. In bone, recruitment of class II 
histone deacytylases like HDAC5, is needed for TGF-β mediated osteoblast differentia-
tion45, which occurs through inhibition of Runx2 function by Smad346. 
Known loci associated with BMD at GWS level
We have replicated at GWS level 7 loci associated with BMD in previous GWA studies12,13,24. 
They include the 1p36 (ZBTB40), 6q25 (ESR1), 8q24 (TNFRSF11B;Opg), 11q13.4 (LRP5), 
12q13 (SP7;Osterix), 13q14 (TNFSF11;RANKL), and 18q21 (TNFRSF11A;RANK) regions. 
Regional association plots for all seven regions are included in Supplementary Figure 3. 
In the 6q25 (ESR1) region at least two independent GWS signals are seen at the sides of a 
high recombination rate peak (Supplementary Figure 3B). This locus showed a complex 
pattern of association in a previous study indicating three independent signals at the 
locus13. In Supplementary Table 8 we report the associations observed in this study for 
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all loci reported previously as attaining GWS or “suggestive” association12,13,24. SNPs from 
the 6p21.32 (MHC), 14q32 (MARK3) and 17q21 (SOST) regions described previously to be 
GWS13 were still significantly associated to BMD in our study, but not at a GWS level. It 
should be noted that in the previous study the 14q32 and the 17q21 regions were as-
sociated with total hip BMD, which differs from the femoral neck BMD phenotype used 
in the current study.  
Gene expression (eQTL) associations
We tested the association of SNPs (or proxies) from the 13 newly GWS associated regions 
with cis-allelic expression of gene transcripts in primary human osteoblasts. All SNPs 
associated with gene expression at P<0.05 and located within the same LD block of 
the strongest associated variants (D’≥0.8) are presented in Supplemental Table 9. As-
sociations were seen for transcripts of GPR177, MEF2C and FOXC2. Similarly, for variants 
in (or in LD with variants in) MEPE the most significant correlation with expression in 
osteoblasts was seen with the integrin bone sialoprotein (IBSP) gene, while MEPE seems 
not highly expressed in osteoblasts. Yet, the statistical evidence is not fully conclusive 
since only subtle overrepresentation of the associated loci was observed (10.5% vs 7% 
for non-associated control SNPs, Chi2=8.9 and P=0.003). The small overrepresentation of 
the associated loci suggests several of the associated genes may be expressed in cell & 
tissues other than osteoblast lineages. 
Combined effect of the 20 GWS BMD loci and fracture risk
We examined the combined effect of the top SNPs arising from the 20 associated BMD 
loci in 4,983 individuals from the prospective population-based Rotterdam study. Risk 
allele counts were derived from the top associated SNPs from the 15 LS-BMD and 10 
FN-BMD loci, all of which followed a normal distribution of their frequency in the study 
population (figure 5). The 15 LS-SNPs combined explained ~2.9% of the variance in 
LS-BMD and the 10 FN-SNPs combined explained ~1.9% of the variance in FN-BMD. A 
highly significant linear decrease in the mean LS-BMD and FN- BMD of individuals was 
seen with increasing numbers of “low BMD” risk alleles, i.e. those carrying 20 or more 
alleles that associated with low LS-BMD (“low BMD” alleles) (n=300) had 0.65 SD (~0.12 
g/cm2) lower BMD (P=3x10-8) compared to those that carried 11 “low BMD” alleles or 
fewer (n=360). A similar (yet less pronounced) trend was seen for FN-BMD. The asso-
ciation between the compound allelic scores and the risk of fracture were assessed in 
2727 radiographically screened individuals (302 vertebral fracture cases) and  in 4865 
individuals followed-up 8.2 years on average (672 non-vertebral fractures). The com-
pound LS-BMD allelic score was not significantly associated with the risk of vertebral 
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fracture in the Rotterdam Study dataset (OR=1.018, 95%CI[0.966,1.073]; P=0.50), while it 
was borderline significant for association with the risk of incident non-vertebral fracture 
(HR=1.031, 95%CI[0.997,1.066]; P=0.07). In contrast, the compound FN-BMD allelic score 
was consistently associated with the risk of vertebral (OR=1.057, 95%CI[1.010,1.107]; 
P=0.02) and non-vertebral (HR=1.033, 95%CI[1.004,1.063]; P=0.03) fracture. Adjustment 
for FN-BMD showed that at least 46% of the genetic effect on vertebral fracture could 
be explained by FN-BMD (ORadjusted= 1.031, 95%CI[0.983,1.080]; P=0.21), and 54% of the 
genetic effect on incident non-vertebral fracture was through FN-BMD (HRadjusted= 1.015, 
95%CI [0.986,1.044]; P=0.32). Power limitations are a very plausible explanation to the 
absence of significant association between the LS-BMD compound allelic score and the 
risk of vertebral fracture. 
DISCuSSIOn
The GEFOS consortium has been assembled to identify the genetic determinants of os-
teoporosis and fracture. This study represents the first step in a collaborative effort and 
expands the current knowledge on the underlying genetics of BMD, a clinical measure-
ment used for the diagnosis of osteoporosis and the assessment of fracture risk. BMD 
measures of the lumbar spine and femoral neck were analyzed independently, because 
despite a relatively high phenotypic correlation, the genetic correlation is not perfect. 
This is illustrated by the site-specificity detected in some of the associations probably 
reflecting genuine biological mechanisms (i.e. differences in cortical vs trabecular bone 
A b
figure 5. Histogram and line plot modeling in the Rotterdam Study the combined allelic effect across 
all genome-wide significant associated loci for A. Lumbar Spine BMD and b. Femoral neck BMD.  Subjects 
were classified according to the number of BMD decreasing (risk) alleles at the lumbar spine BMD (20 
SNPs) and the femoral neck (15 SNPs). The mean for each risk allele-count group was determined and 
the extremes of the distribution counts were pooled into the nearest risk allele-count group of size >100 
individuals.
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content), but also intrinsic measurement differences (i.e. artifacts influencing BMD val-
ues like osteophytes of the lumbar spine or aortic calcifications). 
Performing meta-analysis of GWAS has limitations. False positive associations gener-
ated from multiple hypothesis testing and population stratification are inherent pos-
sibilities. Nevertheless, we applied well-established methods to minimize the impact 
of multiple testing by applying stringent GWS thresholds for determining significance. 
Also, our findings are constrained by the power of our current sample suited to identify 
effect sizes explaining ~0.2% of the variance of the trait. This means we are not powered 
to detect real effects of the same (small) magnitude arising within specific sex and/or 
age groups. Similarly, due to power limitations we cannot address potential gene-gene 
and gene-environment interactions, the effects of rare alleles that are not captured 
by the haplotype tagging approach employed in GWAS nor determine the effect on 
fracture risk. Despite being underpowered to assess heterogeneity of effects, some 
markers displayed significant heterogeneity and were not GWS when analyzed under 
the random effects model. Further evaluation of such markers in larger populations is 
needed to determine the source(s) of heterogeneity across datasets, like inaccuracies in 
the imputations, subtle differences in phenotype ascertainment, differences in linkage 
to the culprit, differences in environmental modifying factors, or genuinely different 
genetic effects across populations.47 Achieving such sufficiently-powered setting is the 
target of the expanding GEFOS consortium. All our top associated markers displayed 
high quality imputation scores, high correlation after de-novo genotyping and/or at 
least one genotyped proxy in complete LD which was also associated at GWS level 
(Supplementary Table 10). Thus, we can exclude imputation inaccuracies as a source of 
heterogeneity and/or false-positive associations.  In addition, we excluded individuals 
with non-European profiles strategy which confines our current findings to the context 
of populations of Northern European-descent. Similarly, test statistics corrected by the 
genomic inflation factors affecting each study, makes unlikely that population stratifica-
tion or cryptic relatedness (like those observed in the ERF, TUK, and dCG populations) 
play an important role in our associations. In addition, we examined the effect of 
applying a second correction for overall meta-analysis genomic control in our results. 
Only one locus (LRP5) drifted away importantly from the GWS threshold after correc-
tion. This approach is likely to be over-conservative considering that the association of 
variants in LRP5 has been consistently replicated at GWS level in at least two previous 
efforts10,24In summary, we identified and/or confirmed at least 20 loci associated with 
lumbar spine and femoral neck BMD, highlighting the complex genetic architecture 
underlying the variation in BMD. Yet, these loci explain only a minor fraction of the 
variance in BMD, and hence, an even smaller fraction of the heritability for fracture 
risk. Nevertheless, these findings underscore molecules within novel and key-known 
biological pathways influencing BMD variation, particularly the Wnt and NF-kappa-B 
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signaling pathways (including about half of the identified loci  GPR177, CTNNB1,FOXC2, 
LRP5, SPTBN1,HDAC5,TNFSF11, TNFRSF11A and TNFRSF11B). None of the SNPs we have 
identified can be unequivocally designated as the underlying “true” variants driving 
the associations. Additional efforts to identify such variants are warranted to maximize 
the application of this genetic knowledge towards the prediction of risk in individuals 
and the translation into new pharmacological agents for the treatment of osteoporosis. 
Increasing further the sample size will aid the identification of additional loci associated 
not only with BMD, but more importantly will allow focusing on the risk of fracture, the 
ultimate consequence of osteoporosis.
OMIM48,49accession numbers
GPR177[611514]; CTNNB1[116806]; MEF2C[600662]; STARD3NL[611759]; 
FLJ42280[None],SHFM1[183600]; SOX6[607257]; DCDC5[612321],DCDC1[608062]; 
FOXC2[602402],FOXL1[603252]; CRHR1[122561]; SPTBN1[182790]; MEPE[6059
12],IBSP[147563],SPP1[166490]; ARHGAP1[602732],LRP4[604270],F2[176930]; 
HDAC5[605315],C17orf53[None]; ZBTB40[612106]; ESR1[133430], C6orf97[None]; 
TNFRSF11B[602343]; LRP5[603506]; SP7[606633]; TNFSF11[602642],AKAP11[604696]; 
TNFRSF11A[603499].
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In this thesis, studies are presented on the genetic and nutritional background of the 
age-related metabolic diseases obesity and osteoporosis, and the relation between the 
two conditions. In addition, determinants of survival in healthy subjects and in persons 
with type 2 diabetes are examined.
PArT I: ePIDeMIOlOGICAl STuDIeS 
I a ) Sex-specific genetic effects on body composition
Despite sex-differences in the occurrence of many diseases and polygenetic traits 
relatively few studies have investigated the sex-specificity of genetic effects. In the 
family-based Erasmus Rucphen Family (ERF) study, our shared heritability studies sug-
gest that gene by sex interactions are present for most body composition traits such as 
fat mass, lean mass and fat distribution, but not for height and BMI. The genetic correla-
tions between men and women were significantly different from 1 for fat percentage, 
lean mass, android fat, android-to-gynoid fat ratio and waist-to-hip ratio (WHR). These 
findings indicate that a given subset of genes contributes differently to the variance 
of these body composition parameters in men and women. Many claims of sex-related 
differences in genetic associations on diseases or traits in the past were found to be 
insufficiently documented or spurious 1. However, a recent meta-analysis of genome-
wide linkage scans provided evidence for sex- and site-specific regulation of bone mass 
although no genome-wide significant loci were found 2. So far, few genome-wide asso-
ciation studies (GWAS) have formally addressed sex-differences in diseases or polygenic 
traits. In a recent meta-analysis from the GIANT consortium, a genetic locus near LYPLA1 
associated with waist-to-hip ratio in women only 3. Large-scale meta-analysis of GWAS 
with formal testing of gene by sex interaction in a sufficiently powered setting will allow 
the identification of sex-specific genetic effects when existing. This is an important area 
of future research for disease prediction, prevention and treatment.
I b.1) Relation between body composition and bone mineral density
Although it has been known for along time that heavier people have higher BMD and 
experience fewer fractures than lighter individuals, there is an ongoing debate about 
which part of body weight, namely fat mass or lean mass, is responsible for these ben-
eficial effects on bone. Differences in study design and population characteristics may 
underlie these inconsistent findings. A complicating factor of all these analyses is that 
fat mass and lean mass are correlated in a complex manner with each other. When a 
person gains fat he or she will develop more muscle mass in response to the weight 
bearing demands of the extra fat mass. On the other hand, during physical inactiv-
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ity muscle mass and bone mineral density may decrease while fat mass may increase. 
Cross-sectional relationships between lean and fat mass may be dependent on the 
level of adiposity. Therefore, it is difficult to accurately assess independent relations of 
these body composition parameters with bone. However, it is important to realize that 
the significance of BMI as a risk factor for fracture varies according to the level of BMI 
and the contribution to fracture risk is much more marked at low values of BMI than 
at values above the median 4. As such, low BMI should be regarded as a stronger risk 
factor for fracture than obesity as a protective factor. This could be related to a greater 
protective effect of lean mass compared to fat mass on fractures, or to factors related 
to frailty (such as muscle weakness, greater risk of falls or nutritional deficiencies). In 
our study, we found that the positive association between android fat distribution and 
BMD is explained by higher BMI, but not by higher insulin and/or lower adiponectin 
levels in obesity states. After adjustment for BMI, android fat was inversely associated 
with BMD, suggesting that android fat deposition (as measured by circumference ra-
tios and DXA-based android-to-gynoid fat ratio) is not beneficial and possibly even 
deleterious for bone health. Physical activity could be a potential intermediary of this 
inverse association but this needs further investigation together with the role of other 
potential mediators such as glucocorticoids, growth- and sex-steroid hormones, leptin 
and inflammatory adipokines. Additional prospective studies are needed to evaluate 
the relation of changes in body composition, including lean mass, fat mass and fat 
distribution, with changes in BMD and occurrence of fractures over time. Moreover, it 
will be of great interest to study if and how genetic loci emerging from GWAS on body 
composition traits (BMI, fat mass, lean mass and fat distribution) could influence bone 
traits like BMD, bone geometry and fractures and vice versa. Other areas of investigation 
on the complex cross-trait interactions between the metabolism of bone, fat, and lean 
tissue are needed, e.g., on the recently discovered intriguing role for the skeleton in 
energy metabolism in mice, related to osteocalcin 5. 
I b.2) Will treatment of obesity induce osteoporosis?
Weight loss is associated with a decrease in bone mineral density in both men and wom-
en and irrespective of the level of adiposity 6, 7. An advice to patients with osteoporosis 
not to loose weight might be in conflict with an advice for obesity related diseases like 
type 2 diabetes. The growing epidemic of obesity and related incidence of type 2 dia-
betes will necessitate weight loss measures for obese persons. It is predicted that many 
morbidly obese subjects with type 2 diabetes will undergo bariatric surgery within the 
near future, since this is the only approach that has consistently shown sustained weight 
loss and improvement or even disappearance of diabetes. Gut hormones are important 
in appetite regulation as a result of the signals from the periphery to the brain 8. Changes 
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in the production of these hormones after bariatric surgery as well as changes in the 
production and/or sensitivity of leptin, insulin, adiponectin and other hormones and 
adipokines might impact bone mineral density 9, 10. Prospective studies on the relation of 
changes in these hormones and adipokines with changes in BMD and body composition 
will give more mechanistic insight. 
It will be very important for this group of patients to monitor their BMD and ensure 
optimal intake of calcium and vitamin D, since absorption of these nutrients can be 
severely compromised after bariatric surgery 11. A diet high in protein, dairy, and cal-
cium may attenuate bone loss during weight loss 12. More studies are needed on the 
effect of the composition of the diet on BMD after bariatric surgery. Bone resorption 
inhibitors may be considered by physicians for treatment of decreased BMD with high 
bone turnover after bariatric surgery. However, it is essential to recognize osteomalacia 
in these patients as a cause for decreased BMD, as treatment with bisphosphonates 
in the presence of unrecognized osteomalacia is unwanted 13 and may lead to severe 
hypocalcaemia when administered intravenously 14. It is also important to consider that 
oral bishosphonates may lead to increased local adverse events after gastric bypass 
procedures 15. Follow-up studies after bariatric surgery should not only focus on BMI but 
on a wide range of physiological measurements, in particular on BMD and on fractures. 
Increased physical exercise may counteract an effect of weight loss on BMD and bone 
turnover 16-18 but not all studies are consistent in this respect 19, 20. Irrespective of body 
weight regulation, exercise programs may prevent falls in elderly persons by improving 
strength, flexibility, balance, and endurance 21. Overall, promotion of active life styles 
may help reduce the incidence of obesity and osteoporosis. 
I c) Effect of homocysteine-related B vitamins on BMD and fracture risk
An elevated homocysteine concentration is a novel and potentially modifiable risk fac-
tor for age-related osteoporotic fractures 22, 23. The most common cause of homocysteine 
elevation is poor vitamin B status, most notably of cobalamin (vitamin B12) and folate 
(vitamin B11) but also of riboflavin (vitamin B2) and pyridoxine (vitamin B6). In the Rot-
terdam study we found that increased dietary intake of riboflavin and pyridoxine (but 
not of folate and cobalamin) was associated with higher BMD of the hip. Furthermore, 
a reduction was found in the risk of fracture in relation to dietary pyridoxine intake 
independent of BMD and, in a subset of subjects, also independent of serum homocys-
teine levels. Based on these findings it cannot be concluded if the association between 
pyridoxine and fracture risk is causal and this certainly needs further study. The efficacy 
of homocysteine reduction via supplementation with B vitamins has not been demon-
strated in accurately designed clinical trials, despite the existing biological plausibility 
for an effect on fracture incidence. Currently, the effect of vitamin B supplementation 
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on fracture incidence is being assessed in elderly people in a double blind randomized 
placebo-controlled trial in collaboration between three academic centers in the Neth-
erlands (Free University Amsterdam, Erasmus University Rotterdam and Wageningen 
University).
PArT II: CAnDIDATe Gene STuDIeS On SIRT1
Since the discovery of the Sir2 gene in yeast as a regulator of gene silencing, ageing and 
survival, a wealth of information on this family of deacetylases, and especially on the 
mammalian homologue, SIRT1, has emerged in many high impact scientific journals. 
Sirtuins are NAD+ dependent, which may form a link between nutritional status and age-
ing. They may mediate the life prolonging effect of caloric restriction, which is one of the 
most robust methods for extending lifespan and delaying age-related disease among 
various species 24, 25. SIRT1 can be stimulated not only by caloric restriction but also by 
naturally occurring small molecules such as resveratrol, present for example in grapes 
and red wine. This observation has fuelled speculation that SIRT1 stimulators may ben-
eficially influence metabolic and age-related diseases such as obesity, type 2 diabetes, 
cardiovascular disease and dementia, and possibly even prolong human survival. 
II a) SIRT1 and mortality and obesity in humans
Consistent with findings by others 26, 27, we found no association between SIRT1 genetic 
variation and mortality in the overall population of elderly subjects from the Rotterdam 
study. However, in subjects with type 2 diabetes, SIRT1 genetic variation influenced sur-
vival per se and in interaction with dietary niacin and smoking. These findings suggest 
that correction of niacin deficiency and treatment with SIRT1 modulators may prolong 
the life span of patients with diabetes. Awaiting replication in independent populations 
and functional studies on the SIRT1 variants, these findings may lead to prospective 
placebo controlled clinical trials with SIRT1 modulators in subjects with type 2 diabetes. 
The same genetic variants that were associated with mortality in type 2 diabetes were 
also associated with BMI and risk of obesity in subjects of the Rotterdam study. These 
findings were confirmed in the ERF Study. Carriers of the minor alleles of two SIRT1 
polymorphisms have 13-18 % decreased risk of obesity and they gain less weight over 
time. The availability of SIRT1 stimulators like resveratrol makes these findings relevant 
in light of the growing epidemic of obesity. Currently, newer and more potent SIRT1 
stimulators are being tested in clinical studies. Diabetes and smoking are demanding 
metabolic situations with reduced SIRT1 expression and/or activity and increased 
oxidative stress, where benefits of resveratrol may become evident. Whether resveratrol 
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and other newer compounds have therapeutic potential in such situations needs to be 
studied when more data on pharmacology and possible side effects in humans become 
available. Clinical trials will also be needed to study an effect on obesity and other age-
related diseases. Regarding the utility of treating type 2 diabetics with such compounds, 
it should be considered that a positive effect of SIRT1 stimulators through modulation 
of BMI and insulin secretion by the pancreas might be offset by a stimulatory effect on 
gluconeogenesis in the liver 28.
II b) SIRT1 and bone
SIRT1 may also influence bone. We have shown that SIRT1 is expressed in osteoblasts 
during differentiation and mineralization (J. P.T.M van Leeuwen et al, unpublished 
data). Activation of SIRT1 during differentiation of mesenchymal stem cells decreases 
adipocyte formation and stimulates osteoblast formation via inhibition of peroxisome 
proliferator-activated receptor-gamma 2 (PPARγ2) 29, 30. Age-related bone loss has been 
associated with high levels of marrow adipogenesis. A role of estrogen in this age-
related bone loss might be mediated through the regulation of SIRT1 expression within 
the bone marrow 31. Moreover, SIRT1 inhibits nuclear factor-κB (NF-κB), a ‘master’ protein 
that controls genes associated with inflammation and immunity, also mediating in-
creased bone resorption. It was recently shown that this protein also inhibits new bone 
formation 32. SIRT1 could also influence bone indirectly by an effect on muscle mass 33, 
34. Human studies on the relation between SIRT1 genetic variants and body composition 
and BMD and fractures are currently lacking and are being performed within our group.
II c) SIRT1 and diet
Our findings that interactions between SIRT1 genetic variants and diet influence obesity 
needs further follow up in larger studies to pin down the exact underlying dietary fac-
tors explaining these interactions. Vitamin E is abundant in foods such as nuts, seeds, 
vegetable oils and green leafy vegetables. High intake of vitamin E may thus represent 
a healthy diet or an otherwise healthy lifestyle. Although for many years the use of an-
tioxidants has been advocated to protect the body from damaging free radicals, clinical 
trials have not provided evidence that routine use of for example vitamin E supplements 
prevents cardiovascular disease or mortality. Intriguing findings in some recent studies 
actually suggest that free radicals may under certain circumstances be beneficial to the 
body by a process called “hormesis”. This represents an effect of adaptations where a 
toxic substance acts like a stimulant in small doses, but is an inhibitor in high doses. A 
recent paper found that vitamin C and E supplements inhibited exercise-induced ben-
eficial effects on insulin sensitivity in healthy young men, by preventing the promotion 
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of endogenous antioxidant defense capacity 35. It will be of interest to study a potential 
role of SIRT1 in such exercise-induced anti-oxidant defense. 
Further research on SIRT1 gene-diet interactions is needed within large-scale studies. 
This will require meta-analysis of data from multiple studies within international con-
sortia after standardization of different methods used to assess dietary intake. Gene-
environment interactions may explain part of the so-called “dark matter” in unexplained 
heritability and it is of great importance to uncover such interactions in the growing 
epidemic of obesity. Knowledge on gene-diet interaction may modify dietary advices, 
which will be preferable to new and costly medication with potential side effects.
II d) Might SIRT1 stimulators increase the risk of developing cancer?
The role of SIRT1 in cancer is currently under debate due to recent discrepant findings. 
The concern that stimulating SIRT1 may elevate cancer risk in mammals has arisen from 
the fact that SIRT1 inhibits tumor suppressor P53 activity and also because increased 
SIRT1 expression has been observed in certain types of cancer 36. In fact, SIRT1 inhibitors 
are currently under investigation as anti-tumor drugs 37, 38. On the other hand, caloric re-
striction extends life span and decreases cancer risk. Also, it was recently demonstrated 
that increased expression of SIRT1 reduces colon cancer formation in a mouse model 39. 
In addition, resveratrol, exhibits chemo preventive activity against various cancers40-42 
despite its activating effect on SIRT143. Furthermore, in a SIRT1 mutant mouse model 
SIRT1 was shown to play an important role in DNA damage repair, genomic integrity, 
and inhibition of tumorigenesis 44. Another recent study showed that increased SIRT1 
levels mice protect mice from irradiation-induced cancer and also provided evidence 
that increasing SIRT1 activity or quantity may actually reduce instead of promote 
tumorigenesis through increased genomic stability 39, 45. However, because the effects 
of manipulation of SIRT1 may be tissue and context dependent 46, any intervention in 
humans targeted at SIRT1 should keep potential side effects in mind. 
PArT III: GenOMe-WIDe ASSOCIATIOn STuDIeS
There have been impressive advances recently in the understanding of the genetic 
background of common complex diseases. During the past 2 years, more than 200 GWA 
studies have reproducibly described over 300 common genetic variants associated with 
common diseases 47, 48. Many successes in identifying genes for obesity and osteoporosis 
have occurred within the powered settings of international consortia. In our study within 
the international CHARGE consortium a new gene was uncovered, the neurexin 3 gene 
(NRXN3), influencing waist circumference. This gene has been previously implicated in 
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studies of addiction and reward behavior, providing further evidence that our genes 
may influence the desire for and consumption of food and, in turn, the susceptibility to 
obesity. Obesity and addiction may share common neurologic underlying mechanisms 
49. Other well-replicated obesity loci, including melanocortin 4 receptor gene (MC4R), 
have also been shown to be associated with centrally-mediated phenomena including 
binge eating behavior 50-52. Studies in mice indicate that the fat mass and obesity associ-
ated (FTO) gene expression is particularly pronounced in regions of the brain known to 
regulate energy balance 53, and recent data suggest that variants in the FTO gene may 
regulate food intake and selection 54.
In our meta-analysis of five genome-wide association studies in 19,195 Caucasian 
subjects within the GEFOS consortium we identified 20 loci associated with femoral 
neck and/or lumbar spine BMD with genome-wide significance, of which 13 map to new 
regions. The novel SNPs map to genes in signaling pathways of potential relevance to 
bone metabolism. 
In general, most top signals in GWAS are found within intronic or intergenic non-
coding regions of the genome and often implicate genes with yet unknown function. 
Much work lies ahead in uncovering the causal variants involved, using techniques such 
as fine-mapping, re-sequencing and functional studies. 
A recently criticized aspect of the findings from GWAS is that the combined effect of 
all discovered genetic variants explains only a small percentage of the heritability of 
the complex diseases or traits 47. The explained trait variance is typically in the order 
of 3% as was also the case for the 20 loci found in our meta-analysis within the GEFOS 
consortium for bone mineral density. The currently discovered common variants explain 
together too little of the variance to make them a useful tool in disease prediction 47,55. 
However, this is different for the potential to develop new therapeutic compounds and 
therapies. Even though effects of common variation in individual genes on BMD are 
quite small (such as for genes in the RANKL-RANK-OPG pathway), the functional impact 
of the related proteins on the physiological pathway can be substantial. Recently de-
veloped drugs that interfere with this pathway, (e.g., a monoclonal antibody against 
RANKL which mimics the endogenous effects of osteoprotegerin or OPG) can produce 
significant increases in BMD and decrease fracture risk. The same holds for drugs target-
ed at PPARγ (thiazolidinediones) for the treatment of type 2 diabetes. These examples 
show that there is not necessarily a relation between effect sizes of genetic variants 
and biological relevance. For patient care it will also be important to study whether 
genetic information can predict the effect of drugs or medication, in the so-called field 
of pharmaco-genomics but this is a so far largely unexplored area. The main impact 
from the GWAS studies at this moment is the potential for discovery of new biological 
pathways underlying common diseases and traits that will lead to better understanding 
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of health and disease. There is, however, still a long way to go before all this knowledge 
will be translated into clinical practice. 
III a) Dark Matter in heritability
Part of the so-called “dark matter” or “missing genes” in heritability may be explained 
by structural variants such as copy number variations, inversions and rare variants with 
potentially larger effect sizes. Also, the sex chromosomes have not been systematically 
incorporated in GWA studies so far, mainly due to difficulties to impute SNPs from the 
sex chromosomes that are not on the arrays. Recent advances in techniques will allow 
investigation of all these variants on a large-scale basis in the near future. On the other 
hand, one should also realize that narrow-sense heritability estimates are population 
specific and largely ignore shared environmental and dominance effects as well as 
interactions and may be inflated, especially in twin studies. Part of the dark matter in 
heritability could thus be explained by overestimation of heritability for some traits so 
far. Also, it is possible that epigenetic changes are passed on to the next generation 
and thus influence heritability estimates without changes in the coding of DNA. Recent 
studies suggest that epigenetic mechanisms with histone modifications such as DNA 
methylation may underlie intrauterine programming 56. It has been shown that some 
metabolic traits that result from low birth weight can be transmitted to subsequent gen-
erations, suggesting the possibility of epigenetic changes maintained during meiosis, as 
is observed for the agouti coat-color variant in mice 56. A recent study on DNA methyla-
tion profiles in monozygotic and dizygotic twins suggests that also in humans molecular 
mechanisms of heritability may not be limited to DNA sequence differences 57. It will 
be of great interest to examine the effects of intra-uterine programming using more 
global techniques for monitoring gene expression and chromatin structure. Since SIRT1 
deacetylates histones, it is not unthinkable that epigenetic changes induced by SIRT1 
during fetal malnutrition can be involved in an adverse metabolic response later in life.
III b) Interaction studies
Important aspects that have not been studied on a large-scale basis so far that may 
explain part of the dark matter in heritability are the gene-gene and gene-environment 
interactions. By definition these interactions underlie complex diseases and are there-
fore essential to incorporate in future research. 
Gene-environment interactions:
Diet and physical activity are lifestyle and behavioral factors that play an important role 
in the etiology, prevention, and treatment of many chronic diseases, including obesity 
and osteoporosis. Other environmental factors influencing both obesity and osteoporo-
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sis are habits like tobacco smoking and the use of alcohol. An improved understanding 
of how gene-environment interactions affect disease risk may lead to better prevention 
and treatment options. Limitations to current gene-environment interaction studies are 
1) the need for very large studies in order to have sufficient statistical power to detect 
them, 2) difficulty in harmonizing environmental trait assessment between studies, and 
3) general difficulties in measuring accurately environmental effects, since exposures 
may vary in time and instruments used to quantify these variables (e.g. questionnaires) 
are subject to several sources of bias. 
For more accurate assessment of dietary intake and physical activity, new techniques 
are being developed or existing technologies are being adapted. They include the use 
of devices such as sensors, scanning and imaging techniques, wireless technologies and 
bio-informatics tools. Examples of more accurate dietary assessment include the use 
of digital cameras to identify foods and estimate portion sizes. This can be combined 
with audio recording and bar code scanners and wireless technology for real-time 
data transmission. Also, personal digital assistant (PDA) technologies are being refined 
to assess dietary and supplement intake. Assessment of physical activity is complex 
because several important elements have to be taken into account like the type, inten-
sity, frequency and duration of activity. New devices to estimate physical activity can 
integrate sensors to detect motion and posture with physiologic markers such as heart 
rate, respiration, and temperature. This will also generate information on time a person 
spends sleeping, which will be important given the effect of sleep on metabolic dis-
eases. These measurements should be repeated over time in order to detect changes in 
lifestyle factors. Adoption of these new techniques with more accurate data on dietary 
intake and physical activity into large-scale epidemiological studies will allow better 
identification and understanding of the determinants of health and disease and provide 
better assessments to study gene-environment interactions. It will also be of interest 
for the determination of heritability of outcomes measured by these techniques (e.g., 
physical activity, sleep patterns, food preferences) and to search for genes underlying 
these traits using GWAS. 
Gene-Gene interactions:
Another challenge that lies ahead of us is the investigation of gene-gene interactions. 
To study this with about 2.5 million polymorphisms currently used in GWAS will require 
large computational capacities and well-powered studies within international consortia. 
Recent studies imply that systems-based approaches might be a valuable tool to ad-
dress complex interactions in both animals and humans 58-60.
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III c) Systems biology
Systems biology is a biology-based inter-disciplinary study field that focuses on the system-
atic study of complex interactions in biological systems. It can integrate data that come from 
studies of DNA variation, global mRNA expression array analysis (providing information on 
transcript levels from gene expression) and high-throughput technologies for screening of 
proteins and metabolites (proteomic and metabolomic data) such as mass spectrometry. 
Subsequently, these data can be used in combination with clinical phenotypes 58-60. Loci 
that control transcript levels, named expression or e-QTL’s can be mapped and used to 
prioritize positional candidates 61. System-based approaches aim to study beyond simple 
correlations of levels to determine how components interact. These interactions are often 
described in terms of networks that consist of parts (collaborating proteins) and their con-
nections. The network concept has proven very useful in studies of metabolic traits 59. We 
also recently adopted system-based approach in prioritizing candidate genes from GWAS 
on BMD and bone geometry (Y Hsu et al., manuscript under review). 
fuTure DIreCTIOnS
There have been impressive advances recently in elucidating the genetic background 
of many complex diseases, including obesity and osteoporosis but much, if not most, 
is yet to be discovered. Important aspects of future research are integrated studies on 
interactions such as gene by sex, gene by environment (diet, physical activity, tobacco 
smoking, use of drugs and alcohol), and gene-by-gene interactions. Adopting new strat-
egies to more accurately assess dietary intake and physical activity in population-based 
studies will greatly enhance our understanding of how gene-environment interactions 
affect disease risk. This may ultimately lead to better prevention and treatment options. 
More genetic variants underlying complex diseases and traits will be discovered by 
expanding international consortia but the discovered genetic effects will consequently 
be even smaller. As discussed, genes with small effect sizes may still have significant bio-
logical relevance. Most top signals from GWAS are found within intronic and sometimes 
intergenic regions and often implicate genes with yet unknown functions. Follow-up 
studies are needed to find the causal genetic variants involved using techniques such 
as fine-mapping, resequencing and functional studies. Future studies will target other 
types of genetic information, e.g., on structural variants such as copy number variations, 
inversions and rare variants with potentially larger effect sizes. The sequencing of 1000 
genomes within the ‘1000 Genomes’ project (www.1000genomes.org) will identify more 
common, rare and structural genetic variants. 
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It will be important to investigate how functional genetic variants operate in a tissue-
specific manner. Studies on DNA methylation will give more insight into the contribution 
of epigenetics on complex diseases. An important challenge for future research in obesity 
lies in uncovering the mechanisms leading to a set point in body weight regulation, which 
determines a person’s predestined weight range. This set point is likely to be determined by 
genes and by environmental conditions, especially by conditions evolving during pregnancy. 
Despite all technological innovations, hypothesis-based studies with candidate genes will 
remain important as is shown by our findings on the SIRT1 gene. Associations of SIRT1with 
obesity were not detected by GWAS in large-scale studies because of very stringent criteria 
for multiple testing needed in these studies. Well-powered association studies with SIRT1 
are needed for other age-related diseases such as diabetes, hyperlipidaemia, osteoporosis, 
dementia and cancer. Deep sequencing of the gene may lead to the discovery of rare vari-
ants with larger effects. It will be of great interest to study the other 6 human SIRT genes and 
their interactions. This could be extended to pathway analyses using interacting genes such 
as those in the NAD+ salvage pathway (CD38 and Visfatin), FOXO genes, PGC-1α, and one of 
the master regulators of metabolism, i.e., AMP-activated protein kinase (AMPK). One of the 
potential translations of genetic research into clinical practice lies in identifying and testing 
modulators of genes discovered in relation to the phenotype of interest. This can be done by 
analyzing gene-environment interaction (e.g. SIRT1 with diet and physical exercise). Natural 
or chemical modulators of AMPK and SIRT1 may also aid in the prevention of age-related 
loss of muscle mass (sarcopenia), which may have a large effect on morbidity and mortality 
in the elderly. Very recently it was demonstrated that also in rhesus monkeys moderate 
adult onset caloric restriction lowers the incidence of ageing-related deaths and delays the 
onset of age-associated pathologies such as diabetes, cancer, cardiovascular disease, brain 
atrophy and loss of muscle mass 62.  Given the obvious parallels between rhesus monkeys 
and humans, this suggests that beneficial effects of caloric restriction may also occur in 
humans. These findings should give a boost to studies on the ability of potential caloric 
restriction mimetics such as SIRT1 stimulators to improve health and survival in humans. 
COnCluDInG reMArk
The medical problems associated with ageing, obesity, osteoporosis and type 2 diabetes 
are far from being resolved and still require extensive investigations at different multi-
disciplinary levels. Nevertheless, the findings presented in this thesis provide improved 
insight into how underlying genetic and nutritional factors influence these morbid 
conditions. Hopefully, such insight may be translated into future interventions capable 
of providing humans in general, and patients with obesity, osteoporosis and diabetes in 
particular, a longer and healthier life.
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SuMMArY AnD COnCluSIOnS
Obesity and osteoporosis are common and complex diseases resulting from the inter-
play between genetic factors and environment with increasing prevalence worldwide. 
The incidence of both conditions increases with age but obesity appears to protect from 
osteoporosis. Despite the high heritability of body mass index (BMI) and bone mineral 
density (BMD), knowledge on the genetic background of obesity and osteoporosis is still 
very limited and even less is known about interactions between genes and environmen-
tal factors like diet, tobacco smoking and physical activity. 
In this thesis, epidemiological, genetic and nutritional studies are presented on the 
metabolic diseases obesity and osteoporosis, and on survival. In the epidemiological 
studies, the relationship is investigated between body fat distribution and bone mineral 
density, and a relation is described between the intake of dietary B vitamins and bone 
mineral density and fractures. The genetic studies in this thesis use two main approaches 
to disentangle the genetic background of these conditions, namely 1) a family-based 
design for the estimation of trait heritability, and 2) the association design with both 
the candidate gene and genome-wide association (GWA) approach. In the heritability 
study, evidence for the existence of sex-specific genetic effects on body composition 
is presented. In addition, using the candidate gene approach we show how variants in 
the SIRT1 gene influence BMI, the risk of obesity and longitudinal BMI-changes. Within 
the context of large-scale collaborative genome-wide association studies we identified 
NRXN3 as a novel locus influencing waist circumference and identified 20 loci influenc-
ing BMD variation. Furthermore, results are described of investigations on gene-diet 
interactions on body mass index and survival at the SIRT1 locus. 
Chapter 1 presents the introduction and outline of the thesis. 
The main concepts introduced in the next chapter emphasize the well-known sexual 
dimorphism in human body composition with adult males having greater body height, 
bone mineral density (BMD), and total lean mass and a lower fat mass than females. 
Moreover, there are differences in fat distribution with males showing more upper body 
(trunk) or so called “android” distribution of adipose tissue, and females more peripheral 
or “gynoid” distribution with larger hips and thighs. Android or so-called “apple-shaped” 
obesity is associated with a greater risk of disease, e.g., type 2 diabetes and cardiovascular 
disease than the gynoid or “pear-shaped” type of obesity. Chapter 2 shows the results of 
the study on heritability and on sex-specific genetic and environmental effects in body 
composition, assessed by dual energy x-ray absorptiometry (DXA) and anthropometry 
in 2,506 subjects from the Erasmus Rucphen Family (ERF) study. After accounting for 
age, sex and inbreeding, heritability estimates ranged from 0.39 for fat mass index (FMI) 
to 0.84 for height. Sex-specific genetic effects were found for several body composition 
traits including fat percentage, lean mass, android fat and parameters of fat distribution 
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but not for BMI and height. It was concluded that sex-specific genetic effects underlie 
sexual dimorphism in various body composition traits, including fat distribution. The 
findings are relevant for studies on the relationship of body composition with common 
diseases like cardiovascular disease and type 2 diabetes, and for genetic association 
studies.
Despite a clear positive association between body weight or BMI and BMD, the role of 
fat distribution on BMD is far from clear. Chapter 3 presents the results of the study on 
relationships between fat distribution and BMD in 2,631 participants from the ERF study. 
Also, the role of BMI and serum insulin and adiponectin levels as possible confound-
ers or intermediaries in these relations is described. BMD was measured at the hip and 
lumbar spine and BMC at the total body by dual-energy x-ray absorptiometry (DXA). Fat 
distribution was assessed by the waist-to-hip ratio, waist-to-thigh ratio and DXA-based 
trunk-to-leg fat ratio and android-to-gynoid fat ratio measurements. Using linear regres-
sion (adjusting for age, height, smoking and use of alcohol) most relationships between 
fat distribution and BMD and BMC were positive. After adjustment for BMI, most cor-
relations were negative. No consistent influence of age, gender or menopausal status 
was found. Insulin and adiponectin levels did not explain either positive or negative 
associations. It was concluded that positive associations between android fat distribu-
tion and BMD and BMC are explained by higher BMI but not by higher insulin and/or 
lower adiponectin levels found in obesity. Inverse associations after adjustment for BMI 
suggest that android fat deposition is not beneficial and possibly even deleterious for 
BMD.
Recently, elevated homocysteine concentrations were identified as a novel and 
potentially modifiable risk factor for age-related osteoporotic fractures. In Chapter 4 
the association is described between intake of the homocysteine-related B vitamins, 
including riboflavin (vitamine B2), pyridoxine (vitamine B6), folate (vitamine B11) and 
cobalamin (vitamine B12) and femoral neck BMD (FN-BMD) and the risk of fracture in 
5,304 elderly individuals from the Rotterdam study. A small but statistically significant 
positive association was observed between dietary pyridoxine (ß=0.09, p=1x10-8) and 
riboflavin intake (ß=0.06, p=0.002) and baseline FN-BMD. In addition, after control-
ling for gender, age and BMI, pyridoxine intake was inversely correlated to the risk of 
non-vertebral fracture during a mean follow-up period of 7.4 years. This relation was 
independent of BMD and, in a subgroup, also independent of homocysteine levels. In 
conclusion, we found that increased dietary riboflavin and pyridoxine intake are associ-
ated with higher FN-BMD and that higher dietary pyridoxine intake is associated with a 
reduced risk of fracture. Clinical trials are needed to show if lowering of homocysteine 
levels in the elderly using vitamin B supplements will reduce the incidence of fractures. 
SIRT1 is an intriguing new candidate gene for metabolic diseases and survival. Chap-
ter 5 presents the results of the analysis on the association between SIRT1 genetic varia-
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tion and BMI, the risk of obesity (BMI > 30kg/m2), and with longitudinal BMI-changes. 
In 6,251 elderly men and women from the Rotterdam study, three Single Nucleotide 
Polymorphisms (SNPs) in the SIRT1 gene were genotyped. Cross-sectional data in 2,347 
participants from the ERF study were used for replication. Minor alleles of two common 
SIRT1 SNPs were significantly associated with lower BMI in the Rotterdam study. These 
associations were replicated in the ERF study. Combined analysis in both study popula-
tions showed a 13-18% decreased risk in carriers of these alleles for being obese (p<0.02). 
In the Rotterdam study, the two variants were also associated with lower increase in BMI 
after 6.4 years of follow-up. In conclusion, carriers of two common genetic variants in 
SIRT1 have a lower BMI and a 13-18% decreased risk of obesity. The availability of SIRT1 
stimulators, like the polyphenol resveratrol found in grapes and red wine, makes these 
findings relevant in light of the growing epidemic of obesity. 
In Chapter 6 the results are shown of the study on the association of SIRT1 genetic 
variation with mortality in elderly subjects and in persons with increased oxidative stress 
(type 2 diabetes and smokers) in relation with dietary niacin intake (vitamin B3). In 4,573 
participants from the Rotterdam Study with dietary information, including 413 subjects 
with prevalent and 378 with incident type 2 diabetes, 3 SIRT1 tagging SNPs were geno-
typed and all-cause mortality was studied (average follow-up12 years). No association 
was found between SIRT1 variation and mortality in the total population and smokers. 
In subjects with prevalent type 2 diabetes, homozygous carriers of the most common 
SIRT1 haplotype 1 had 1.5 times (95%CI 1.1-2.1) increased mortality risk compared to 
non-carriers. This risk further increased when these subjects smoked or when they had 
low niacin intake. In the lowest tertile of niacin intake, mortality risk was increased 2.3 
(95%CI 1.1-4.9) and 5.7 (95%CI 2.5-13.1) times for heterozygous and homozygous carri-
ers of haplotype 1, respectively. Subjects with incident diabetes showed similar findings 
but only when they smoked. In conclusion, SIRT1 genetic variation influences survival in 
subjects with type 2 diabetes per se and in interaction with dietary niacin and smoking. 
Correction of niacin deficiency and SIRT1 modulators may prolong life of patients with 
diabetes. 
In Chapter 7 results are reported of a study of gene-diet interaction on BMI at the 
SIRT1 locus. In 4,575 participants from the Rotterdam study an interaction was studied 
with nutrients that may modify SIRT1 expression or activity, i.e., dietary intake of energy, 
fat, calcium, milk, antioxidant vitamins (betacarotene, vitamin C and E) and niacin as pre-
cursor for NAD+. No difference was found in energy and fat intake by SIRT1 genotypes, 
suggesting that the effect of SIRT1 genetic variants on BMI is not mediated by altered 
caloric intake (or a change in appetite). Significant associations were found between 
two SIRT1 SNPs and haplotype 1 with BMI in the lowest tertiles of intake of energy, fat 
and vitamins and in the highest tertile of calcium and milk intake. Significant interaction 
between SIRT1 variants and intake of vitamin E and calcium was found. In ERF, where 
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only information on milk intake was available, similar associations between the two 
SNPs and BMI were found in the highest tertiles of milk intake. It was concluded that 
dietary intake of anti-oxidants (especially vitamin E) and of calcium and milk modify 
the associations of SIRT1 variants with BMI. These data support evidence that gene-diet 
interactions influence complex traits like BMI. Replication of our findings and further 
in-depth study of specific dietary patterns that can modify SIRT1 can pave the way for 
prospective studies on dietary modification of SIRT1 to influence obesity.
Chapter 8 shows the results of a large-scale genome-wide association study (GWAS) 
for (abdominal) obesity susceptibility genes in 31,373 Caucasian individuals from eight 
population-based studies from the CHARGE consortium. In this study, the role of FTO 
and MC4R in obesity was confirmed. In addition, a novel association of the neurexin 3 
gene (NRXN3) with waist circumference is reported, which was subsequently replicated 
in additional 38,641 participants of the GIANT consortium. The SNP in NRXN3 was also 
significantly associated with BMI and the risk of obesity. The NRXN3 gene has been 
previously implicated in addiction and reward behavior, providing further evidence 
that our genes may influence the desire for and consumption of food and, in turn, the 
susceptibility to obesity. 
In Chapter 9 results from a meta-analysis of five genome-wide association studies 
within the GEFOS consortium are presented. The study aimed to find new loci associ-
ated with femoral neck and lumbar spine BMD in 19,195 Caucasian subjects. Twenty loci 
reaching genome-wide significance (GWS p<5x10-8) were identified, of which 13 are new 
and map to genes in signaling pathways of potential relevance to bone metabolism, 
including GPR177, SPTBN1, CTNNB1, MEPE, MEF2C, STARD3NL, FLJ42280, LRP4/ARHGAP1/
F2, DCDC5, SOX6, FOXC2, HDAC5 and CRHR1. The meta-analysis also confirmed the role of 
7 known BMD loci, mapping to ZBTB40, ESR1, TNFRS11B/OPG, LRP5, SP7/osterix, TNSF11/
RANKL and TNFRS11A/RANK. These findings highlight the complex genetic architecture 
underlying osteoporosis and identify novel genetic variants that are associated with 
BMD. Additional studies are warranted to identify the underlying causal variants. 
In Chapter 10 the thesis is concluded with a general discussion where the findings are 
placed into perspective and suggestions for future research are given. 
Chapter 12
Samenvatting en conclusies

Samenvatting en conclusies 197
SAMenvATTInG en COnCluSIeS 
Obesitas (ook wel vetzucht genaamd) en osteoporose (ook wel botontkalking genaamd) 
zijn veelvoorkomende complexe aandoeningen met een toenemende prevalentie. Zij 
worden veroorzaakt door een wisselwerking tussen genen en omgeving. De incidentie 
van beide aandoeningen neemt toe met de leeftijd maar obesitas lijkt te beschermen 
tegen osteoporose. Ondanks een hoge mate van erfelijkheid van de body mass index 
(BMI) en van de botminerale dichtheid (BMD) is de kennis over de genetische achter-
grond van obesitas en osteoporose is nog steeds erg beperkt. Nog minder is bekend 
over interacties tussen genen en omgevingsfactoren, zoals voeding, roken en lichame-
lijke activiteit. 
In dit proefschrift worden de resultaten beschreven van onderzoek op het gebied van 
de epidemiologie, genetica (erfelijkheid) en voeding naar de metabole zieken obesitas 
en osteoporose en naar overleving. In de epidemiologische studies wordt de relatie tus-
sen verdeling van lichaamsvet en de BMD beschreven en wordt een verband getoond 
tussen de inname van B vitaminen met de voeding en de BMD en fracturen. De gene-
tische studies in dit proefschrift maken gebruik van twee methoden om de genetische 
achtergrond van beide aandoeningen te ontrafelen namelijk 1) een op familieonderzoek 
gebaseerde methode om de erfelijkheid van lichaamssamenstelling te berekenen en 2) 
associatieonderzoek met zowel de kandidaatgenmethode als genoomwijde associatie 
(GWA). In de erfelijkheidstudie worden aanwijzingen gepresenteerd voor het bestaan 
van geslachtspecifieke genetische effecten op de lichaamssamenstelling. Vervolgens 
wordt met de kandidaatgenmethode aangetoond hoe genetische variaties in het SIRT1 
gen van invloed zijn op de BMI, het risico op obesitas en longitudinale veranderingen in 
BMI. Tenslotte wordt beschreven dat binnen grootschalige samenwerkingsverbanden 
met GWA het NRXN3 gen werd ontdekt als een nieuw locus voor de middelomvang en 
dat 20 loci met de BMD zijn geassocieerd. Tevens wordt beschreven hoe interacties tus-
sen variaties in het SIRT1 gen en voeding de BMI en overleving beїnvloeden. 
hoofdstuk 1 geeft een algemene inleiding en de indeling van het proefschrift.
In het volgende hoofdstuk wordt uitgegaan van de bekende verschillen in lichaamssa-
menstelling tussen mannen en vrouwen. Mannen zijn langer, hebben een grotere BMD 
en spiermassa (vetvrije massa) en een lager vetpercentage dan vrouwen. Bovendien 
hebben mannen een andere vetverdeling met meer vet op het bovenlichaam oftewel 
een zogenaamde “androide” of “appelvormige” vetverdeling, terwijl vrouwen relatief 
meer vet hebben op de heupen en dijen, een zogenaamde “gynoide” of “peervormige” 
vetverdeling. Het appelvormige type van overgewicht vormt een groter risico op het 
krijgen van ziekten zoals bijvoorbeeld type 2 diabetes mellitus en hart- en vaatziekten 
dan het peervormige type. 
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hoofdstuk 2 toont de resultaten van het onderzoek naar de erfelijkheid van lichaams-
samenstelling en naar het bestaan van geslachtspecifieke genetische en omgevings-
factoren hierop. De lichaamssamenstelling werd gemeten met behulp van dual energy 
x-ray absorptiometrie (DXA) and anthropometrie bij 2506 deelnemers van de Erasmus 
Rucphen Familie (ERF) studie. Rekening houdend met leeftijd, geslacht en mate van 
verwantschap berekenden wij dat lichaamssamenstelling voor 39% (vetmassa gecor-
rigeerd voor lengte) tot 84% (lengte) door genetische factoren wordt bepaald. Wij von-
den dat er geslachtspecifieke genetische factoren zijn voor verschillende componenten 
van lichaamssamenstelling, zoals het vetpercentage, de vetvrije massa, de hoeveelheid 
buikvet en de vetverdeling maar niet voor de body mass index of voor lengte. Con-
cluderend heeft onze studie aangetoond dat er geslachtspecifieke genetische effecten 
ten grondslag liggen aan verschillen in lichaamssamenstelling en vetverdeling tussen 
mannen en vrouwen. Deze bevindingen zijn van belang om verbanden tussen lichaams-
samenstelling en ziekten zoals suikerziekte en hart- en vaatziekten te onderzoeken en 
voor genetische associatie studies. 
Ondanks overtuigende aanwijzingen dat een hogere BMI gepaard gaat met een 
hogere BMD is de relatie tussen vetverdeling en BMD is niet precies bekend. hoofdstuk 
3 beschrijft de resultaten van onderzoek naar deze relatie bij 2631 deelnemers van 
het ERF studie en van de invloed hierop van de BMI en van serumspiegels van insuline 
en adiponectine. Met behulp van dual-energy x-ray absorptiometrie (DXA) werd de 
BMD gemeten ter plaatse van de heup en de lendenwervels alsmede de hoeveelheid 
botmineraal van het hele lichaam (BMC). De vetverdeling werd bepaald middels de 
verhouding tussen de middel- en heupomtrek en tussen de middel- en dijbeenomtrek 
alsmede met de verhouding tussen romp- en beenvet en tussen buik- en dijbeenvet 
gemeten met DXA. In een lineaire regressie (met correctie voor leeftijd, lengte, roken en 
alcoholgebruik) werden voornamelijk positieve verbanden gevonden tussen appelvor-
mige vetverdeling en BMD en BMC. Na correctie voor de BMI waren de verbanden voor-
namelijk negatief. Er werd geen duidelijke invloed vastgesteld van leeftijd, menopauze 
of van insuline en adiponectine spiegels. Concluderend worden positieve verbanden 
tussen appelvormige vetverdeling en de BMD en BMC verklaard door een hogere BMI 
en niet door hogere insuline en/of lagere adiponectine spiegels bij obesitas. Negatieve 
verbanden na correctie voor BMI suggereren dat een appelvormige vetverdeling zeker 
niet gunstig en mogelijk zelfs ongustig is voor de BMD. 
Recent is vastgesteld dat verhoogde serum spiegels van homocysteine een nieuwe 
en mogelijk behandelbare risicofactor vormen voor botbreuken door osteoporose. 
In hoofdstuk 4 wordt de relatie beschreven tussen de inname met de voeding van 
met homocysteine geassocieerde B vitaminen riboflavine (vitamine B2), pyridoxine 
(vitamine B6), foliumzuur (vitamine B11) en cobalamine (vitamine B12) en de BMD van 
de heup en het risico op botbreuken bij 5304 deelnemers van de Rotterdam studie. Er 
Samenvatting en conclusies 199
werd een klein maar statistisch significant positief verband gevonden tussen inname 
van vitamine B6 (ß=0,09, p=1x10-8) en vitamine B2 (ß=0,06, p=0,002) en de heup BMD. 
Bovendien werd na correctie voor geslacht, leeftijd en BMI een omgekeerd verband 
gevonden tussen inname van vitamine B6 en het risico op (niet-wervel) botbreuken na 
een gemiddelde observatieduur van 7,4 jaar. Deze relatie was onafhankelijk van de BMD 
en, in een subgroep, eveneens onafhankelijk van homocysteine spiegels. Concluderend 
vonden wij dat een hogere inname met de voeding van vitamine B2 en vitamine B6 
gepaard gaat met een hogere BMD van de heup en dat een hogere inname van vitamine 
B6 gepaard gaat met een kleinere kans op botbreuken. Klinische studies zullen moeten 
aantonen of verlaging van de homocysteine spiegels met behulp van B vitaminen zal 
leiden tot minder botbeuken bij ouderen.
SIRT1 is intrigerend nieuw kandidaatgen voor metabole ziekten en overleving. hoofd-
stuk 5 toont de resultaten van het onderzoek naar de associatie tussen variaties in het 
SIRT1 gen en BMI en het risico op obesitas (BMI > 30kg/m2) en BMI veranderingen in de 
tijd. Bij 6251 ouderen in de Rotterdam studie werden drie zogeheten Single Nucleotide 
Polymorphismen (SNPs) in the SIRT1 gen gegenotypeerd. Gegevens van 2347 deelne-
mers aan de ERF studie werden gebruikt om de bevindingen te bevestigen. Dragers van 
de minst voorkomende allelen van twee SNPs in SIRT1 hadden een significant lagere BMI 
in de Rotterdam studie en in ERF. Een gecombineerde analyse in beide populaties toonde 
een afname van 13-18% op het risico van obesitas bij dragers van deze allelen (p<0,02). 
In de Rotterdam studie waren deze twee genetische varianten ook geassocieerd met 
een geringere toename van de BMI bij een vervolgonderzoek na gemiddeld 6.4 jaar. Er 
werd geconcludeerd dat dragers van twee veelvoorkomende varianten in het SIRT1 gen 
een lagere BMI hebben en minder kans op obesitas. Het bestaan van SIRT1 stimulatoren, 
zoals resveratrol in druiven en rode wijn, maakt deze bevindingen van belang in het licht 
van de groeiende obesitas epidemie. 
In hoofdstuk 6 worden de bevindingen getoond van onderzoek naar de associatie 
tussen variatie in het SIRT1 gen en mortaliteit bij ouderen en bij personen met ver-
hoogde oxidatieve stress (type 2 diabetes mellitus en rokers) in relatie tot inname van 
niacine (vitamin B3) met de voeding. Bij 4573 deelnemers van de Rotterdam studie met 
dieetgegevens, inclusief 413 personen met type 2 diabetes mellitus bij aanvang en 378 
personen die diabetes ontwikkelden tijdens follow-up, werden drie SNPs in the SIRT1 
gen gegenotypeerd . Een relatie met mortaliteit, ongeacht de oorzaak, werd bestudeerd 
met een gemiddelde follow-up duur van 12 jaar. Er werd geen verband gevonden 
tussen variaties in het SIRT1 gen en mortaliteit in de gehele populatie en bij rokers. Bij 
personen met type 2 diabetes bij aanvang hadden homozygote dragers van het meest 
voorkomende SIRT1 haplotype 1 een 1,5 maal (95%CI 1,1-2,1) grotere kans op overlijden 
dan niet-dragers. Dit risico nam toe wanneer deze personen tevens rookten en wanneer 
ze weinig inname hadden van vitamine B3. In het laagste tertiel van vitamine B3 inname 
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was de kans op overlijden 2,3 maal (95%CI 1,1-4,9) and 5.7 (95%CI 2,5-13,1) verhoogd 
voor, respectievelijk, heterozygote en homozygote dragers van haplotype 1. Personen 
die diabetes tijdens follow-up ontwikkelden vertoonden vergelijkbare verschillen maar 
alleen wanneer zij rookten. Er werd geconcludeerd dat bij mensen met type 2 diabetes 
genetische variaties in SIRT1 de overleving beïnvloeden dat er een interactie bestaat 
met vitamine B3 inname en roken. Herstel van een mogelijk vitamine B3 tekort en toe-
passing van middelen die SIRT1 beinvloeden zouden de levensverwachting van mensen 
met type 2 diabetes kunnen verlengen. 
hoofdstuk 7 beschrijft de bevindingen van het onderzoek naar een mogelijke inter-
actie tussen variaties in het SIRT1 gen en voeding op de BMI. Bij 4575 deelnemers van 
de Rotterdam studie werd een interactie bestudeerd met nutriënten die de expressie 
of activiteit van SIRT1 zouden kunnen beїnvloeden zoals de inname van energie, vet, 
calcium, melk, anti-oxidante vitamines (betacaroteen, vitamine C en E) alsmede van 
vitamine B3 als bouwsteen van NAD+. Er werd geen verschil gevonden in inname van 
energie of vet tussen de verschillende SIRT1 genotypen, hetgeen suggereert dat het ef-
fect van SIRT1 genetische varianten op de BMI niet het gevolg is van een verandering in 
energieinname of eetlust. Significante associaties werden gevonden tussen twee SNPs 
and haplotype 1 in SIRT1 met de BMI in het laagste tertiel van inname van o.a. energie, 
vet en van de vitaminen en in het hoogste tertiel van inname van calcium en melk. 
Er werd een statistisch significante interactie gevonden tussen SIRT1 varianten en de 
inname van vitamine E en calcium. In ERF, waar alleen gegevens over melkinname be-
schikbaar waren, werden vergelijkbare associaties gevonden voor de twee SNPs met BMI 
bij personen in de hoogste tertielen van melkinname. Geconcludeerd werd dat inname 
in de voeding van anti-oxidante vitaminen (met name van vitamine E) en van calcium en 
melk de relatie tussen SIRT1 genetische variaties en BMI beїnvloedt. Deze bevindingen 
ondersteunen aanwijzingen dat interacties tussen genen en voeding complexe ziekten 
of kenmerken zoals BMI kunnen beїnvloeden. Bevestiging van deze bevindingen en 
verdere analyse naar specifieke voedingspatronen met invloed op SIRT1 kunnen leiden 
tot prospectieve studies met als doel om via SIRT1 obesitas te beїnvloeden. 
hoofdstuk 8 toont de bevindingen van een grootschalige genoomwijde associatie 
studie (GWAS) naar gevoeligheidsgenen voor (abdominale) obesitas in 31.373 caucasi-
sche deelnemers van 8 bevolkingsonderzoeken binnen het CHARGE consortium. In deze 
studie werd de rol van FTO and MC4R bij obesitas bevestigd en er werd bovendien een 
nieuw locus gevonden dat geassocieerd was met de middelomvang in het zogenaamde 
neurexine 3 gen (NRXN3). Deze associatie werd bevestigd bij 38.641 deelnemers van het 
GIANT consortium. De SNP in NRXN3 was ook significant geassocieerd met BMI and het 
risico op obesitas. Dit NRXN3 gen werd eerder in verband gebracht met verslaving en 
met beloningsgedrag, hetgeen verdere steun geeft aan de gedachte dat onze genen 
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van invloed zijn op verlangen naar en inname van voedsel en derhalve op gevoeligheid 
voor obesitas.
In hoofdstuk 9 worden de resultaten gepresenteerd van een meta-analyse van vijf 
GWA studies in 19.195 Caucasische deelnemers binnen het GEFOS consortium met als 
doel om nieuwe loci te vinden die geassocieerd zijn met botminerale dichtheid van de 
heup en/of lumbale wervels. Er werden 20 loci geїdentificeerd met een genomewijde 
significantie (p<5x10-8), waarvan 13 in nieuwe regio’s, ter plaatse van genen in signaal-
paden die mogelijk van belang zijn voor botmetabolisme waaronder GPR177, SPTBN1, 
CTNNB1, MEPE, MEF2C, STARD3NL, FLJ42280, LRP4/ARHGAP1/F2, DCDC5, SOX6, FOXC2, 
HDAC5 and CRHR1. Tevens werd in deze meta-analyse de rol bevestigd van 7 bekende 
BMD loci ter plaatse van ZBTB40, ESR1, TNFRS11B/OPG, LRP5, SP7/Osterix, TNSF11/RANKL 
and TNFRS11A/RANK. Concluderend benadrukken deze bevindingen de complexe 
genetische architectuur van osteoporose en identificeren nieuwe genetische variaties 
geassocieerd met BMD. Toekomstige studies zijn nodig om precies vast te stellen welke 
causale varianten ten grondslag liggen aan de gevonden associaties.
In hoofdstuk 10 wordt besloten met een algemene discussie waarbij de bevindingen in 
perspectief worden geplaatst en suggesties worden gedaan voor toekomstig onderzoek. 
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